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Sofosbuvir is a uridine based nucleotide inhibitor of the hepatitis C viral (HCV) 
polymerase that is the backbone of many treatment regimens. In combination with 
drugs targeting other viral enzymes (including the poorly potent guanosine analogue 
ribavirin or highly potent inhibitors of viral NS5A or protease) most patients clear virus 
and resistance to sofosbuvir is rare, allowing effective retreatment with sofosbuvir. 
Patients with Genotype 3 HCV respond less well than other genotypes and response 
is reduced in those previously exposed to interferon. Here we show that patient-
derived virus from patients with Genotype 3 HCV who relapse to sofosbuvir-based 
therapies have a reduced sensitivity to SOF in an in-vitro phenotyping assay. Analysis 
of viral sequencing data revealed two distinct polymorphisms  (A150V and K206E) in 
the HCV polymerase that are associated with treatment failure and in-vitro; they 
reduce sofosbuvir sensitivity against genotype 3 hepatitis C virions. However both 
polymorphisms modify the cellular response to type I interferon and in cells lacking 
response to interferon the impact on sofosbuvir sensitivity is minimal.  The A150V 
polymorphism reduces the response to interferon 70 fold whereas the K206E 
substitution has minimal effects on interferon in isolation but in combination with 
A150V reduces the response 100 fold. Preliminary data indicates that the A150V 
polymorphism interferes with the late response to type I interferons enabling the virus 
to overcome the induction of interferon-stimulated genes. These data indicate a 
complex interaction between direct acting antiviral drugs and the innate antiviral 
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Hepatitis C Virus (HCV) remains a major human pathogen. Hepatitis C-related liver 
disease causes 300-500,000 deaths each year, with a further 150 million people 
infected worldwide; 3.2 million of these are within the European union (Razavi, 2017; 
World Health Organization, 2015). Infection with HCV causes both acute and chronic 
liver disease developing into cirrhosis of the liver and hepatocellular carcinoma. In 
recent years treatment of this virus has dramatically improved from sub-optimal 
pegylated-interferon (pegIFN) and ribavirin (RBV) therapy to a new age of direct acting 
antivirals (DAAs). The new DAA regimens achieve a high cure rate or sustained 
virological response (SVR) for the majority of the 6 main HCV genotypes. HCV 
genotype 3 (G3), which infects 58 million people globally (Gower et al., 2014), remains 
difficult to treat with DAA therapy with relapse to new treatments more common than 
any other genotype. The virological reasons why G3 HCV is more refractory to new 
treatments remains unknown, yet there remains a clinical need to understand why 
relapse is more common in this genotype.  
 
1.1 Discovery of HCV 
HCV was initially classified as Non-A Non-B viral Hepatitis (NANBH) by two studies 
showing the majority of transfusion-associated hepatitis patients tested negative for 
specific serological tests for Hepatitis A and Hepatitis B (Alter et al., 1975; Feinstone 
et al., 1975).  Both studies speculated that the aetiological origin of post-transfusion 
NANBH was likely viral in origin, triggering a search for the virus responsible for this 
condition. It was not until 1989 that the causative agent was identified and proved to 
be the aetiological origin by scientists working at the CDC, NIH and industry. The new 
virus was called hepatitis C. The process of discovery began with blind 
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immunoscreening of cDNA libraries with serum antibodies derived from infected 
patients revealing a positive clone. Further experiments revealed that cDNA from this 
clone hybridised to a 9600-nucleotide RNA molecule distally related to Flaviviral 
genomes. Additionally, circulating antibodies from this group of patients were shown 
to be specific for gene products of this clone providing further evidence for a viral 
aetiology of NANBH (Choo et al., 1989; Reviewed in Houghton, 2009).  
 
1.2 HCV genotypes 
HCV like other RNA viruses encodes its own RNA-dependent RNA polymerase to 
replicate its genome. The lack of proof reading by this polymerase introduces 
mutations at a rate of 8.4x10-3-1.4x10-6 per site with each round of replication (Powdrill 
et al., 2011). This high level of genetic variability of HCV is a key element in HCV 
persistence, resistance to therapy and the development of genetically distinct 
genotypes (Figlerowicz et al., 2003; Jackowiak et al., 2014). 
 
The seven known HCV genotypes vary in their geographical distribution. Genotype 1 
is the most prevalent comprising approximately 83.4 million cases worldwide, with the 
majority of cases in North America. Genotype 3 is the next most prevalent comprising 
of an estimated 54.3 million cases worldwide most of which are located in South Asia. 
Genotypes 2,4 and 6 make up most the remaining of the global HCV cases with 
genotype 5 causing the fewest cases (Messina et al., 2015). Several HCV subtypes 
have also emerged; specifically genotypes 1a, 1b, 2a and 3a in high-income HCV 
infected countries. These were thought to have spread rapidly in the days before the 
discovery of HCV by unscreened blood transfusions and intravenous drug use 
(Magiorkinis et al., 2009; Pybus et al., 2005) 
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1.3 Biology of the Hepatitis C Virus 
HCV is an enveloped, single-stranded positive sense RNA virus from the Flaviviridae 
family (Lindenbach et al., 2013). The 9.6 Kb genome of HCV consists of a single open 
reading frame flanked by a 5’ and 3’ un-translated region (UTR) (Fig 1.1). The 5’UTR 
contains 6 stem loop structures, which form the internal ribosome entry site (IRES), 
critical for the translation of the non-capped HCV RNA genome (Wang et al., 1993). 
The 5’UTR also regulates HCV RNA replication and translation by interaction with the 
liver specific micro RNA-122 (miR122), which has been shown to increase levels of 
HCV replication when expressed in non-hepatic cells (Chang et al., 2008). The 3’ UTR 
contains a variable region followed by a (poly U/UC) tract ending with a highly 
conserved 3’ tail shown to be essential for RNA replication (Kolykhalov et al., 1996). 
The poly (U/UC) tract is one of the key molecular patterns recognised by the innate 




Fig 1.1: HCV genome structure and protien functions 
Schematic of the HCV genome adapted from (Liang et al., 2000) showing the positions of the genes as 
well as the distinction between structural and non-structural proteins. The functional properties of the 
viral proteins are described in the table below the schematic. 
 
1.3.1 Viral Particle 
The HCV genome encodes a single poly-protein that is cleaved first by host and then 
viral proteases into 10 functional proteins that consist of structural proteins (those that 
comprise the viral particle) and non-structural proteins (involved in genome replication, 
particle assembly and immune interference) (Fig 1.1). The HCV structural proteins 
core, E1 and E2 as well as the RNA genome form the membrane enveloped HCV viral 
particle, which is approximately 40-50nm in diameter (Bradley et al., 1985) (Fig 1.2). 
The interaction between the RNA genome and the core protein forms the viral 
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nucleocapsid. A lipid rich viral envelope shrouds the nucleocapsid with the E1/E2 
glycoproteins displayed on the surface of the particle to mediate viral entry via host 
cell receptor binding (Nielsen et al., 2004). 
 
HCV viral particles derived from both patient sera and cell culture have a remarkably 
low buoyant density compared to other enveloped RNA viruses [Reviewed in 
(Lindenbach & Rice, 2013)]. This is due to the interaction of HCV particles with serum 
lipoproteins such as ApoA, ApoB, ApoC, and ApoE forming ‘lipoviral particles’ (LVPs) 
that are thought to facilitate entry and prevent antibody neutralisation (Grove et al., 
2007; Meuleman et al., 2012). The exact structure of HCV within LVPs remains 
unknown and questions remain as to the interactions that mediate LVP formation as 
well as how the HCV glycoproteins are arranged to support viral entry.  
 
Fig 1.2: The HCV particle  
(A) Schematic of a HCV particle. E1–E2 glycoproteins are located on the surface encompassing the 
viral nucleocapsid consisting of the core protein and viral RNA. (B) Proposed representation of a 
lipoviral particle, showing the virus sharing a lipid envelope with lipoprotein particles. Adapted from 




The HCV core protein is an integral component of the viral nucleocapsid, the mature 
form of which is a 21 kDa protein a-helical protein with RNA and lipid binding properties 
(Santolini et al., 1994). Compared to other Flaviviruses such as West Nile and Dengue 
HCV core is unique in terms of size and increased hydrophobicity [reviewed in (Gawlik 
& Gallay, 2014)]. The protein itself is 191 amino acids in length consisting of two 
distinct domains in terms of amino acid composition and hydrophobic properties 
(McLauchlan, 2000). Domain 1 is hydrophilic comprised of basic residues located at 
the N-terminal region of the protein as well as RNA binding properties, thought to 
mediate packaging of the HCV genome into the viral particle during particle assembly 
(Cristofari et al., 2004). Domain 2 comprises the C-terminal end of core and comprised 
of two-amphipathic a-helices separated by a hydrophobic loop. This motif is critical for 
interaction of the protein with lipid droplet (LD) membranes and the endoplasmic 
reticulum (Boulant et al., 2006). Core association with LDs along with its RNA binding 
properties is thought to be the anchor around which the formation of the LVPs occurs. 
NS5A is thought to deliver the HCV genome to core anchored in the LD membrane to 
form the viral nucleocapsid, which is then fully immersed into the center of the LD 
subsequently forming the LVP [Reviewed in (Bartenschlager et al., 2011; Lindenbach 
& Rice, 2013). 
 
1.3.3 Envelope Glycoproteins E1 and E2 
HCV has two envelope glycoproteins E1 and E2 that are heavily glycosylated and 
critical for entry. Both proteins have distinct functions; E1 forms the fusogenic subunit 
while interactions with cellular receptors during entry are mediated by E2. 
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Glycosylation sites on E1 and E2 are highly conserved and comprise of mannose 
based side chains which play a crucial role in folding of the glycoprotein as well as 
interactions with entry receptors (Goffard et al., 2005). E1 and E2 are type I 
transmembrane proteins forming a non-covalent heterodimer within infected cells, 
however in the context of the viral particle they form large covalent complexes 
stablised by disulphide bonds (Vieyres et al., 2010). The key role of the HCV 
glycoproteins is to interact with a range of receptors (critically CD81 and scavenger 
receptor type B class 1, discussed further in section 1.4.1) to gain entry of the 
circulating virus into the cell (Grove et al., 2007; Scarselli et al., 2002; Sharma et al., 
2011). E2 is central to this process as well as immune evasion due to the presence of 
two hypervariable regions, which have a particularly high rate of mutations driven by 
the constant targeting of E2 by neutralising antibodies (Boulestin et al., 2002; Polyak 
et al., 1998)  
 
1.3.4 p7 
p7, also known as the HCV viroporin, is a small 6kDa protein consisting of only 66 
amino acids with two a helical transmembrane domains. During HCV polyprotein 
processing p7 is cleaved by host signal peptidases within the ER. Its transmembrane 
domains span the ER membrane with N- and C-terminus orientated towards the ER 
lumen (Carrere-Kremer et al., 2002). While the precise function of p7 ion channel is 
unknown it is indispensable for virus particle assembly and release (Yu et al., 2009). 
Studies have suggested that the transmembrane domain proximal to the C-terminus 
of p7 functions as a signal sequence for NS2 promoting its translocation to the lumen 
of the ER for cleavage by host signal peptidases (Tellinghuisen et al., 2007). 
Additionally, p7 has been associated with suppressing acidification of intracellular 
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organelles thereby protecting newly formed virions from pre-mature acid inducted 
conformational changes (Wozniak et al., 2010). 
  
1.3.5 NS2 
NS2 is a key non-structural protein essential for the HCV replication cycle. It is the first 
of two HCV proteases that process the HCV polyprotein into functional viral proteins. 
The 23 kDa protein consists of three transmembrane domains within the highly 
hydrophobic N-terminus of the protein, which insert into the ER membrane (Jirasko et 
al., 2010). The C-terminal end of the protein however protrudes into the cytoplasm and 
contains the catalytic residues essential for the cysteine protease activity of NS2 the 
function of which is significantly enhanced by the N-terminal part of NS3 (Schregel et 
al., 2009). Cleavage at the NS2/3 junction is a key stage of the viral lifecycle, critical 
to the release of the mature NS3 protein without which processing of further essential 
non-structural proteins such as the NS4-NS5B cannot occur. 
 
1.3.6 NS3/4A protease 
 The NS3/4A protease is the largest viral protein complex in the HCV life with a range 
of functions mainly, but not limited to, processing of the HCV polyprotein. NS3 is a 
67kDa protein with the serine protease active site located in the N-terminal region of 
the protein, while the C-terminus is associated with NTPase/helicase activity (Gallinari 
et al., 1998). NS4A is a much smaller protein in comparison to NS3. Its highly 
hydrophobic N-terminus is responsible for targeting NS3 to the ER membrane and 
anchoring the NS3/4A complex to the ER membrane through a transmembrane helix 
(Bartenschlager et al., 1993). The C-terminal region of the NS4 associates with the 
core of the NS3 activating the serine protease active site and increasing the efficiency 
 26 
of protease cleavage (Kim et al., 1996). In addition to cleavage of the HCV polyprotein 
the NS3 NTPase/helicase uses ATP hydrolysis in a “ratchet like fashion” to unwind 
double stranded or single stranded RNA with substantial secondary structure (Gu & 
Rice, 2010). The helicase activity is critical for HCV RNA replication and is also 
implicated in infectious viral particle assembly though the exact role remains elusive 
[reviewed in (Murray et al., 2008)].  
 
The sub-cellular localisation of NS3/4 is not just restricted to the ER membrane and 
HCV replication complexes but to a lesser extent the membranes of mitochondria 
(Horner et al., 2011). This additional location of NS3/4A may explain how the protease 
is able to cleave the mitochondrial antiviral signalling protein (MAVS) a critical 
component of the RIG-I signalling pathway (Meylan et al., 2005). In addition to MAVS 
cleavage NS3/4A also cleaves TIR-domain containing adaptor-inducing interferon-ß 
(TRIF) an essential adaptor in TLR3 signalling as well as blocking IRF-3 nuclear 
translocation of interferon-regulatory factor 3 (IRF-3) (Foy et al., 2005; Foy et al., 2003; 
Li et al., 2005). These inhibitory events on the innate immune response impede the 
induction of IFN inducible genes blunting the ability of the cell to response effectively 
to HCV infection.   
 
1.3.7 NS4B 
The specific function of NS4B is relatively less-well characterised yet it is essential for 
the formation of the HCV replication complex. It is a small 27 kDa protein consisting 
of two amphipathic a-helices in the N-terminus, four transmembrane domains in the 
centre of the protein and a further two highly conserved a-helices in the C-terminus of 
the protein (Alexopoulou et al., 2001; Lundin et al., 2006; Meylan et al., 2005). NS4B 
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localises to the ER membrane where it interacts with other viral RNA and non-
structural proteins, inducing alterations to membranous vesicles that function as a 
scaffold for the HCV replication complex, referred to as the membranous web (Gosert 
et al., 2003). Microscopy studies have shown that NS4B forms oligomers with the N- 
and C-terminal helices crucial for oligomerisation. Mutations that disrupt NS4B 
oligomerisation perturb membranous web formation demonstrating that NS4B 
complexes are essential for the induction of the HCV replication scaffold (Paul et al., 
2011). While the specific details of the various interactions NS4B has with the HCV 
non-structural proteins are still elusive, its pivotal role in the formation of the 
membranous web is a lynchpin in the establishment of HCV replication.   
 
1.3.8 NS5A 
Perhaps one of the most extensively studies HCV non-structural proteins; NS5A is a 
hydrophilic phosphoprotein with key roles in replication, assembly and viral-host 
interactions. Originally NS5A attracted considerable interest due to mutations within a 
specific region of the protein termed the interferon sensitivity determining region 
(ISDR) appearing to modulate response to IFNa therapy (Enomoto et al., 1996) but it 
is now a key target for antiviral drugs. The structure of NS5A comprises of three 
domains separated by two low complexity sequences (LCS) (Tellinghuisen et al., 
2004). Domains I and II are primarily involved in RNA replication with crystal structure 
studies indicating that a dimeric form of domain I contains a basic groove in-between 
the dimers, which may form an RNA binding site (Lambert et al., 2014; Love et al., 
2009). Domain I also contains a lipid biding motif critical for the association of NS5A 
with lipid droplets (Miyanari et al., 2007). Domain III, while dispensable for RNA 
replication is essential for virion assembly (Appel et al., 2008; Kim et al., 2011; 
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Tellinghuisen et al., 2008). Furthermore, deletions and insertions within domains II and 
III are relatively well tolerated and several reporter viruses and replicons have been 
generated with insertions of fluorescent genes. A recent example is the insertion of 
the nano luciferase gene in the c-terminal end of domain III in both a subgenomic 
replicon and infectious viral system (Eyre et al., 2017). Surprisingly the authors 
uncovered the presence of NS5A in the extracellular environment in both cell culture 
models and then in a chimeric mouse model, implying that NS5A may have additional 
roles in the extracellular environment.  
 
NS5A is extensively phosphorylated, existing in two forms, basally phosphorylated (56 
kDa) and hyper-phosphorylated (58 kDa) with key phosphorylation residues mostly 
located within the LCS1 domain. Cell culture adaptive changes often occur in this 
region such as the S2204I mutation that increases replicon efficiency in almost all 
genotype specific replicons except JFH-1 [Reviewed in (Ross-Thriepland & Harris, 
2015)]. In genotype 1 this mutation reduces NS5A hyper-phosphorylation which 
boosts replication efficiency (Blight et al., 2000), yet this is not seen in JFH-1. While 
NS5A phosphorylation status is key to the functionality of the protein yet the molecular 
mechanisms as to how phosphorylation regulates NS5A function remains elusive.  
 
In addition to its functions on the HCV life cycle NS5A also interacts with numerous 
cellular proteins to manipulate the host-cellular environment to favour HCV replication 
and assembly. A recent example of this defined the interaction of NS5A with a specific 
subset of host proteins nucleosome assembly protein 1-like protein 1 (NAP1L1), 
bridging integrator 1 (Bin1) and vesicle-associated membrane protein-associated 
protein A (VAP-A) as essential for HCV replication and NS5A dissemination 
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throughout the cellular cytoplasm (Goonawardane et al., 2017). NS5A plays a key role 
in establishment of the HCV replication complex by stimulating phosphatidylinositol 4-
kinase IIIa (PI4KIIIa) activity to increase the level of phosphatidylinositol 4-phosphate 
lipids, essential to the formation of the membranous web (Reiss et al., 2013). It is 
through the many facets of the HCV lifecycle NS5A occupies that resulted in drugs 
such as daclatasvir, ledipasvir and more recently velpatasvir being such potent 
inhibitors of HCV. While all the functions and interactions of this protein are not yet 
defined, its extensive study has led to great advances in both HCV molecular biology 
and drug treatment.   
 
1.3.9 NS5B  
In a fashion typical to other Flaviviridae such as Dengue, West Nile and Yellow Fever 
virus, replication of the HCV positive sense RNA genome occurs through a synthesis 
of a negative strand intermediate, which serves as a template through which nascent 
genomes are synthesised. This process is performed by the virus encoded RNA-
dependent-RNA polymerase (RdRp), which in the case of HCV is designated NS5B. 
The NS5B protein is 65 kDa in size and displays the ‘fingers’, palm and thumb motif 
common to all RdRps as well as signature motifs such as the GDD sequence within 
the catalytic domain which is critical to the functionality of the active site (Poch et al., 
1989). Studies on the 3D structure of the protein have revealed extensive interactions 
between the fingers and thumb domain, revealing a closed conformation of NS5B that 
completely encompasses the active site consistent with de-novo initiation of RNA 
synthesis (Moradpour & Penin, 2013; Simister et al., 2009). The catalytic domain itself 
is located within the palm region where the two critical aspartic acid residues (D-220 
and D-318) chelate two divalent metal ions (magnesium or manganese) as cofactors 
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for the polymerase reaction. The groove formed in between the fingers and thumb 
domain directs the RNA towards the active site [Reviewed in (Moradpour & Penin, 
2013)]. NTPs enter from a specific tunnel to the rear of the protein leading to the active 
site for addition onto the newly synthesised RNA strand. Once initiated NS5B can 
elongate the nascent RNA along the entire length of the RNA genome without 
requiring a helicase to un-wind RNA secondary structures (Lohmann et al., 1999). The 
mechanisms behind the termination of RNA synthesis remain poorly defined, however 
it may be that the NS5B simply disassociates from the genome once it has reached 
the end of the template.   
 
The error-prone nature of RNA synthesis by NS5B is one of the most distinguishing 
features of HCV, giving rise to the high genetic diversity of clinical isolates. Powdrill 
and colleagues recently defined the error rate as 10-3 substitutions per site, with a 
strong preference for G:U/U:G mismatches in NS5B (Powdrill et al., 2011). The 
mutation rate in HCV driven by NS5B is the highest reported for any RNA virus, 
resulting in HCV infection consisting of a diverse, closely related population of viruses 
or quasispecies (Martell et al., 1992; Simister et al., 2009). This feature of NS5B allows 
the virus to continuously adapt to immunological challenge, by providing beneficial 
mutations to avoid neutralising antibodies produced by the host in response to 
infection (Farci et al., 1996). The constant mutating and adaption of viral epitopes also 
contributes to the host failing to mount an effective cytotoxic CD8+ T-Cell response 
through failure in cells being able to recognise viral epitopes or present epitopes in the 
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context of major-histocompatibility-complex-class I (Bowen & Walker, 2005; Chang et 
al., 1997; Erickson et al., 2001; Tsai et al., 1998).  
 
The key role NS5B plays in the viral life cycle has resulted in it being a target for the 
development of therapeutic strategies to combat HCV replication. This has resulted in 
the development of the most effective HCV antiviral drug Sofosbuvir (SOF), a 
guanosine nucleotide analogue which binds to and inhibits the NS5B active site (Sofia 
et al., 2010). The high barrier to resistance of SOF as well as combination with NS5A 
inhibitors Ledipasvir, Daclatasvir (discussed later) and weak antiviral Ribavirin has 
transformed clinical management of HCV replacing the old ‘gold standard’ of IFN 
based therapy achieving limited efficacy to a new highly effective regime with greatly 
improved response rates.   
  
1.4 Viral life cycle 
The lifecycle of HCV is typical of that expected from a member of the Flaviviridae 
family [Reviewed in (Gerold et al., 2017; Mukhopadhyay et al., 2005)]. Virions enter 
through receptor-mediated endocytosis, through interaction with a range of receptors 
with different binding affinities. Release of the RNA genome into the cytoplasm occurs 
through conformational changes of the virion brought about by acidification of the 
endosomal vesicle. Translation of the positive sense RNA genome yields a single 
polyprotein processed into functional domains by host and viral proteases. Virion 
assembly occurs on the surface of the endoplasmic reticulum (ER) with nascent virus 




1.4.1 Entry  
The first stage in HCV infection is attachment to the host cell surface. HCV entry to 
hepatocytes occurs on the basolateral surface beginning with a low affinity interaction 
with low-density-lipoprotein-receptor (LDLR) and with glycosaminoglycans (GAGs) 
(Germi et al., 2002; Monazahian et al., 1999). Both LDLR and GAGs interact with viron 
associated ApoE to bring the virus close to the cell surface to complete the early 
attachment phase. After the initial contact with LDLR and GAG further interactions 
between the HCV particle and additional surface receptors are essential for entry; the 
most crucial are CD81, scavenger receptor class B member 1 (SRB1), claudin 1 and 
occludin, their individual roles are summarised in Error! Unknown switch argument..  
 
The interaction between these receptors and lipoprotein-associated viral particles 
allow progression of the virus from cell surface attachment to entry into the hepatocyte. 
The lipid transfer ability is thought to be a key step in progression from initial contact 
by enabling the dissociation of the lipoproteins from the viral particle and exposing the 
CD81 binding domains of the HCV E2 glycoprotein (Dao Thi et al., 2012; Zahid et al., 
2013). The CD81-bound viral particles are then transported laterally to the tight 
junctions of the cell to where the interaction with claudin-1 stimulates clatherin-
mediated endocytosis (Farquhar et al., 2012). This cell surface trafficking is dependent 
on the remodelling of cortical actin controlled by signal transduction pathways through 
epidermal growth factor receptor (EGFR) signalling and downstream RHO- and RAS-
GTPase signalling (Lupberger et al., 2011). While occludin is essential for HCV entry 
its precise role is unclear. Studies point to occludin binding directly to the HCV E2 
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glycoprotein in the tight junction region as well as being one of the last steps in HCV 
entry yet; the exact part occludin plays remains to be fully uncovered (Sourisseau et 
al., 2013).  
Table 1.1 Receptors essential for HCV entry into hepatocytes  
Receptor Role in HCV entry 
CD81 
• Tetraspanin binding protein 
• Necessary but not sufficient for HCV entry.  
• Binds HCV E2 glycoprotein and is one of the first HCV co-
receptors discovered (Pileri et al., 1998)  
• Indicated in post-attachment events, as HCV binding requires a 
conformational change in E2 (Petracca et al., 2000). 
• Has also been shown to prime HCV glycoproteins for low-pH 
activation during entry (Sharma et al., 2011) 
SRB1 
• Highly expressed on hepatocytes, binds high- and very-low-
density lipoproteins. 
• Indicated as a HCV entry co-factor by increasing HCV 
permissiveness for CD81 deficient HepG2 cells 
• Interacts with virus associated lipoproteins 
• Lipid transfer activity of SRBI is important for HCV post binding 
entry (Zahid et al., 2013) 
• Interaction with E2 causes a conformational change promoting 
CD81 binding (Scarselli et al., 2002).  
Claudin-1 
• Tight junction protein found on the basolateral surface of 
hepatocytes   
• Indicated as HCV entry factor by cDNA library expression (Harris 
et al., 2010). 
• Does not directly interact with HCV but is thought to stabilise virus 
internalisation by interacting with CD81 (Evans et al., 2007). 
Occludin-1 
• Tight junction protein 
• Functions at a post attachment step of HCV entry (Sourisseau et 
al., 2013). 
• Whether it directly interacts with the virus has yet to be elucidated. 
• Contributes to species tropism of HCV as mice become permissive 
for HCV when human Occulin -1 is expressed (Ploss et al., 2009). 
 
After clatherin-mediated endocytosis the virus is trafficked to an endosomal 
compartment were the lipid transfer activities of SRB1 are thought to modify the virus 
and the associated lipoproteins (Dao Thi et al., 2012). This modification is possibly to 
expose the viral envelope to prime E2 by CD81 so that the glycoprotein can trigger 
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low pH induced membrane fusion between the endosomal membrane and the viral 
envelope (Sharma et al., 2011). The fusion event between the endosomal 
compartment and the viral membrane releases the HCV genome into the cytosol 
where translation and replication can be initiated. 
 
1.4.2 Translation/Replication 
The site of HCV replication is the rough endoplasmic reticulum (rER). Here HCV faces 
a barrier to genome translation; the lack of a 5’-cap. All eukaryotic mRNA possess this 
modification allowing the recruitment of ribosome initiation factors to begin translation 
by scanning for the initiation codon. The virus overcomes this block by the presence 
of an internal ribosome entry site (IRES) in its 5’UTR region, which has been shown 
to be sufficient to induce the formation of an active 80S ribosome complex without the 
need for a 5’-cap (Wang et al., 1993). This exhibits one of many mechanisms whereby 
the virus can subvert the host replication machinery for its own purposes.      
 
Translation of the viral genome yields a single polyprotein approximately 3000 amino 
acids in length that is processed by cellular signal peptidases and viral serine 
proteases (NS2, NS3/4) to generate the 10 functional viral proteins. The HCV 
replication complex and subsequent polyprotein processing form a ‘membranous web’ 
within the rER (Miyanari et al., 2003). This membranous web consists of double-
membrane vesicles, HCV RNA, ER membranes and lipid droplets (Gosert et al., 
2003). Replication of the viral genome occurs within the membranous web by the 
NS5B RdRp using the positive strand RNA genome as a template to generate a 
negative strand intermediate that is used to produce further positive strand genomes 
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[reviewed in (Kim & Chang, 2013)].  The proposed model of this process is shown in 
Fig 1.3. 
 
Fig 1.3 Model of the HCV Replication Complex  
Schematic diagram adapted from Gu et al of the proposed model of the HCV RNA replication. After 
translation and cleavage of the HCV polyprotein non-structural proteins as well as host factors will form 
the HCV replication complex to replicate the positive strand RNA genome for packaging into new 
particles. Viral RNA is replicated through a negative strand RNA intermediate (Black) by the NS5B in 
this environment, which provides protection from proteases and nucleases. The positive strand RNA 
genome generated in this process is proposed to exit the complex for packaging and subsequent 
release of nascent particles. 
 
Several host factors have been indicated in HCV replication, such as 
phosphatidylinositol-4 kinase-IIIα (PI4K-IIIα), cyclophillin A (CypA) and miR-122. 
PI4K-IIIα is a lipid kinase recruited to the membranous web by NS5A stabilising the 
HCV replication complex and promoting the integrity of the membranous web (Reiss 
et al., 2011). Cyclophillin A is a peptidyl-prolyl isomerase that catalyses proline residue 
peptide bond isomerisation in protein folding and has been shown to be an essential 
cofactor for HCV replication and membranous web formation through interactions with 
NS5A and NS5B (Yang et al., 2008). Finally the liver specific micro RNA miR-122 
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stimulates HCV RNA translation by binding to the 5’UTR promoting cap-independent 
translation in conjunction with the IRES (Roberts et al., 2011).  
 
1.4.3 Assembly and release 
HCV assembly occurs at the surface of cytosolic lipid droplets (LD) and is highly 
dependent on the association between the core and these LDs. During HCV infection 
the core protein stimulates LD formation and recruits the viral non-structural proteins 
and the replication complex to the LD- associated membranes (Barba et al., 1997). 
The association between the HCV replicase and LD appears critical for particle 
assembly as disruption of this interaction severely impairs virus production (Targett-
Adams et al., 2008) 
 
The first step in viral assembly is the interaction between NS5A and LD-associated-
core protein. Two further non-structural proteins p7 and NS2 interact with the NS3-4A 
serine protease to release the LD-associated-core to form the nascent viral particle 
and bring the E1 and E2 glycoproteins to the site of assembly (Jirasko et al., 2010).  
Mutations in the RNA helicase domain of the NS3 protein have been shown to perturb 
HCV assembly, which may indicate a possible RNA genome-packaging role for the 
NS3 helicase during nucleocapsid formation (Pietschmann et al., 2009). A recent 
study has highlighted an interesting role for the cellular factor heterogeneous nuclear 
ribonucleoprotein K (HNRNPK) in regulating the availability of the HCV RNA genome 
for virion packaging. HNRNPK was shown to bind to the HCV RNA genome thereby 
preventing its inclusion in new viral particles, demonstrating an interesting usurpation 
by HCV of host proteins to aid assembly (Poenisch et al., 2015). Maturation of the 
HCV is dependent on VLDL synthesis as the mature particles are enriched with 
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proteins involved in VLDL assembly such as apoE, apoB and microsomal transfer 
protein (Huang et al., 2007). The matured particles are then released from the cell 
through the secretory pathway during which the E1, E2 glycoproteins are post-
translationally modified to prime them for pH-mediated fusion in the next infection cycle 
(Vieyres et al., 2010).  
 
1.5 In vitro methods to study HCV 
 Since the discovery of HCV several attempts have been made to propagate the virus 
in cell culture by infection with virus derived from patient sera. While replication can 
be detected in hepatoma cell lines and primary human hepatocytes, replication levels 
were often so low that detection relied heavily on highly sensitive reverse transcription 
(RT) qPCR [reviewed in (Bartenschlager & Lohmann, 2001)]. Since in vitro replication 
of patient derived HCV remains a considerable challenge the majority of the research 
into the biology of the virus has relied on replicon models that have been adapted for 
in vitro use. 
 
1.5.1 The HCV subgenomic replicon system 
Key discoveries that lead to the creation of the first HCV replicon were based on the 
observation that positive strand RNA viruses belonging to the flavi-and pestivirus 
family do not require their structural proteins for genome replication. This inspired the 
development of the first HCV subgenomic replicon, Con1, derived from viral cDNA of 
a patient with a chronic genotype 1b infection.  The Con1 replicon is a bicistonic 
construct where the HCV IRES drives a G418 selectable resistance marker, while the 
HCV non-structural proteins, crucial for RNA replication, are expressed through a 
encephalomyocarditis virus (EMCV) IRES (Lohmann et al., 1999). Stable replicon-
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containing cell lines were generated through RNA transfection of the construct 
followed by antibiotic selection. This system does not produce infectious particles due 
to the lack of structural proteins only permitting study of the replication complex of 
HCV.  
 
Several viral adaptive mutations were discovered from the replication of the HCV 
subgenomic replicons that have led to the selection of variants that have a higher 
replicative fitness. These mutations cluster in the NS3, NS4B, NS5A and NS5B 
regions with the bulk located in the NS5A just upstream of the interferon sensitivity-
determining region (ISDR) (Blight et al., 2000; Lohmann et al., 2003). Mutations in 
NS4B also have a strong effect on the replicative ability of the Con1 replicon, however 
mutations in the NS3 and NS5B have a more moderate adaptive effect often being 
found in conjunction with other highly adaptive mutations in the NS5A (Lohmann et 
al., 2003; Lohmann et al., 2001). Adaptive mutations seen in replicon models are not 
observed in clinical HCV isolates therefore it is likely that they are specific to the Huh7 
cell culture environment by modulating interactions between viral and cellular proteins 
to make a more favourable setting for HCV replication. The replicon system has now 
to date expanded beyond genotype 1b to include genotypes 1a (H77), 2a (JFH-1), 3 
(S52), 4 (ED43), 5a and 6a [reviewed in (Catanese & Dorner, 2015)]. 
 
In addition to identification of mutations that boost replication efficiency, the 
subgenomic replicon lines lead to the development of cell lines with more permissive 
for HCV replication. This was based on the observation that cells ‘cured’ of the replicon 
using IFNa or a HCV specific drug had greatly improved rates of HCV replication. A 
clone of cured cells termed Huh7.5 cells were found to contain a mutation in the 
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retinoic-acid-gene I (RIG-I), an inducer of the interferon response through HCV RNA 
recognition, rendering it functionally non-viable (Blight et al., 2002; Sumpter et al., 
2005). The high permissiveness of Huh7.5 to HCV replication has enhanced the study 
of HCV by providing a suitable platform to propagate both subgenomic replicons and 
cell culture derived HCV.  
 
1.5.2 Genotype 3 sub-genomic replicons 
Despite the efficient replicon models available for genotypes 1 and 2, replicons based 
on other genotypes generally replicate poorly in cell culture.  For genotype 3 the most 
developed sub-genomic replicon model was developed by Saeed et al based on the 
consensus clone S52, which required several adaptive mutations namely P1226S, 
D1437H and S2210I to generate high numbers of stable colonies [ref Saeed et al]. 
While stable cell lines offer robust models for studying HCV replication, transient 
replicon assays are a preferable alternative for antiviral drug testing. These assays 
are well established in JFH-1 based sub-genomic replicons but replication levels in 
genotype 3 replicons are much lower. Recent work has looked to improve replication 
levels of G3 replicons by removal of the neomycin resistance cassette, reducing the 
CpG dinucleotide content of the replicon and overexpressing the recently described 
host factor SEC14L2  [wittevedlt et al]. From this study removal of the neomycin and 
over expression of SEC14L2 had the most positive impact on replication of the 
genotype 3 replicon. 
 
1.5.3 Cell culture derived HCV 
Inoculation of patient derived HCV in cell culture models do not result in productive 
infection. There is however one exception, a genotype 2a isolate obtained from a 
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Japanese patient who developed fulminant hepatitis as a result of HCV infection (a 
very rare outcome), designated JFH-1. This isolate is the only HCV virus that can infect 
and propagate within the Huh7 cell culture model, allowing our knowledge of HCV 
biology to be greatly enhanced (Kato et al., 2003; Wakita et al., 2005). JFH-1 has 
allowed the elucidation of novel factors in HCV entry, such as NPC1L1, EGFR and 
EphA2 as well as the development of a HCV humanised mouse model (Dorner et al., 
2013; Kelly et al., 2017). Recently the use of the JFH-1 model system has uncovered 
a novel viral assembly mechanism mediated whereby an interaction between the p7 
viroporin and NS5B regulates the morphogenesis of the viral particle enhancing 
infectivity (Aligeti et al., 2015).   
 
A recent development has been the creation of a robust model of infectious genotype 
3 HCV termed DBN3acc that can infect and propagate to similar levels as JFH-1 as 
well as producing high levels of infectious virus upon transfection (Ramirez et al., 
2016). This clone is a marked improvement on the S310 G3 infectious model, which 
took several weeks to propagate yielding low titre virus (Kim et al., 2014). The adaption 
of this clone is extensive, 15 mutations were engineered across the length of the 
genome with mutations spanning core-NS5A critical to overcome the host barrier of 
Huh7.5 cells to achieve virus replication. In line with adaption of JFH-1, any reversion 
of adaptive mutations in the NS4A-NS5B regions significantly reduced viability of 
DBN3a however the authors note that they did not investigate the molecular 
mechanisms behind this.  
 
This model may provide valuable insight into G3 HCV the study of which until now has 
been restricted to a poorly replicative infectious clone or subgenomic replicon. With 
 41 
relapse to new antiviral therapy still a recurrent issue for G3 HCV use of this model 
could help to elucidate the mechanisms behind this. Though the considerable adaption 
this clone has undergone to make it viable in-vitro should be considered when drawing 
conclusions from its use. Yet, it remains an important and useful development for the 
study of the specifics of G3 HCV.  
 
 
1.5.4 Limitations to replicons 
The HCV replicon systems have allowed the dissection of various aspects of the viral 
life cycle. The development of cell culture derived HCV has confirmed early work 
through subgenomic replicon models on HCV RNA replication and expanded our 
knowledge of the various entry, assembly and release stages of the virus life cycle. 
However, one of the restrictions of the JFH-1 system is the heavy reliance on a single 
isolate that can produce infectious virus in vitro. While subgenomic replicons have 
been developed for other genotypes, robust infectious clones only exist for G2 and 
recently G3, making the study of any possible nuances in the viral life cycle between 
the 7 HCV genotypes especially in terms of assembly and release a challenge.  
 
In terms of antiviral drug design HCV subgenomic replicons have been extensively 
used as they contain the primary direct acting antiviral drug targets, the NS3, NS5A 
and NS5B. Genetic manipulation of subgenomic replicons allows the construction of 
chimeras containing a non-structural gene of interest from HCV isolate. These can be 
then fused to a fluorescent or luminescent reporter system, which because of the 
robust and strong readout can be used in high-throughput drug screening assays 
(Bartenschlager, 2002; Gottwein et al., 2011). For example, replacement of the NS5B 
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derived from clinical isolates in the Con-1 replicon has been used to develop 
phenotypic drug resistance assays to novel polymerase inhibitors (Middleton et al., 
2007). It has however been noted that the replacement of the NS3 or NS5B from 
different genotypes within JFH-1 can severely impair its replicative ability (Murayama 
et al., 2007), making the study of antiviral drug resistance with the only full length viral 
model a challenge. 
 
The use of the HCV replicon models has contributed enormously to the design of new 
powerful antiviral drugs for HCV and provided a robust model system to assess drug 
resistance. However, the replicon systems are unable to provide a system where 
patient derived HCV can be studied and phenotyped for drug resistance. Despite the 
new age of DAA therapy for HCV, which achieves high SVR rates, resistance to 
therapy remains a problem. While the generation of chimeric replicons derived from 
clinical isolates allow specific areas of the virus to be studied, they do not give the full 
picture in context with the rest of the natural virus. To accurately determine the 
mechanisms of relapse to the new DAA therapies, patient derived HCV must be 
studied. 
 
1.5.5 Study of Clinical Isolates of HCV 
Direct culture of HCV from clinical isolates has remained a constant challenge in HCV 
research with most isolates replicating at levels below well below detection of standard 
methods such as immunofluorescence and western blotting. While infection of primary 
human hepatocytes with clinical isolates is possible once the cells are in culture they 
have a limited life span and can down regulate factors characteristic of mature 
hepatocytes (Elaut et al., 2006). With the recent development of techniques 
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associated with induced-pluripotent-stem-cells (iPSCs), a model that shows great 
promise is differentiation of hepatocytes like cells (HLCs) from these stem cell 
progenitors. The chief advantage of this system is the ability to obtain an unlimited 
supply of HLCs with without the variation of PHHs obtained from donors. Studies have 
demonstrated productive infection of HLCs with both cell-culture and patient derived 
HCV (Roelandt et al., 2012; Schwartz et al., 2012; Wu et al., 2014). Although these 
cells do not recapitulate the full phenotype of mature hepatocytes they do robustly 
express key receptors such as CD81, SR-B1 and occludin as well as miR-122 (Sa-
Ngiamsuntorn et al., 2016b).  
 
Improvements to the cell line based assays to replicate patient isolates have recently 
been enhanced by the discovery of SEC14L2 by Saeed et al, which in addition to 
boosting replicon replication could also support replication of clinical isolates from 
genotypes 1 and 3 albeit from clinical samples with high viral loads (Saeed et al., 2015; 
Witteveldt et al., 2016).  The proposed mechanism as to how SEC14L2 promotes HCV 
infection is by inhibition of vitamin-E mediated lipid peroxidation though the authors 
note other mechanisms yet to be elucidated may exist. Although SEC14L2-expressing 
cell lines are a major step forward in our understanding of both cell-culture adaption 
and propagation of HCV clinical isolates, their abilities in resistance testing of virus to 
anti-viral agents remains largely untested.  
 
1.5.6 The HCV ‘Capture-Fusion’ Assay 
In an ideal scenario, being able to predict whether a patient infected with HCV was 
going to respond to the treatment prescribed would be the most effective and 
economical approach to drug selection. Deep sequencing of clinical isolates can 
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detect baseline resistant yet resistance with HCV are often complex and not entirely 
defined. Thus, being able to phenotypically determine the antiviral sensitivity of patient 
derived HCV would be of particular clinical benefit. Phenotypic assays using 
subgenomic replicons are time-consuming and often only focus on a specific region of 
the viral genome.  
 
A technique developed by our research group represents a novel method by which the 
antiviral sensitivity of patient derived HCV genotypes 1-6 can be determined. The 
assay is based on the observation that HCV can associate with peripheral-blood-
mononuclear cells (PBMCs) (Coquillard & Patterson, 2009; Ducoulombier et al., 2004; 
Mellor et al., 1998; Pham et al., 2008) and although extra-hepatic replication of virus 
remains controversial, fusion of patient monocytes to Huh7.5 cells permits replication 
of virus albeit at a low level (Cunningham et al., 2014). The assay was further 
developed to utilise a THP-1 monocyte cell line to ‘capture’ virus from patient serum 
when stimulated with phorbol 12-myristate 13-acetate (PMA) and IFNg (Fig 1.4) and 
this form has been used to assess sensitivity of clinical isolates to a range of antiviral 
drugs including recently an experimental RIG-I agonist (Jones et al., 2017). Questions 
remain as to the specific mechanisms of the capture fusion assay, namely why patient 
derived virus needs to be delivered to Huh7.5 cells via association with monocytes as 
opposed to direct infection. Additionally, the association of virus with THP-1 cells 
remains incomplete as it was shown to be independent of the classical HCV receptors 
such as CD81 and SR-B1. Though pre-treatment with PMA and IFNg up-regulated Fc-
receptor expression resulting in the hypothesis that THP-1 cells can associate with 
HCV antibody complexes to take up the virus (Marino et al., 2005).  
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The capture fusion assay remains the only tested phenotypic assay that can determine 
the antiviral sensitivity of un-adapted clinical HCV isolates regardless of genotype. 
Replication in the assay is often low-level, relying on a sensitive RT-qPCR method to 
detect virus, yet the assay has been shown to correctly predict clinical response to 
Telaprevir where a NS3-based biochemical assay could not (Cunningham et al., 
2014). The phenotypic data that this assay can produce has the ability to determine 
virological causes of treatment failure in clinical HCV. Next-generation sequencing of 
clinical isolates can identify potential resistance variants but phenotypic assays such 
as capture fusion can define their effect on antiviral sensitivity.   
 
Fig 1.4 The HCV Capture Fusion Assay 
Schematic representation of the key steps involved in the capture fusion assay. THP-1 cells pre-
stimulated with phorbol 12-myristate 13-acetate (PMA) and IFNg are inoculated with patient serum. 
Cells are then fused to the highly permissive Huh7.5 cell line using polyethylene-glycol (PEG). HCV 
can undergo a full replication cycle detected both by RT-qPCR and passage of virus onto naive Huh7.5 
cells. Treatment of fused cells with antiviral drugs allow dose response curves to be generated and 
therefore determine the drug sensitivity of patient derived HCV. 
 





1.6.1 Interferon in HCV treatment 
Treatment with type 1 interferon (IFN) and ribavirin (RBV) has been the gold standard 
of HCV treatment for many years, achieving around a 50% cure rate (Scheel & Rice, 
2013). IFN alpha is an antiviral cytokine produced in response to infection. The binding 
of the IFNs (Table 1.2) to their respective receptors results in the activation of the 
signal transducer and activator of transcription complexes (STAT) via a cascade of 
signalling events. 
 
Table 1.2: Classes of Interferon 
Class Receptor 
Type I (IFNα, IFNβ, IFNω) IFN-α receptor (IFNAR) 
Type 2 (IFNγ) IFN-γ receptor (IFNGR) 
Type 3 (IFNl 1-4) Complex of IL10RB and IFNl receptor (IFNLR) 
 
The activation of STATs, specifically STAT1 and STAT2, cause a cascade of signals 
via the janus-kinase-STAT (JAK-STAT) pathway resulting in the transcription of IFN 
stimulated genes (ISG) such as IRF7, MX1 and OAS1 (Donnelly & Kotenko, 2010b). 
Failure in ISG activation can result in resistance to IFN treatment. The HCV core 
protein can interact with regulators of the IFN signalling cascade thereby preventing 
activation of ISGs and resulting in IFN insensitivity. However, the exact mechanisms 
and interactions between the all HCV proteins and the IFN pathway are not completely 
understood (Qashqari et al., 2013). 
 
1.6.1.1 The role of viral factors in IFN resistance  
HCV viral proteins have been found to interfere with various stages of the IFN 
response. For example, the Core and NS5A inhibit transcription factor STAT1 by 
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preventing STAT1/STAT2 dimerization (Core) or decreasing the levels of 
phosphorylated STAT1 (NS5A) (Kumthip et al., 2012). The HCV serine protease NS3-
4A prevents ISG expression by cleaving TRIF a key adaptor protein in the stimulation 
of IFN response mediated by NFκB and TLR3. Additionally, both E2 and NS5A have 
been shown to interfere with the antiviral effects of the IFN-induced protein kinase R 
(PKR) by inhibiting PKR protein synthesis (Chayama et al., 2000; Francois et al., 
2000).   
 
1.6.1.2 Host factors in IFN resistance 
Host factors such as age, body weight, obesity, diabetes and insulin resistance 
influence patient response to IFN therapy (Asselah et al., 2010). Insulin resistance in 
particular has been shown to have an inhibitory effect on the IFN intracellular signalling 
pathway and increase steatosis and liver fibrosis progression (Romero-Gomez, 2006).  
 
Genome-wide-association studies have revealed host genetic polymorphisms 
upstream of the IL-28B gene within the IFN-λ3 gene that can predict the outcome of 
IFN therapy. Specifically, two single nucleotide polymorphisms (SNP) designated 
rs12979860 and rs8099917 have been strongly associated with treatment outcome 
and spontaneous viral clearance (Tillmann et al., 2010). The preferred variants 
rs12979860CC and rs8099917TT are associated with a favourable SVR where as 
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other variants such as rs12979860CT/TT or rs8099917TG/GG are more likely to fail 
IFN therapy (Fischer et al., 2013). 
 
1.6.1.3 Interferon Lambda (l) in HCV infection  
Type III IFNs (also referred to as IFNls) are a key component of the innate antiviral 
response against HCV infection. The family consists of 4 members IFNl1, IFNl2, 
IFNl3 and IFNl4, which between them have a high degree of both similarity and size 
(Hamming et al., 2013). The receptor for the IFNls consists of 2 sub-units: IFN-
lambda-receptor-1 (IFNLR1), the alpha sub-unit specific for IFNls and IL10RB, the 
beta subunit, also shared with type II cytokine receptors for IL-10, IL-22 and IL-26 
(Donnelly et al., 2004). Not all tissues can respond to IFNl since expression of the 
IFNLR1 is restricted to tissues with a high epithelial content such as the lungs and liver 
(Sommereyns et al., 2008). 
 
IFNl signalling occurs through dimerisation of the IFNLR1 and IL10B1 subunits 
activating Janus Kinase-1 (JAK1) and tyrosine kinase-2 (TYK2), phosphorylating 
IFNLR1 resulting in the recruitment of STAT1 and STAT2. Phosphorylated STAT1/2 
form a heterodimer with IRF9 to form IFN-stimulated gene factor 3 (ISGF3), which 
translocates to the nucleus where it binds the IFN-stimulated response element (ISRE) 
to drive IFN stimulated gene (ISG) synthesis (Donnelly & Kotenko, 2010a).  ISGs 
induced by IFNa and IFNl are largely similar resulting in a broadly similar antiviral 
effect, though it has been noted that IFNl tends to induce a slower more sustained 
antiviral response (Bolen et al., 2014; Kalie et al., 2008). Among the many genes up 
regulated by IFNa and l notable examples include myxovirus resistance gene 1 (MX1) 
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2’ -5’ - oligoadenylate synthetase 1–3 (OAS-1–3) and protein kinase R (PKR). A 
distinctive feature of IFNl induction is the up-regulation of anti-inflammatory ISGs 
USP18 and suppressor of cytokine signalling (SOCS) 1-3, which obstructs STAT 1 
and 2 phosphorylation causing the cell to lose sensitivity to the effects of type I and III 
IFNs (Francois-Newton et al., 2011; Mahlakoiv et al., 2012; Yoshimura et al., 2007). 
In terms of inhibition of HCV, differences in the mechanisms of ISG induction between 
IFNa and l have been shown to exist. Using knock out cells, both STAT-1 and STAT-
2 were found to be essential for anti-HCV ISG expression by IFNl, whereas IFNa was 
found to be able to induce ISG production in the absence of STAT-1 but not STAT-2 
(Yamauchi et al., 2016).  
 
In addition to signalling through the phosphorylated form of ISGF-3 a second related 
factor exists consisting of un-phosphorylated STAT-1/STAT2 and IRF-9 termed U-
ISGF3, which prolongs expression of a subset of ISGs such as MX1, 2’ -5’ – OAS and 
ISG-15 that can inhibit chronic HCV infection (Cheon et al., 2014; Cheon et al., 2013; 
Cheon & Stark, 2009). A recent study has shown that IFNl produced as a result of 
HCV infection significantly up regulates levels of U-ISGF3, which subsequently render 
cells unresponsive to IFNa. The mechanism identified for this loss of type I IFN 
responsiveness was found to be ISG15-mediated stabilisation of USP18 a well-
documented negative regulator of the IFN response as mentioned previously (Sung et 
al., 2015). 
 
1.6.2 Ribavirin in HCV treatment 
RBV has been used in conjunction with IFN for HCV treatment since it was shown to 
improve SVR rates in patients with chronic HCV (Davis et al., 1998). Randomised 
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clinical trials demonstrated that combination therapy improved SVR rates from 15% 
with IFN mono-therapy to 36% with IFN and RBV (Brillanti et al., 1994; Poynard et al., 
1998). RBV is a synthetic guanosine analogue with a broad spectrum of antiviral 
activity against several RNA viruses such as respiratory syncytial virus and poliovirus. 
The similar chemical structure of RBV to guanosine allows the molecule to be 
incorporated into the viral genome causing errors in the coding sequence or directly 
inhibit the activity of the HCV polymerase (Fig 1.5). The addition of RBV to IFN 
increases antiviral effect but its greatest benefit is the prevention of relapse to therapy 
(Pawlotsky et al., 2004).  
 
Fig 1.5 Chemical structure of Ribavirin 
Schematic diagram of the chemical structure of Ribavirin and guanosine. RBV is a guanosine analog 
similar in structure but with alterations to the base group of the nucleotide. Upon entering the cell RBV 
is phosphorylated with RBV-triphosphate being the active compound that can bind to the active site of 
the polymerase. Specific details concerning the proposed mechanisms of action are discussed below. 
Chemical structures were adapted from Sigma Aldrich. 
 
1.6.2.1 Mechanism of Action  
RBV does not have one single mechanism of action. Since its discovery and clinical 
use as an antiviral a number of mechanisms have been identified. Even today the key 
overriding antiviral mechanism remains elusive. The reasons as to why this has 
remained unclear lie in the nature of the drug itself. RBV being a weak antiviral can 
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only exert a significant antiviral effect against HCV in combination with IFN, making 
the determination of the antiviral contribution of RBV among the highly complex IFN 
response a challenging task.  
 
1.6.2.2 Inhibition of the HCV polymerase 
Upon entry of RBV into the host cell it is phosphorylated into its active form RBV-
triphosphate (Miller et al., 1977). Since the HCV polymerases utilises the host 
nucleotide pool for genome replication RBV-triphosphate can be recognised by the 
HCV polymerase due to its similarity to guanosine. Once bound RBV may prevent 
further elongation by chain termination or sit in the active site of the polymerase 
preventing the binding of other nucleotides (Bougie & Bisaillon, 2003). Studies have 
shown in vitro that RBV can both bind to the active site of the HCV polymerase and 
inhibit chain elongation (Bougie & Bisaillon, 2003; Maag et al., 2001). Clinical studies 
investigating the mutation rate of the NS5B in chronic HCV with RBV monotherapy 
identified mutations within the viral polymerase, which were shown in vitro not to confer 
resistance to RBV (Lutchman et al., 2007). A possible explanation as to why RBV 
monotherapy did not yield any resistant mutations in the NS5B may be because RBV 
is not sufficiently potent antiviral to drive growth of resistant strains.  
 
1.6.2.3 RNA mutagenesis 
Another mechanism of action was proposed based on the observation that RBV could 
be incorporated into the HCV RNA genome and base pair with either cytosine or uracil. 
This would then result in an increase in the number of mutations within the HCV 
genome, perhaps to the point where the virus would be rendered non-viable (‘error 
catastrophe’). Studies investigating mutation rate upon exposure to RBV have 
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produced controversial data as to whether an increase in the mutation rate is either 
‘seen’ or ‘not seen’ with RBV monotherapy [Reviewed in (Thomas et al., 2013)]. As 
mutagenesis would occur randomly throughout the genome, a single resistant strain 
would not necessarily be selected for. An approach the virus could utilise to escape 
lethal mutagenesis would be the selection of a higher fidelity polymerase. This would 
not be necessarily a selective advantage for a virus such as hepatitis C as one of its 
strengths is its population diversity, allowing rapid selection of variants in response to 
the interventions both by the cell and antiviral drugs. The failure of RBV monotherapy 
and the controversy surrounding whether RBV does in fact increase mutation rates 
may suggest that this mechanism of action may occur at a rate below detection. Some 
evidence to support this comes from studies investigating RBV uptake into the HCV 
genome that show RBV is incorporated at best every 1/7000 nucleotides (Maag et al., 
2001).  
 
1.6.2.4 Inosine Monophosphate Dehydrogenase (IMPDH) inhibition 
The mechanisms of action of RBV discussed thus far target the virus directly, however 
additional indirect antiviral mechanisms have been shown such as the inhibition of the 
IMPDH enzyme. IMPDH converts inosine-5-monophosphate to xanthine-5-
monophoshate, which is the rate-limiting step in the production of guanosine 
nucleotides. RBV has been shown to competitively bind to the active site of IMPDH 
blocking the access of inosine-5-monophosphate resulting in the downstream 
depletion of GTP pools (Malinoski & Stollar, 1981; Streeter et al., 1973). As GTP is a 
critical requirement for viral genome replication its depletion would prevent efficient 
HCV genome replication. Trials with IMPDH inhibitors such as VX-497 showed an 
increased potency than RBV against hepatitis B virus (HBV), RSV and parainfluenza-
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3 virus but not HCV (Markland et al., 2000). The consequence of this has lead to 
IMPDH inhibition not being considered as a primary antiviral mechanism of RBV in 
HCV. However, IMPDH inhibition and the subsequent depletion of GTP pools may 
enhance the direct acting antiviral mechanisms of RBV of error catastrophe and RdRp 
inhibition by forcing the virus to incorporate RBV into its genome as an alternative to 
GTP. Therefore, it is possible that the summation of the relatively weak direct and 
indirect antiviral mechanisms of RBV that drive a significant antiviral response in HCV 
therapy.    
 
 
1.6.2.5 Additional mechanisms 
Work looking at the effect of RBV therapy on the immune system has revealed that 
RBV can drive the activity of the more cytotoxic T-helper-1 phenotype while supressing 
T-helper 2 cells. In vitro experiments demonstrated that RBV enhanced the Th1 
cytokine by up-regulating both the mRNA and protein levels of IL-2, IFNγ and TNFα 
while down regulating cytokines associated with the Th2 response (IL-4, IL-5, IL-10) 
(Hultgren et al., 1998; Ning et al., 1998; Tam et al., 1999). Skewing of the T-cell 
response towards a more cytotoxic phenotype by RBV would facilitate the clearance 
of virally infected cells and could enhance the antiviral effect of IFNa; this remains 
poorly defined. Studies examining the role of T-cells in IFN/RBV treated patients have 
not shown enhancement of HCV specific T-cell response in patients (Rahman et al., 
 54 
2004) therefore suggesting that this may not be a significant antiviral mechanism of 
RBV. 
 
A final immune mediated mechanism implicated in RBVs activity is the augmentation 
of the IFN response when given in combination with IFNa. Gene expression studies 
performed on liver biopsies from HCV infected patients treated IFN/RBV revealed a 
higher ISG expression with the dual therapy. Furthermore, patients pre-treated with 
RBV displayed amplified induction of ISGs and down regulation of genes involved in 
IFN inhibition (Feld et al., 2007).  Further studies have confirmed in vitro and in vivo 
that RBV can promote the IFN response through several mechanisms such as PKR 
up-regulation (Liu et al., 2007), activation of p53 and mTOR pathways (Su et al., 2009) 
and heightened IFN-ß and IL-8 production (Tokumoto et al., 2012).  
 
 
1.6.2.6 Resistance  
As RBV is an effective mutagen with error catastrophe being a suggested antiviral 
mechanism of action, resistant mutations are often found in the RdRp which cause an 
increased fidelity of the polymerase. Examples of this are found in the RBV resistant 
poliovirus where a G64A mutation within the polymerase increased the accuracy of 
replication (Vignuzzi et al., 2008). Further examples can be found in foot and mouth 
disease virus and Coxsackie virus where RBV resistant variants identified in the RNA 
polymerase increase fidelity of replication (Gnadig et al., 2012; Zeng et al., 2014). 
 
In HCV treatment RBV resistant mutations were identified by passage of HCV replicon 
cells in high concentrations of RBV. Sequencing of the RBV resistant replicon cells 
 55 
revealed resistant mutations initially identified in the C-terminus of NS5A that 
conferred resistance to 300μM of RBV comparable to physiological concentrations 
(Pfeiffer & Kirkegaard, 2005a).  
 
More recent experiments, which looked to develop RBV resistant JFH-1 by the serial 
passage in high RBV concentrations, resulted in a range of mutations throughout 
genome (Feigelstock et al., 2011). Table 1.3 summarises currently known mutations 
associated with RBV resistance. The precise resistance conferring mutation as well 
as the mechanism of resistance remains unclear. A possible explanation could be 
increased replication fidelity conferred by RBV resistance associated variants, as 
these variants also have been shown to resist other mutagens such as 5-FU (Mihalik 
& Feigelstock, 2013). 
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Table 1.3 Identified RBV resistance mutations 




























* Table adapted from (Feigelstock et al., 
2011; Pfeiffer & Kirkegaard, 2005a) 
 
The contribution of all these changes to RBV resistance remains unclear, however 
mutations G404S and E442G NS5A were shown by Pfieffer and Kirkegaard to confer 
resistance to RBV in replicon cells. While they did not identify the mechanism of 
resistance, they speculated that these changes may affect the interaction between 
NS5A and NS5B making the polymerase less error-prone and thus less likely to 
incorporate RBV (Pfeiffer & Kirkegaard, 2005b).  Mutations in the NS5B remain under 
characterised since their identification, with none of the sites located near the active 
site of the polymerase, their contribution to RBV resistance remains elusive. Indeed, 
the authors commented on the need for additional studies to fully characterise these 
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mutations (Feigelstock et al., 2011). 
 
 
1.6.3 Efficacy of peg-IFN/RBV treatment  
The addition of RBV to peg-IFNa treatment was shown in three randomised clinical 
trials to significantly improve response rates compared to individual monotherapy 
(Fried et al., 2002; Hadziyannis et al., 2004; Manns et al., 2001). The clinical benefit 
of RBV addition was shown to be higher on-treatment response rates and reduced 
incidences of virological relapse compared to RBV monotherapy (McHutchison et al., 
1998; Pawlotsky et al., 2004). Efficacy of pegIFN/RBV varied across different HCV 
genotypes resulting in genotype specific recommendations for treatment (Ghany et 
al., 2009). Treatment duration for patients infected with HCV G2 and 3 was 24 weeks 
of pegIFN/RBV, which achieved SVR in 75-85% of patients. However, this treatment 
regimen was less effective for those infected with genotype 1 and 4 HCV achieving 
SVR rates between 40-50% and 55-65% respectively even with an increased duration 
of treatment to 48 weeks (Fried et al., 2002; Hadziyannis et al., 2004; Manns et al., 
2001)  
 
Patients who fail to respond to IFN based therapy either show a null-response, where 
no appreciable drop in serum HCV RNA is observed (most common with G1 infection), 
or relapse where viral RNA levels drop but return after cessation of treatment (most 
common in G3) (Fig 1.6). In either case further treatment options are limited. Re-
treatment with the same course of therapy is not recommended resulting in SVR in 
less than 5% of cases (Cheruvattath et al., 2007). Treatment with a different pegIFNa-
subtype such as 2A to 2B only improves SVR rate if patients had received IFN mono-
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therapy and not infected with genotype 1 HCV (Jacobson et al., 2004; Shiffman et al., 
2004; Taliani et al., 2006). Patients who experience virological relapse (resurgence of 
virus after 12 weeks), while likely to respond to the same treatment regime a second 
time still face high rates of relapse even with higher doses of pegIFN (Cheruvattath et 
al., 2007). 
 
Fig 1.6 Virological responses to pegIFN/RBV treatment 
Rapid virological response (RVR) defined as clearance of the virus detected by qPCR 4 weeks after 
the start of therapy. A ≥2-log drop in serum RNA at week 12 is referred to as early virological response 
(EVR) and if patients continue to be HCV RNA negative 24 weeks after the cessation of therapy this is 
described as a sustained virological response (SVR). Non-response is categorised as: null-response 
where treatment shows no substantial drop in HCV RNA after 24 weeks treatment and partial non-
response where a ≥2-log drop is observed but patients are still HCV RNA positive at week 24. Virological 
relapse occurs when HCV RNA in the serum reappears after the end of treatment. Adapted from (Ghany 
et al., 2009). 
 
Several factors can influence response to pegIFN/RBV therapy. Of these factors, none 
can robustly predict treatment outcome but only indicate the probability of achieving 
SVR. The presence of advanced liver fibrosis or cirrhosis is one of the strongest 
negative influences on the achievement of an SVR regardless of genotype.  Response 
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rates with cirrhosis are reduced from 41%-34% in genotype 1 and 79%/71% to 
66%/44% for genotypes 2 and 3 respectively (Lee et al., 2006). To a lesser extent the 
presence of co-morbidities such as obesity, insulin resistance, intra-venous drug use, 
alcoholism and co-infection with HIV also have a negative impact on SVR rates 
(Ghany et al., 2009). HCV genotype as alluded to earlier, is also a major indicator of 
treatment response. G1 infection is intrinsically more resistant to pegIFN/RBV therapy, 
characterised by a delay in the clearance of infected cells compared to genotypes 2 
and 3. The mechanism for this lack of response to IFN treatment in G1 remains 
relatively unknown but it is noteworthy that treatment does not select for viruses that 
are inherently resistant to IFN (Pawlotsky et al., 1998a; Pawlotsky et al., 1998b).   
 
1.7 Recent advances in HCV treatment  
The field of HCV treatment has changed dramatically in the last few years. The 
classical pegIFN/RBV regime, fraught with adverse effects and low SVR rates has 
been replaced with a new class of drugs, the direct acting antivirals (DAAs). The DAAs 
have raised the cure rate of chronic HCV from 50% to almost 90% especially in 
genotype 1 infection (Kowdley et al., 2014). First generation DAAs were inhibitors of 
the NS3 protease such as telaprevir, boceprevir and more recently simeprevir. Since 
2011 protease inhibitors have been introduced as the primary treatment regime for 
genotype 1 infection in combination with pegIFN/RBV, however adverse effects were 
still observed with this regime (Jacobson et al., 2011; Poordad et al., 2011). Second 
generation DAAs included a pan-genotypic NS5B polymerase inhibitor sofosbuvir 
(SOF) as well as NS5A inhibitors daclatasvir (DAC), ledipasvir (LDV) and more 
recently velpatasvir (VEL), which present a much more potent treatment regime with 
reduced side effects.  
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1.7.1 Protease Inhibitors (-previrs) 
Cleavage of the HCV polyprotein by the NS3/4 serine is an essential part of the viral 
life cycle. Its blockage therefore would seriously disrupt the viral replication cycle and 
ultimately prevent the generation of new infectious viral particles. The first drugs 
shown to inhibit NS3 by binding to the active site of the protease approved for clinical 
use were telaprevir (TEL) and Boceprevir (BOC). Triple therapy with TEL or BOC in 
combination with pegIFN/RBV showed up to 75% SVR rates in naïve G1 infection 
when given over 24-48 weeks (Jacobson et al., 2011; Poordad et al., 2011). May 2014 
saw the approval of a second-generation protease inhibitor simeprevir (SIM), which 
was regarded as a superior drug to TEL and BOC in terms of dosing (single 150mg 
tablet) and reduced side effects. In a clinical trial setting SIM achieved improved SVR 
rates (up to 80%) compared to TEL and BOC when used in combination with 
pegIFN/RBV (Jacobson et al., 2014).  
 
The treatment algorithms for regimes with TEL and BOC differed. BOC regimes 
consisted of a 4-week lead in with pegIFN/RBV followed by an additional 4 weeks of 
pegIFN/RBV/BOC. If viral RNA was detected at week 8 then therapy was continued 
for 48 weeks, if not therapy was stopped after 24 weeks. TEL based regimes consisted 
of an initial 12 weeks of pegIFN/RBV/TEL with viral RNA levels monitored at 4 and 12 
weeks. Detection of HCV RNA ≥1000IU/ml at either week 4 or 12 resulted in 
subsequent treatment of pegIFN/RBV for 48 weeks otherwise patients were only given 
an additional 12 weeks of pegIFN/RBV (Barritt & Fried, 2012; Marks & Jacobson, 
2012). The addition of protease inhibitors significantly improved SVR rates among 
patients with cirrhosis, however these rates were reduced compared to patients with 
 61 
mild fibrosis.  Furthermore, response rates were markedly reduced in response guided 
regimes compared to longer fixed dose courses of therapy, resulting in 48 weeks 
therapy being recommended for cirrhosis to maximise the potential to achieve high 
SVR rates (Bacon et al., 2011; Jacobson et al., 2011; Poordad et al., 2011; Zeuzem 
et al., 2011). 
 
BOC and TEL are strong inhibitors of CYP3A, which can affect the plasma 
concentration of certain drugs metabolised by this pathway. For this reason, TEL and 
BOC are contraindicated with the drugs given in birth control, anti-cholesterol drugs 
and antidepressants. Additionally, the antiretroviral drug efavirenz decreases the 
plasma concentration of BOC making this drug combination unfavorable in patients 
infected with HIV. In terms of adverse events, patients receiving BOC were more likely 
to discontinue therapy due compared to control groups. Common adverse events were 
anemia, rash, flu like symptoms and nausea for BOC treatment, whereas 
gastrointestinal disorders such as nausea and diarrhea were more common in TEL 
regimens (Jacobson et al., 2011; Poordad et al., 2011; Wilby et al., 2012; Zeuzem et 
al., 2011).  
 
A low genetic barrier to resistance has hindered use of protease inhibitors. Specifically, 
the pre-existence of resistance-associated mutations such as the Q to K polymorphism 
at position 80 in NS3 severely comprises the efficacy of protease inhibitors such as 
SIM in G1a infection (Jacobson et al., 2014; Manns et al., 2014). EASL and AASLD 
2015 guidelines recommend the use of viral sequencing to exclude patients with the 





1.7.2 NS5A inhibitors (-asvirs) 
The NS5A protein plays a key role in several aspects of the viral life cycle such as 
replication complex formation and viral packaging as well as interacting with several 
cellular functions [Reviewed in (Pawlotsky, 2013)]. NS5A is believed to exist as a 
dimer and is commonly found on ER-derived membranes in HCV infection existing in 
a basally phosphorylated and hyper-phosphorylated form. Precisely how NS5A 
regulates viral replication or assembly is unknown. As a result the exact impact NS5A 
inhibitors have on the HCV replication cycle is not completely understood however, it 
is thought that they disrupt NS5A dimerisation, preventing replication complex 
formation (Ascher et al., 2014). NS5A inhibitors have been found to have a much wider 
more potent activity against the various HCV genotypes than the protease inhibitors, 
inhibiting HCV replication at picomolar concentrations (Gao et al., 2010). Since NS5A 
inhibitors also have a low genetic barrier to resistance they are used in combination 
with other antivirals. Recently, they have been approved for use as part of the all-oral 




Daclatasvir (DAC) was the first NS5A inhibitor discovered. It has since demonstrated 
pan-genotypic antiviral activity with a minimal side-effect profile. When combined with 
pegIFN/RBV, DAC is a well-tolerated treatment regime achieving 80% SVR rates in 
genotype 2 and above 60% in genotype 3. The frequency of post-treatment relapse 
was higher in patients with cirrhotic genotype 3 infection (Dore et al., 2015). Phase III 
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studies have shown that in non-cirrhotic genotype 3 infection the combination of DAC 
plus sofosbuvir (SOF) can achieve 98% SVR rates after 12 weeks of therapy without 
the need for RBV (Nelson et al., 2015). Several mutations in the NS5A cause 
resistance to DAC including M28T, Q30E/H/R, L31M, H58D, and Y93H/N. The 
mutations found in the majority of G1 infected patients who did not achieve SVR were 
L31M/V and Y93H/N (Lontok et al., 2015; Nelson et al., 2015).   
 
1.7.2.2 Ledipasvir 
Since 2014 ledipasvir (LDV) with SOF has been available as a fixed dose combination 
oral therapy (HARVONI) for the treatment of genotypes 1, 3 and 4. SVR rates of 99% 
have been achieved with LDV in combination with SOF in genotype 1-treatment naïve 
patients without the need for RBV. Use of LDV also demonstrated high SVR rates of 
94% in previous G1 non-responders after only 12 weeks of therapy, which increased 
to 99% with and extension to 24 weeks (Afdhal et al., 2014). Overall data from several 
clinical trials suggest that 12 weeks of therapy with LDV/SOF achieve SVR rate of 
96% with genotype 1 infection. This drops to 90% in treatment experienced patients 
suggesting that these patients may require a longer duration of therapy [reviewed in 
(Thiagarajan & Ryder, 2015)]. Mutations identified to confer resistance to LDV are 
similar to those for DAC including Q30E/R, L31M, and Y93C/H/N [reviewed in (Lontok 
et al., 2015)]. This is not surprising as both drugs have the same NS5A binding site. 
 
1.7.3 NS5B inhibitors (buvirs) 
The HCV NS5B RNA-dependent-RNA-polymerase is critical for replication of the viral 
genome. The inhibition of this enzyme will stall viral replication and prevent the 
formation of infectious virons. NS5B inhibitors exist in two types; nucleoside and non-
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nucleoside analogues. Nucleoside analogues bind to the active site of the enzyme 
causing premature chain termination, while non-nucleoside inhibitors bind to allosteric 
sites resulting in conformational changes inactivating the enzyme. Due to necessity to 
conserve the active site across the HCV genotypes gives the potential for pan-
genotypic activity for nucleoside inhibitors. Recent years has seen the development of 
one of the most effective anti-HCV drugs to date, sofosbuvir (SOF) a nucleoside 
analogue that has dramatically improved SVR rates across all HCV genotypes (Fig 
1.7). 
 
Fig 1.7 Chemical structure of Sofosbuvir 
Sofosbuvir is a nucleoside analog that upon entering the cell is phosphorylated into its active 
triphosphate form. This then acts as a defective substrate for the polymerase binding to the active site 
preventing chain elongation. Chemical structre was adapted from Sigma Aldrich 
 
1.7.3.1 Sofosbuvir 
SOF has recently been approved for treatment of all HCV genotype. Data from phase 
III clinical trials FISSION and VALENCE revealed that SOF/RBV is effective for all 
genotypes. However reduced SVR rates were observed with G3 achieving 85% SVR 
compared to 93% for G2, 90% for G1 and 96% for G4 (Lawitz et al., 2013; Zeuzem et 
al., 2014b). NEUTRINO revealed that SOF with pegIFN/RBV for 12 weeks achieved 
a 90% response rate in patients infected with genotypes 1, 2 and 4. Notably SVR rates 
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for genotype 3 infections were markedly reduced compared to genotype 2 (56% vs 
97%) with 12 weeks of SOF/RBV treatment as part of the FISSON study (Lawitz et al., 
2013). Increasing treatment duration to 24 weeks increased SVR at week 12 (SVR12) 
to 92% in treatment naïve non-cirrhotic G3 patients (Zeuzem et al., 2014a). Previous 
treatment experience with IFN in G3 resulted in low SVR12 rates of only 30% when 
treated with 12 weeks of SOF/RBV, this however was found to double to 60% when 
treatment duration was extended to 16 weeks (Jacobson et al., 2013).  Presence of 
cirrhosis in treatment experienced patients was found to negatively impact SVR rates 
with 12 and 16 weeks of SOF and RBV treatment alone. Two further clinical trials 
BOSON and LONESTAR tested adding pegIFN to SOF and RBV regimens which, 
subsequently achieved SVR12 of 83% and 85% respectively amongst G3 treatment 
experience cirrhotic patients (Foster et al., 2015b; Lawitz et al., 2015). The BOSON 
trial in particular contained a high proportion of patients with both advanced liver 
disease and previous treatment failure.  
 
The combination of SOF plus LDV in the ION clinical trial series for genotype 1 
revealed that high SVR rates (95%) could be achieved after just 8 weeks of therapy 
compared to 12 weeks (Afdhal et al., 2014). Treatment of genotype 3 with SOF 
remains sub-optimal. Data from the ELECTRON-2 clinical trial shows SVR rates in 
treatment naive genotype 3 patients with SOF/LDV are improved by the addition of 
RBV (100% compared to 64% without RBV) after 12 weeks of therapy. The reasons 
why RBV improves SVR rates are unknown.  
 
NS5B variants have been identified that confer resistance to SOF therapy. These were 
first identified in laboratory studies of the HCV replicon where they emerge relatively 
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frequently. However in patients these mutations are much less common, perhaps 
indicating that they are less replication competent.  The first SOF resistance 
associated variant found was S282T and was isolated in a genotype 2 patient who 
was treated with SOF monotherapy thought its subsequence occurrence in patients is 
rare (Gane et al., 2013). Other mutations have been found by a combination of 
sequence analysis and replicon selection. Substitutions such as L159F and V321A 
have been identified form collated data from phase 3 SOF trials treating G3 infection 
(Svarovskaia et al., 2014). When these mutations have been engineered into 
replication models they only cause a modest reduction in SOF sensitivity (Lontok et 
al., 2015). The mechanism as to how these substitutions contribute to virological 
relapse to SOF remains unknown.  
 
1.7.3.2 Modern HCV treatment regimens 
All oral therapy for HCV is based on three classes of DAAs: protease inhibitors, NS5A 
inhibitors and NS5B inhibitors (Table 1.4). DAA treatment regimens are always given 
in combination to achieve effective inhibition of HCV replication and a high barrier to 
resistance. While most DAA therapy potently represses HCV replication they have a 
low barrier to resistance when given in monotherapy. The only exception to this is 
SOF, which can be given in monotherapy with RBV, but higher SVR rates are achieved 
when SOF is coming with a protease or NS5A inhibitor. Additionally, a treatment 
combination of three DAAs with low barriers of resistance such as 
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Paritaprevir/Ombitasvir plus Dasabuvir can achieve a high barrier of resistance when 
given together (Welzel et al., 2014). 
Table 1.4 Direct Acting Antivirals 













At the time of writing the international guidelines for treatment of HCV G1 and G4 are 
SOF combined with an NS5A inhibitor with or without RBV (Table 1.5). The most 
recent EASL guidelines recommend three treatment options: SOF with LDV, DAC, or 
Velpatasvir (VEL) all of which achieve high SVR rates (EASL, 2017). Treatment for 12 
weeks with either of those combinations is sufficient to treat G1b patients regardless 
of the presence of cirrhosis. RBV is still recommended for treatment experienced G1a 
with and without cirrhosis (Afdhal et al., 2014; Feld et al., 2015; Poordad et al., 2016; 
Sulkowski et al., 2014). Additionally, as an alternative to non-SOF based regimens the 
non-nucleoside inhibitor Dasabuvir combined with Paritaprevir and Ombitasvir achieve 
SVR rates of 98% when given for 8 weeks (Ara & Paul, 2015). Treatment for G4 follows 
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the guidelines for G1a with SIM still having a role in treatment experience patients with 
RBV.  
Table 1.5: Summary of HCV treatment options by Genotype 
Genotype Treatment Rationale Drugs Duration 
1 
SOF with NS5A 
inhibitor – RBV if 
treatment  
experienced 
SOF+ LDV, DAC, 
VEL 12 weeks 
2 
SOF with NS5A 
inhibitor – RBV if 
previously treated 
with IFN 





SOF with NS5A 
inhibitor – RBV if 
previously treated 
with IFN 





SOF with NS5A 
inhibitor – RBV if 
treatment  
experienced 
SOF+ LDV or DAC 12 weeks 
 
 
For G2 and G3 SOF in combination with DAC or VEL has largely replaced SOF/RBV 
or SOF/pegIFN/RBV as treatment options (EASL, 2017).  RBV is no longer required 
to treat naïve non-cirrhotic patient with SOF/DAC or SOF/VEL representing an 
equivalent treatment option. For patients receiving SOF and DAC regimens RBV is 
still recommended for the treatment of patients with previous exposure to IFN based 
regimens as well as patients with cirrhosis regardless of treatment experience, 
although for the SOF/VEL regimen ribavirin is only recommended in patients with 
decompensated cirrhosis (Foster et al., 2015a; Leroy et al., 2016; Nelson et al., 2015).  
SVR rates for G3 even with these regimens are still lower compared to other 
genotypes, for reasons yet unknown.  
 
1.8 Project Aims/Hypothesis 
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Therapy for G3 HCV remains sub-optimal with relapse to treatment occurring at a 
clinically significant rate. The virological reasons for relapse remain poorly defined due 
to the inability to study patient derived HCV. Interestingly the use of RBV appears to 
boost SVR rates in cirrhotic G3 HCV. Why this occurs is unknown. The establishment 
of a novel HCV phenotyping assay in our lab has permitted the study of the drug 
phenotype of clinical HCV samples across all HCV genotypes (Cunningham et al., 
2014). It is the aim of this study to use this assay to examine the antiviral drug 
sensitivity of G3 HCV to determine if a virological insensitivity exists in patients who 
relapse compared to those who achieve SVR. The hypotheses for this study are:  
1. A reduced sensitivity to antiviral drugs in pre-treatment G3 samples is 
associated with treatment failure 
2. Antiviral-drug sensitivity is reduced in post treatment samples from relapse 
samples 
3. Mutations in HCV are associated with antiviral drug ‘resistance’ 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Molecular Biology buffers 
TAE Buffer 50X stock: 2M Tris Base (Trizma) with 
57.1ml Glacial Acetic acid and 0.05M EDTA 
(pH 8.0). Make up to 1L with ddH2O. 
10X MOPS 0.2M MOPS, 0.05M sodium acetate, 0.01M 
EDTA, pH 5.5-7. For 1L: 41.86g MOPS, 
4.102g sodium acetate, 3.72g EDTA in 
800ml of DEPC ddH2O. Adjust pH with 
NaOH. 
10X TBS Tris 100mM, NaCl 1.5M. For 1L: 12.11g 
TRIS, 87.66g NaCl in 1L of ddH2O 
TBS-T wash buffer TBS diluted to 1X supplemented with 0.05% 
(vol/vol) Tween20 
Blocking solution TBS-T supplemented with 5% Non-Fat-Dry-
Milk (weight/vol) 
SDS-PAGE Running buffer 25mM Tris, 192mM Glycine, 0.1% SDS. For 
1L: 3g Tris, 14.5g Glycine, 1g SDS in 1L H2O. 
Transfer Buffer 24mM Tris, 1.92mM Glycine, 10% Methanol. 
For 1L: 2.9g Tris, 1.45g Glycine, 100ml 
Methanol. 
DEPC-Water 1ml DEPC to 1L ddH2O, Leave overnight at 




2.1.2 Buffers for Bacterial Culture and to generate competent cells 
Luria-Bertani Broth (LB) For 1L, 10g Tryptone 5g Yeast extract and 10g of Sodium 
Chloride were dissolved in 1L of water and sterilised by 
autoclave 
RF1 100mM Rubidium Chloride, 50mM Manganese (II) chloride 
tetrahydrate, 30mM Potassium acetate, 10mM Calcium chloride 
dihydrate, 15% (v/v) glycerol, buffered to pH 5.8 with glacial 
acetic acid 
RF2 10mM MOPS, 10mM Rubidium Chloride, 75mM Calcium 
chloride dihydrate, 15% Glycerol (v/v), Buffered to pH 6.8 with 
NaOH 
SOC 2%(w/v) tryptone, 0.5% (w/v) yeast extract, 20mM glucose, 
10mM NaCl, 2.5mM MgCl2, 10mM MgSO4 
XL-10 Recovery media 80mM of Magnesium Chloride, 80mM Magnesium Sulphate 








RIPA Buffer 20mM Tris pH 7.5, 2mM EDTA, 150mM 
NaCl, 1% NP40 (IGEPAL) 
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2.1.3 Mini Prep buffers 
P1 (resuspension buffer) 50 mM Tris-HCL, 10mM EDTA pH8, supplemented with 
50μg/ml RNase A (Sigma). 
P2 (Lysis Buffer) 0.2M NaOH with 1% SDS. 
P3 (Neutralisation Buffer) 4M Guanidine Hydrochloride with 0.5M potassium acetate 
buffered to pH 4.2 with glacial acetic acid. 
PB (wash buffer I) 5M Guanidine Hydrochloride, 20 mM Tris-HCL (pH 6) 38% 
ethanol (final concentrations after the addition of ethanol). 
PE (wash buffer II) 20mM NaCl, 2mM Tris-HCL (pH 7.5), 80% ethanol (final 
concentrations after the addition of ethanol).  
 
2.1.4 Primers for HCV taqman expression assay 
Primer Name Sequence 5’-3’ 
HCV F GCCTTGTGGTACTGCCTG 
HCV R CACGGTCTACGAGACCTCC 
HCV Probe ATAGGGTGCTTGCGAGTGCCCCGGG 
  
2.1.5 Primers for Sybr Green qPCR 
Primer Name Sequence 5’-3’ 
HCVneg F GCGAACCGGTGAGTACAC 
HCVneg R TACCACAAGGCCTTTCGC 
5S F TGTGATTTCCGCTGGTACGG 
5S R AGCCATCTCGAACCAGACAC 
MxA F AACAACCTGTGCAGCCAGTA 




2.1.6 Primers used for amplification of VSVG 




2.1.7  Primers used for PCR mutagenesis of the S52-Subgenomic replicon and 
DBN3acc constructs 
Outer NS5B primers encoding XhoI and XbaI restriction sites at the 5’ and 3’ end of NS5B 
S52-5B XhoI F  TGCCTCCTCTCGAGGGAGAG 
S52-5B XbaI R  GGTCGACTCTAGACATGATCTGC 



















2.1.8 Primers used for NS5B amplification 




2.1.9 Primary antibodies 
Mouse anti Β-Actin (Abcam-8224) Western Blot 1:5000 
Mouse anti STAT-1 (BD-61085) Western Blot 1:1000 
Mouse STAT-2 (BD-61087) Western Blot 1:1000 
Mouse anti NS5A (Millipore) Western Blot 1:2500 
Sheep anti NS5A (Kind Gift from Mark Harris) Western Blot 1:2500 
Immunofluorescence 1:1000 
Rabbit anti-VSVG (Millipore) Western Blot 1:2500 
Rabbit anti NS5B (Abcam 65410) Immunofluorescence (1:100) 
 
2.1.10 Secondary antibodies 
Sheep anti Mouse (VWR NA931) Western Blot 1:5000 
Donkey anti-Rabbit (Stratatech-711-036-152-JIR)  Western Blot 1:25,000 
Donkey anti-sheep Alexa 488 (Life technologies A11015) Immunofluorescence 1:1000 







2.1.11 Plasmid Vectors 
pGEMT-Easy TA Cloning vector from PROMEGA. T7 promoter,  Antibiotic 
resistance: Ampicillin 
pTRIP-VSVG Lentiviral expression vector expressing the G protein from 
VSVG, CMV promoter, Antibiotic resistance: Ampicillin 
pcDNA3.1 Mammalian expression vector CMV promoter, Antibiotic 
resistance: Ampicillin 
pRetroX Lentiviral expression vector (Kindly Donated by Dr Richard 
Sloan, Queen Mary University of London), CMV promoter, 
Antibiotic resistance: Ampicillin 
pDBN3acc Plasmid construct encoding the full length DBN genotype 3 
infectious isolate. (Kindly Donated by Prof Jens Bukh, 
University of Copenhagen) HCV genome under control of HCV 
IRES, Antibiotic resistance: Ampicillin 
pS52-(SHI)-SG Genotype 3 subgenomic replicon encoding the NS3-NS5B non-
structural proteins. Structural proteins were replaced with a 
Firefly luciferase/Neomycin cassette driven by HCV IRES 
(Kindly donated by Prof Charlie Rice, Rockefeller Institute). 
HCV non-structural proteins driven by EMCV promoter. 
pVSVG Lentiviral envelope plasmid. CMV promoter, Antibiotic 
resistance: Ampicillin 
pMD1.1 Lentiviral packaging plasmid encoding Gag and Pol accessory 
proteins. CMV promoter, Antibiotic resistance: Ampicillin 
pNL1.1 Expression vector driving expression of the Nano luciferase 
reporter (Promega). CMV promoter, Antibiotic resistance: 
Ampicillin 
pGL4.45 Reporter vector containing the interferon-stimulated response 
element driving transcription of the luciferase reporter gene 





2.1.12  Competent cells 
XL-10-Gold 
Ultracompetant cells 
TetR ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac Hte [F ́ proAB lacIqZ∆M15 Tn10 (TetR) 
Amy CamR] 
JM109 recA1, endA1, gyrA96, thi, hsdR17 (rK–,mK+), relA1, supE44, 
Δ(lac-proAB), [F ́, traD36, proAB, lacIqZΔM15] (4). 
 
2.1.13  Cell lines used in this study 
Cell line Description 
THP-1 Monocyte cell line 
Huh7 Hepatoma cell line 
Huh7.5 Permissive hepatoma cell line for HCV infection due to non-
functional RIG-I pathway 
Huh7 Lunets Hepatoma line generated from cured HCV replicon cells. Kindlty 
donated by Gilead Sciences 
Huh7.5-SEC14L2 Huh7.5 cells over expressing the SEC14L2 gene, kindly donated 
from Peter Simmonds (University of Oxford)  
Huh7.5-VSEC Huh7.5 cells overexpressing both SEC14L2 and PIV5-V protein/ 
Kindly Donated from Mark Harris (University of Leeds) 
S52-Wt Huh7.5-cells stably expressing the S52-SG replicon 
S52-K100R Huh7.5-cells stably expressing the S52-SG replicon with a K-R 
mutation at amino acid position 100 in NS5B 
S52-G188D Huh7.5-cells stably expressing the S52-SG replicon with a G-D 
mutation at amino acid position 188 in NS5B 
S52-K206E Huh7.5-cells stably expressing the S52-SG replicon with a K-E 
mutation at amino acid position 206 in NS5B 
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2.1.14 Antiviral drugs used in this study 
Sofosbuvir – Stock 10mM kindly donated by Gilead Sciences 
Ribavirin- Stock 20mM, Sigma 
Daclatasvir- Stock 10mM Kindly Donated by Bristol-Myers-Squib 

























2.2.1 Clinical material 
HCV patient sera were obtained from the HCV Research UK national bio-bank under 
tissue transfer agreement TR00335. Ethical approval for the study was given by 
London – City Research Ethics Committee and informed consent was obtained from 
all patients for the use of their samples in laboratory research.  
 
2.2.2 Cell Culture 
2.2.2.1 Passage of adherent cell lines 
Media was aspirated and cells were washed with 1XPBS. Cells were removed from 
the flask surface with 2mL 1XTrypsin-EDTA, incubated at 37˚C for 5 minutes. Cells 
were then collected by adding DMEM supplemented with 10% fetal calf serum (FCS) 
and centrifuged at 200xg for 5mins. The cell pellet was re-suspended in 10mls DMEM 
10% FCS, then split at a 1:3-1:10 ratio into a new T75cm2 flask and maintained at 
37˚C with 5% CO2. Cells were passaged approximately every 3-4 days or when they 
reached 80-90% confluence.  
 
2.2.2.2 Passage of suspension cell lines 
The contents of a confluent flask were transferred into a 50mL falcon tube and 
centrifuged at 250xg for 5 min. Media was discarded and cell pellet re-suspended in 






2.2.3 HCV Capture Fusion Assay 
2.2.3.1 THP-1 Stimulation/infection 
1x106 THP-1 cells were seeded in 6 well plates and stimulated overnight with 200ng/ml 
of PMA and 10ng/ml of IFNγ. Cells were washed in RPMI containing 2%FCS before 
inoculation with HCV sera at a multiplicity of infection (MOI) of 1. 24hrs post infection 
THP-1 cells were washed in PBS twice before removing from the plastic with a cell 
scraper.  
 
2.2.3.2 Fusion of infected THP-1 and Huh7.5 cells 
Huh7.5 cells were combined with the THP-1 cells at a ratio of 1:1 and centrifuged at 
200xg for 5mins. Supernatant was removed and polyethylene glycol (PEG-Roche) 
was added drop wise directly to the THP-1/Huh7.5 cell pellet and incubated at 37ºC 
for 2mins. PEG was diluted out with serum free DMEM and incubated for a further 
5min recovery period before centrifuging at 200xg for 5min. Fused cells were seeded 
at a density of 5x105 in 6 well plates and maintained at 37ºC for a maximum of 5 days 
before harvesting into TRIzol (Invitrogen). For antiviral drug experiments media was 
replaced 24hrs after fusion with drug-containing media at a range of concentrations. 
This was subsequently replenished 3 days post fusion. 
  
2.2.3.3 Cell Colouring  
Cells were typsinised, pelleted by centrifugation at 200xg and washed in 1XPBS. 
Working solutions of the cytoplasmic dyes were made by diluting the Cell trace violet 
(Invitrogen) and CMRA orange (Invitrogen) to 1μM and 10μM respectively. Cells were 
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then re-suspended in 1ml of the either dye working solution and incubated at 10mins 
at 37˚C. To assess staining intensity, cells were fixed in 4% paraformaldehyde for 
10mins at room temperature and then analysed by flow cytometry with a LSRII (Becton 
Dickenson) 
 
2.2.4 RNA Extraction 
RNA was extracted from capture fusion experiments using TRIzol reagent (Invitrogen) 
according to manufacturer’s protocols. 1ml of TRIzol was added to each well of a 6 
well plate and transferred into a 1.5ml eppendorf tube. To this 200µl of chloroform 
(Sigma) was added to and spun at 12,000xg for 15mins at 4ºC. The upper aqueous 
layer was removed into 0.5ml of isopropanol (Sigma) and incubated at room 
temperature to precipitate the RNA. This was re-spun at 12,000xg for 15mins at 4ºC 
before washing with 75% molecular grade ethanol (Sigma). A further spin was 
performed at 7500xg before re-suspension in 30-50µl of RNase free ddH20. All RNA 
was stored at -80ºC 
 
2.2.5 Quantitation of RNA by Ribogreen 
To determine accurate RNA concentrations for PCR all RNA from capture fusion was 
quantified using the Quant-IT RiboGreen assay (Invitrogen). 1ug of RNA was DNase 
treated in a 10µl reaction containing 10x buffer and 1U of DNase (Promega) at 37ºC 
for 30mins.  This was diluted 1:50 in 1XTE buffer and added in equal volume to the 
RiboGreen dye on a 96 well plate in duplicate and incubated for 5mins at room 
temperature. Fluorescence intensity at 485nm was recorded on a BMG FLUOstar 
optima plate reader. RNA concentrations were determined from a standard curve of 
known 16S RNA standard (Fig 2.1).  
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Fig 2.1 RiboGreen Standard Curve. 
To enable RNA quantification a set of known RNA concentrations was prepared with each RiboGreen 
assay. Each standard was run in duplicate 
 
2.2.6 Quantitative PCR  
HCV RNA copy number was quantified using a one-step reverse transcription qPCR 
with the QuantiTect Viral Nucleic Acid detection kit according to manufacturer’s 
instructions in 20µl reactions. Each reaction contained: 
Reagent Amount per 20µl Reaction 
5X QuantiTect virus master mix 4µl 
Primer/Probe mix  1µl 
QuantiTect Virus RT mix 0.2µl 
RNA template 50ng 
RNase/DNase-free ddH2O Volume to 20µl 
 
For HCV F/R Primer and HCV probe sequences see section 2.1.4. Each sample was 
run in triplicate with a standard curve of known amounts of in-vitro transcribed JFH-1 
RNA in every PCR run (Fig 2.2). PCR steps consisted of Reverse transcription 20mins 
50ºC, Hot-start activation step 95ºC 5mins, 40 cycles of denaturation 15secs at 95ºC 















and annealing/extension 45secs at 58ºC. PCR runs were performed on a Rotorgene 
6000 (Corbett Biosciences) 
 
Fig 2.2 HCV qPCR standard curve 
Standard curve generated by serial dilutions of JFH-1 RNA.  
  
2.2.7 cDNA Synthesis 
In a sterile RNase free 1.5ml eppendorf tube 1µg of DNase digested RNA was added 
to 0.5µg of random primers (Promega) in a volume of <14µl of water. This was heated 
to 70ºC for 5mins to melt any secondary structure within the RNA template. The tube 
was cooled to 4ºC immediately to prevent the secondary structure from reforming. To 
this mixture the following was added: M-MLV 5X Reaction buffer, dNTP 10mM mix 
(Final concentration 0.5mM/NTP), 200U M-MLV RT, Nuclease free water to a volume 
of 50µl. The reaction was incubated at 37ºC for 60mins after which cDNA yield was 
quantified. 
 
2.2.8 Quantification of mRNA expression by SYBR green qPCR 
Quantification of mRNA expression was performed using the QuantiTect- SYBR-
Green real time PCR system (Qiagen). cDNA was diluted to a concentration of 



































QuantiTect SYBR-Green PCR MasterMix 1μL forward and 1μL reverse primer (final 
concentration 0.5µM). Cycling conditions were: Hot-Start Activation: of 95̊ºC for 15 
minutes, followed by 35 cycles of denaturation of 94̊C for 15 sec, annealing at 58ºC 
for 30 sec and extension of 72ºC for 30 sec. Data acquisition was performed during 
the extension step. Melt curve analysis was performed to check quality of product and 
to exclude presence of primer-dimers from the analysis. Results were normalised to 
expression of 5S from the sample, and expressed as relative gene expression using 
the Pflaffl method (2-ΔΔCT). 
 
2.2.9 PCR amplification with High-fidelity polymerase 
For amplification of DNA where a high degree of accuracy is required such as 
molecular cloning a high-fidelity polymerase with proof reading activity was used. The 
Q5 polymerase system by NEB was used for all high-fidelity PCR reactions as it has 
an error rate 280 fold lower than Taq polymerase. Reactions with this polymerase 
contained 5X reaction buffer, a final concentration of 0.2mM dNTPs, 0.5µM forward 
and reverse primers, 5X GC enhancer and Q5 polymerase at 0.02U/µl. < 10ng of 
plasmid DNA was used as a template. Cycling conditions were based on Initial 
denaturation of 98ºC for 30 seconds 25-30 cycles of denaturation at 98ºC for 30 
seconds, primer annealing at 60ºC (optimised for primer set used) for 30 seconds and 






2.2.10  Agarose gel electrophoresis 
Agarose powder (1% w/v) was dissolved in 1XTAE buffer by heating in a microwave. 
Molten agarose was cooled to a safe temperature after which Ged-Red DNA dye 
10,000X (Biotium). The gel was poured into a cast with a comb and left to set at room 
temperature. After the gel had set it was immersed in 1XTAE with DNA samples 
loaded in 6X loading dye. Gels were run at 5V/cm to allow separation of the DNA 
bands visualised with a UV-trans-illuminator. A DNA ladder was run in parallel with 
samples so that DNA band size could be estimated.  
 
2.2.11 TA-Cloning into pGEMT 
2.2.11.1 PCR amplification  
PCR was carried out using the NEB Phusion DNA polymerase. Samples were 
prepared on ice and placed in a Bio-Rad thermocycler. Cycling conditions were an 
initial denaturation at 95ºC for 30 minutes. Amplification steps consisted of 30 cycles 
of denaturation at 95ºC for 15 seconds, primer annealing at 57-65ºC (depending on 
primer set used) for 30 seconds and extension at 72ºC for 30 seconds/kb of amplicon. 
A final primer extension was carried out at 72ºC for 2 minutes. Due to the proof reading 
activity of the high-fidelity Phusion polymerase a subsequent A-tailing step was 
performed using Go-Taq DNA polymerase (Promega). Reactions consisted of 5X Go-
taq buffer, 400µM dATP, 1.5mM MgC12 and 1.25U of Go-Taq polymerase in a total 
reaction volume of 50µl. The reaction as incubated at 70ºC for 30 minutes. The A-
tailed PCR product was purified using the QiaSpin PCR purification kit (Qiagen) before 
use in the ligation reaction.  Ligation reactions consisted of 2X Rapid ligation reaction 
buffer, 50ng of the pGEM-T easy vector and 3 units of T4 DNA ligase. The A-tailed 
PCR product was added to the reaction in a 3:1 molar ratio of insert to vector. 
 85 
Reactions were incubated for 1 hour at room temperature. Positive control DNA was 
provided by the supplier and a negative control that contained neither control nor PCR 
insert DNA was also used.  
 
2.2.11.2 Transformation of ligation reaction JM109 Chemically competent cells 
with blue white/screening 
5µl of the ligation reactions was added to chemically competent JM109 cells and 
incubated on ice for 30 minutes. The cells were heat shocked at 42ºC for 30 seconds 
to permeabilise the cells for the uptake of DNA and returned to ice. 250µl of sterile 
SOC medium was added to each transformation, which was subsequently incubated 
at 37ºC for 1 hour with agitation. The transformed cells were spread onto LB plates 
containing ampicillin (100µg/ml) supplemented with 0.1mM IPTG and 1mg/ml X-Gal 
and left overnight at 37ºC. White colonies were picked, inoculated into fresh LB media 
containing ampicillin (100µg/ml) and the plasmid DNA was extracted by mini-prep for 
sequencing to confirm the successful cloning of the desired fragments into the pGEM-
T vector.  
 
2.2.11.3 Preparation of plasmid DNA 
Overnight cultures of E. coli were grown in LB broth with an appropriate selective 
antibiotic. Plasmid DNA was extracted using a QIAprep® Mini-prep kit (Qiagen). The 
overnight culture was centrifuged at 3,000xg and re-suspended in 250µl of buffer P1 
(with RNase added). 250µl of buffer P2 was then added to lyse the cells and was 
neutralised after 3-5 minutes by the addition of 350µl of buffer N3. The solution was 
centrifuged at ~17,500xg for 10 minutes to pellet cell debris from the lysis reaction. 
The supernatant was added to a QIAprep spin column and centrifuged at ~17,500xg 
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for 1 minute and the flow through discarded. Two wash steps then occurred with 
buffers PB and PE, discarding the flow through each time. An extra spin was 
performed with the PE wash to remove any residual traces of ethanol. 50µl of 
molecular grade water was added to the centre of the QIAprep spin column filter and 
spun at ~17,500xg for 1 minute to elute the plasmid DNA.  
 
2.2.11.4 Restriction digestion 
5µg of plasmid was digested in 50µl reaction containing 10X cut-smart buffer, 20U 
restriction enzyme and water to 50µl. The reaction was incubated overnight at 37ºC. 
The resulting digest was separated on a 1% agarose TAE gel and purified using the 
Qiaspin Agarose gel extraction kit (QIAGEN) according to manufacturer’s protocol.  
 
2.2.11.5 Dephosphorylation of plasmid vectors 
Digested plasmid vectors typically will possess a 5’ phosphate group that may cause 
the vector to self-ligate. To prevent this and minimise any background activity of the 
cloning process the 5’ phosphate was removed before ligation. 1µg of the digested 
vector was dephosphorylated in a 20µl reaction containing 10x rAPid alkaline 
phosphatase buffer and 1U of alkaline phosphatase enzyme (Roche). The reaction 
was incubated at 37ºC for 10min before inactivation at 72ºC for 2min.  
 
2.2.11.6 Ligation of DNA fragments into plasmid vectors 
The purified digested DNA fragment was ligated into the dephosphorylated vector at 
a insert:vector ratio of 3:1. Vector and insert were diluted in a 5X DNA dilution buffer 
and added to the ligation reaction containing 2X ligation buffer and 5U of T4 DNA 
ligase (Roche). The reaction was incubated for 5min at room temperature before 
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transformation into JM109 cells. Optimum colony numbers were however observed at 
an overnight incubation at 16ºC.  
 
2.2.12 Generation of chemically competent XL-10 gold cells 
XL10 gold cells were streaked from frozen glycerol stock onto an LB agar plate 
supplemented with tetracycline and incubated overnight at 37˚C for 16hrs. Colonies 
were picked into 10ml of LB and incubated overnight at 37˚C with shaking. The 
overnight culture was then used to inoculate a larger 500ml culture, which was grown 
throughout the day until an optical density at 600nm between 0.4 and 0.9 was reached. 
At this point cultures were transferred to 50ml falcon tubes and chilled on ice for 
20mins before centrifugation at 3800x g for 20mins at 4˚C. Pellets were re-suspended 
in 0.8ml of RF1 (see 2.1.2) after which the volume was made up to 20ml with RF1 and 
incubated on ice for 10min. Cells were pelleted by centrifugation at 1000xg for 20mins, 
combined into one 50ml falcon tube and incubated on ice for a further 15mins in 20mls 
of RF2. Cells were aliquoted into sterile eppendorf tubes and left on ice for 2hrs. After 
incubation cells were snap frozen in liquid nitrogen and stored at -80˚C until needed.  
 
2.2.13 Transformation of XL-10 Gold competent cells 
Up to 50ng of DNA/5µl of a ligation reaction were added to a 25µl aliquot of frozen 
cells. This was incubated for 20mins on ice before heat shocking at 42ºC for 45 
seconds. Cells were incubated on ice for 2 mins and recovered in 250µl of XL-10 
recovery media and incubated at 37ºC for 1hr. Transformed cells were then streaked 
on LB agar with appropriate selection media and incubated at 37ºC for 16hrs to so that 
transformed colonies could growth through selection.  
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2.2.14  PCR based, Site directed mutagenesis of the S52-(SHI)-SG replicon 
construct        
To incorporated mutations into the NS5B of the G3-S52-Subgenomic replicon an 
overlapping PCR mutagenesis technique was employed using PCR primers 
containing the desired mutation. This process requires two steps; first the generation 
of two overlapping fragments with primers containing the mutation of interested, the 
second step is then the creation of the full-length insert with the mutation by denaturing 
and then annealing the overlapping fragments. This insert was then cloned into the 
S52-replicon by restriction digestion and ligation. Steps involved in this process are 
described graphically in Fig 2.3.  
 
Fig 2.3 Schematic of PCR mutagenesis 
Mutagenic primers encoding the mutation to be introduced were used to generate two overlapping PCR 
fragments, subsequently used in a second PCR reaction to generate the full length insert. Outer primers 
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used to generate this insert included XbaI and XhoI restriction sites allowing it to be cloned back into 
complementary sites in the replicon.   
 
For each mutation, two first round fragments were generated using the Q5 high-fidelity 
polymerase using a combination of the S52-5B-XhoI forward and mutagenic reverse 
primer and mutagenic forward and S52-5B-XbaI-Rreverse primer (See 2.1.7). 
Reactions were set up containing a final concentration of 0.2mM dNTPs, 0.5µM of 
each forward and reverse primer, G/C enhancer (5µl/25µl reaction), 5X Q5 reaction 
buffer and 10 units of Q5 polymerase. 10ng of the S52-SG replicon plasmid was used 
as a template. Cycling conditions were carried out as follows: initial denaturation of 
98ºC for 30 seconds and 30 cycles of denaturation at 98ºC for 30 seconds, primer 
annealing at 58ºC for 30 seconds and extension at 72ºC for 30 seconds/kb of 
amplicon. A final primer extension was carried out at 72ºC for 2 minutes.  
 
To generate a full-length insert with the engineered mutation purified fragments were 
used in a second-round reaction with both the S52-XhoI-forward and S52-XbaI reverse 
primers. Before the primers were added, an initial 4 rounds of cycling were carried out 
containing the reaction mix as above as well as both fragments in an equimolar ratio. 
The overlapping regions of both fragments would anneal and extend to the end of the 
fragment generating a small amount of the full-length amplicon. The S52-XhoI-forward 
and S52-XbaI reverse primers were then added to the reaction to amplify the insert. 
Cycling conditions for the entire reaction were as follows: Initial denaturation of 98ºC 
for 30 seconds 4 cycles of denaturation at 98ºC for 30 seconds, primer annealing at 
60ºC for 30 seconds and extension at 72ºC for 1 minute. The reaction paused as the 
primers were added and then a further 29 cycles of 98ºC for 30 seconds, 58ºC for 30 
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seconds and extension at 72ºC for 2 minutes, ending with a final extension of 72ºC for 
5mins.  
 
The full-length insert containing the mutation was digested with XbaI and XhoI and 
ligated into the pre-digested S52-replicon plasmid. Colonies containing successful 
recombinants were obtained by transformation of chemically competent XL-10 gold 
cells as above.  
 
2.2.15 Site directed mutagenesis of the DBN3acc construct 
Nucleotide changes were introduced into the genotype 3 DBN3acc infectious clone 
using the Quick-Change II XL site-directed-mutagenesis kit (Agilent) according to 
manufacturers instructions. Reactions consisted of 10x reaction buffer, 10ng of 
plasmid template, 125ng of each mutagenesis primer (see2.1.7), 1µl of Agilent dNTP 
mix, 3µl of Quick solution, 2.5U of PfuUltra HF DNA polymerase and water to a volume 
of 50µl. Cycling conditions were 95ºC for 1min followed by 18 cycles of 95ºC for 
50secs, 60ºC for 50secs, 68ºC for 1min/kb of plasmid length and a final extension of 
68ºC for 7mins. 10U of DpnI was added to reaction and incubated for 1hr at 37ºC to 
digest the parental DNA template after which 5µl of the reaction was transformed into 
the XL-10 Ultracompetant cells as above. Colonies were screened for mutagenesis by 
Sanger sequencing (Source Bioscience, Cambridge).  
 
2.2.16 In vitro transcription  
Replicon plasmids were linearised by restriction digestion with XbaI for 3hrs at 37ºC.  
Reaction volume was then made up to 300µl with ddH20 to which 1 volume of 
Phenol:Chloroform pH 8 was added. Samples were inverted at least 6 times and 
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centrifuged at >15,000xg for 3mins at 4ºC. The upper aqueous layer was removed to 
a fresh eppendorf tube to which 1 volume of chloroform was added, which was then 
re-centrifuged as above. The upper aqueous layer from the chloroform spin was 
removed, placed in a new tube and precipitated by the addition of 0.3M sodium acetate 
(final concentration) and 2.5 volumes of ice-cold ethanol. To achieve maximum 
precipitation samples were incubated at -20ºC for at least 1hr. The overhang from the 
XbaI was cleaved by digestion with Mung bean nuclease. 1ug of purified DNA was 
incubated at 30ºC for 30 minutes in a reaction containing 10 units of nuclease and 10X 
reaction buffer. DNA was then re-purified as above.  
 
In vitro transcription of replicon RNA was performed by use of the T7-Megascript kit 
(Ambion). Reactions were prepared at room temperature to prevent precipitation of 
the spermidine in the 10X reaction buffer. Each 20µl reaction contained 2µl of ATP, 
GTP, CTP UTP, 2µL of 10X reaction buffer, 1µg of linearised template DNA and water 
to make up the volume to 20µl. Reactions were incubated at 37ºC for 3hrs after which 
they were stopped by the addition of 115µl of DEPC-treated water and 15µl of 
ammonium acetate stop solution. RNA was then extracted by addition of an equal 
volume of acidic phenol:chloroform, followed by chloroform. RNA was precipitated 
from the subsequent aqueous layer by the addition of 1 volume of isopropanol followed 
by chilling at -20ºC for at least 1 hr. RNA was pelleted by centrifugation at 16,000xg 
for 15mins, quantified by nanodrop and stored at -80ºC in 10µg aliquots.   
 
2.2.17 Electroporation of HCV replicon constructs 
For electroporation, cells were washed X2 with ice cold PBS and diluted to a 
concentration of 5x106 cells/ml. 5µg of purified RNA was mixed with 400μl of the cell 
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suspension and electroporated using a BioRad Genepulser II on the exponential 
setting (pulse settings: 250V and 950µF). For antiviral drug assays, cells were 
transferred to complete medium and seeded into 96 well plates at a density of 5x103 
cells/well and left to recover for 24hrs. Antiviral drugs were added for 72hrs after which 
cells were lysed in 1Xpassive lysis buffer in a volume appropriate to the size of culture 
dish they were seeded in. Lysates were added to an opaque white 96well luciferase 
plate with the luciferase substrate (promega) added in a 3:1 ratio. Luminescence was 





2.2.18 Transfection of DBN replicon construct to generate infectious G3 virus 
Transfection of the DBN3acc construct and generation of Genotype 3 infectious HCV 
Huh7.5-SEC14L2 cells were seeded in a 6 well plate at a density of 4.2x105 cells/well 
24hrs before transfection. For transfection 3.75µl of Lipofectamine 3000 was diluted 
in 125µl of OptiMEM and 5µg of DBN3acc RNA was diluted in 250µl of OptiMEM. Both 
mixes were incubated at room temperature for 5mins before combining after which the 
reaction mixture was incubated for a further 20mins at room temperature and then 
added drop wise to the cells. Cells were washed once with PBS before transfection 
and placed in 2ml of OptiMEM for at least 20mins before transfection. After 24hrs cells 
were placed in DMEM 10% FCS and expanded into T25 then T75cm2 flasks. At 7 days 
post transfection a sample of transfected cells were seeded on to coverslips to assess 
presence of HCV replication complexes by NS5A immunofluorescence (see 2.2.21). 
Once >50% of cells were deemed to be positive for HCV, supernatants from the 
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transfected cells were filter-sterilised using a 0.45µm syringe filter, aliquoted and 
stored at -80ºC.  
 
2.2.19 Focus Forming assay to titre cell culture derived HCV 
Huh7.5-SEC14L2 cells were seeded in 96 well plates at a density of 3x103 cells/well. 
After 24hrs cells were exposed to 1:3 serial dilutions of supernatants from cells 
transfected with the DBN3acc virus. Cells were then incubated for a further 4 days and 
then washed in 1XPBS before fixation in ice-cold methanol. To visualise HCV foci, 
wells were blocked in PBS 3%FCS for 30mins and then incubated with sheep anti-
NS5A (kind donation from Mark Harris) diluted at 1:1000 for 1hr at room temperature. 
Unbound primary antibody was removed by 3 washes with 1XPBS before incubation 
with AlexaFlour 488 donkey anti-sheep secondary antibody diluted to 1:1000 for 1hr 
at room temperature. Wells were then incubated with DAPI (1:1000) for nucleus 
visualisation. 
 
2.2.20 Quantification of HCV Foci using a INCELL automated microscope 
Huh7.5-SEC14L2 cells were infected, maintained and stained as above for a focus-
forming assay. After secondary antibody incubation cells were stained with a 
1:100,000 dilution of HCS Cell Mask Deep Red Stain (Invitrogen), which uniformly 
stains the cell plasma membrane for 1.5hrs. HCV foci were then quantified using a GE 
High throughput INCA2200 automated microscope with 9 fields taken per well using a 
X20 objective. Images were analysed using the high content analysis software 
Developer toolbox (GE, Version 1.9.2). Raw images were processed to define nuclear 
and cytoplasmic borders based on DAPI and cell mask staining. Acceptance criteria 
for NS5A foci included size and pixel intensity. Targets were linked to quantify 
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nucleated cells containing foci. Workflow is described in Fig 2.4. 
 
Fig 2.4 Quantification of HCV foci by the INCELL automated microscope 
(A) Raw images taken before processing showing NS5A staining as well as nuclear and cell membrane 
staining. (B) Pre-processing of each image to define the nuclear and cell border. Acceptance criteria 











Nuclear, foci and cell mask images were linked to quantify the number of nucleated cells containing foci 
per field and then per well.  
 
 
2.2.21 Indirect immunofluorescence 
Cells were plated on coverslips and fixed with 4% paraformaldehyde for 20mins. The 
cells were permeabilised in PBS 0.25% (v/v) Triton-X then non-specific binding was 
blocked by incubation in PBS/3% BSA. Coverslips were incubated with the primary 
antibody for 1hr at room temp, before washing and then further incubating with an 
appropriate secondary fluorescent antibody for 1hr. Coverslips were counterstained 
with 4’,6-diamidino-2-phenylindole and mounted with Prolong Gold (Invitrogen). Slides 
were viewed on a Leica MM fluorescence microscope (Leica Microsystems, Milton 
Keynes, UK). 
 
2.2.22 Plasmid Transfection 
Cells were seeded in 6 well plates at a density of 1x105 cells/well and incubated 
overnight at 37ºC. Transfection mixes containing plasmid and Lipofectamine 3000 
(Invitrogen) were prepared including a mock transfection control. 3µl of Lipofectamine 
was first diluted in 125µl Opti-MEM and incubated for 5mins at room temperature (tube 
A). In a separate tube 1µg of plasmid was also diluted in 125µl of Opti-MEM 
supplemented with 3µl of P3000 (tube B). Tubes A and B were combined and 
incubated for a further 20 mins at room temperature. The ratio of Lipofectamine:DNA 
was 3:1. The mixture along with a mock transfection control was added drop wise 
directly to the plated cells and incubated overnight at 37ºC. After 24hrs media was 





2.2.23 Lentiviral preparation and transduction 
293FT cells were seeded in a 10cm plate so that they would be 50% confluent on the 
day of transfection. Plasmid mix containing 8μg of the pTRIP-VSVG plasmid, 2μg of 
the pMLV gag/pol plasmid and 0.15μg of the pVSVG envelope plasmid was added to 
25μl Fugene diluted in 500μl of Optimem. The transfection mix was incubated at room 
temperature for 45mins and then added drop wise on to the cells. Lentiviral 
supernatants were harvested at 24 and 48hrs. These were centrifuged at 3000xg for 
10mins to remove cell debris, passed through a 0.45μm filter and stored at -80˚C.  
 
2.2.24 Protein extraction  
Cells were washed with PBS, trypsinised and pelleted by centrifugation at 200xg. Cell 
pellets were resuspended in RIPA buffer supplemented with 1XHALT protease and 
phosphatase inhibitor cocktail (Invitrogen) and incubated on ice for 30mins. Protein 
samples were then centrifuged for 30mins at 16,000xg at 4˚C to pellet DNA and 
nuclear debris. Supernatants containing protein were stored at -20˚C until used. 
 
2.2.25 Protein Quantification by bicinchoninic (BCA) assay 
Copper II Sulphate was diluted 1:50 with the BCA reagent and 200µl aliquoted on a 
clear flat bottom 96-well plate. To this 5µl of protein sample or standard were added 
and the plate incubated at 37ºC to catalyse the colour change to purple. This colour 
change is based on the reduction of Cu+2 to Cu+1 by protein in an alkaline environment. 
The chelation of two BCA molecules with one Cu+1 forms the purple colour, which 
 97 
exhibits a strong absorbance at 562nm. Protein concentrations were determined with 
reference to a standard curve derived from serial dilutions of known concentrations of 
bovine serum albumin.  
 
2.2.26 Western Blotting 
Protein samples were separated by SDS-PAGE using a NuPAGE Novex 4-12% Bis-
Tris Protein Gels at 200V. A protein size marker was included in every run (Amersham-
Full rage molecular weight marker). After electrophoresis the stacking gel was 
removed and the running gel was rinsed in protein transfer buffer. A sheet of 
nitrocellulose membrane (BioRad) was cut to size and then incubated briefly in transfer 
buffer. The NuPage transfer cassette was assembled and the transfer process is 
carried out at 25V for an hour. Following transfer, the membrane was removed and 
rinsed briefly in blocking solution (see section 2.1.1). Non-specific binding sites were 
blocked by immersing the membrane in 1XTBS supplemented with 5% (w/v) non-fat-
dry-milk for 1hr at room temperature. Primary antibody was diluted in blocking solution 
and incubated on the membrane overnight at 4ºC. Membranes were washed with 
TBST for 4x5mins and then incubated with an HRP secondary antibody diluted in 
blocking solution (supplemented with IGEPAL final concentration of 0.1%). A final 
wash step was performed and blots left in wash buffer for 1hr before detection of 
protein bands with ECL (Amersham). After 5min incubation in ECL, the membrane 
was wrapped in clingfilm and exposed to a sheet of autoradiography film (Amersham) 





2.2.27 Next-generation sequencing of HCV genomes 
Full HCV genome sequencing was performed by the University of Glasgow Centre for 
Virology research using a Metagenomic-Illumia RNA-seq method of total plasma RNA 
as previously described (Thomson et al., 2016). 
 
2.2.28  Interferon Stimulated Response Element Luciferase assay 
Cells were seeded onto a 96well plate at a density of 5x103 cells/well. The luciferase 
reporter plasmid pGL4.45 was mixed 2:1 with the Nanoluc expression plasmid 
pNL1.1(see 2.1.11) as a transfection control in a volume of 10µl of OptiMEM. Plasmid 
mixes were then combined with Lipofectamine 3000 in a ratio of 3:1 and allowed to 
complex at room temperature for 5mins. The transfection mix was added to the cells 
so that the final amount of plasmid per well was 150ng of pGL4.45 and 75ng of pNL1.1. 
After 16hrs cells were incubated with 10-1000IU/ml of IFNa-2A for a further 24hrs after 
which cells were lysed in 1X passive lysis buffer. Firefly luciferase corresponding to 
the ISRE reporter was measured as before. To account for transfection efficiency, 
nanoluciferase was measured using the Nanoglo luciferase kit (Promega) according 









3 RESULTS: Optimisation of Methods to Study Patient Derived HCV 
One of the challenges HCV researchers face is the inability to effectively propagate 
clinical virus in vitro. In the face of constant development of HCV direct acting anti-
viral (DAA) treatment, relapse to treatment is becoming increasingly infrequent, yet 
endures, particularly with genotype 3 (G3) infection. The reasons for the increased 
relapse rates in G3 remain unsolved and study of clinical samples derived from 
patients who have relapsed may help to clarify why this genotype remains refractory 
to DAA therapy. Recent studies such as the discovery of SEC14L2 and the use of 
stem cell derived hepatocyte like cells have helped to unravel key host factors that 
hepatocyte cell lines such as Huh7.5 may lack to enable patient derived HCV to 
replicate in cell culture (Sa-ngiamsuntorn et al., 2016a; Saeed et al., 2015; Schwartz 
et al., 2012). However, despite these advances propagation of patient derived hepatitis 
C virus remains problematic, hampering a full understanding of factors that influence 
treatment response. The capture fusion assay developed by our group is an 
established method, which can determine sensitivity of clinical HCV isolates to a range 
of antiviral drugs (Cunningham et al., 2014; Jones et al., 2017). The assay itself is a 
labour intensive, complex procedure with its key component consisting of fusion 
between viral infected THP-1 cells and Huh7.5 by treatment with polyethylene glycol 
(PEG). PEG fusion is an intricate technique causing high levels of cell toxicity resulting 
in a sufficient but relatively low frequency of hybridoma formation (Golestani et al., 
2007; Lovy et al., 2012; Schneiderman et al., 1979). To this end we conducted 
experiments to assess whether the PEG fusion technique could be either enhanced 
or replaced to increase the efficiency of fusion formation between THP-1 and Huh7.5 
cells. We established a simple FACS based assay to provide an indication of the level 
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of cell fusion, which permitted a range of different conditions to be rapidly assessed. 
Our strategy was to identify potential improvements to the assay and then confirm 
them in formal assessments of viral replication from clinical isolates.  
 
The recent publication by Saeed and colleagues uncovered SEC14L2 as a key host 
factor that could permit limited replication of patient-derived HCV when over expressed 
in Huh7.5 cells (Saeed et al., 2015; Witteveldt et al., 2016). Given the potential value 
of cell lines expressing this protein to enhance our understanding of HCV replication 
we assessed the potential of SEC14L2 expressing cell lines to allow replication of 
patient derived viral isolates and compared their ability to determine sensitivity to 
antivirals to that of the capture fusion assay. The aim of these experiments was to 
establish whether SEC14L2 expressing cells were a sufficient model system for HCV 
replication in isolation or if they could be incorporated into the capture fusion model.   
 
3.1 Determining the level of cell fusion in the capture fusion assay 
3.1.1  FACS analysis of fused cells 
Previous studies of PEG mediated cell fusion used FACS based assays to determine 
levels of fusion between two cell populations by staining each with a different 
fluorescent dye (Hoffman et al., 2017; Li et al., 2014). Here we sought to establish a 
FACS assay to measure the efficiency of PEG cell fusion between THP-1 and 
Huh7.5’s. PEG fusion between two cells types amalgamates the cytoplasmic 
membranes between the cells to form a multi-nucleated heterokaryon from both cells 
[Reviewed in (Lentz & Lee, 1999)]. Therefore, staining the two cell types with distinct 
cytoplasmic dyes and then performing PEG fusion should allow the detection of fused 
cells that share dual fluorescence for each cytoplasmic dye.  
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Stimulated THP-1 and Huh7.5 cells were coloured with Cell-Trace-Violet and CMRA 
orange respectively before fusion. Subsequent FACS analysis of the stained THP-1 
and Huh7.5 cell populations revealed that the cytoplasmic dyes achieved discrete 
staining of the THP-1 and Huh7.5 cell populations when compared to the non-stained 
control (Representative examples are shown in Fig 3.1 A-D). Stained THP-1 and 
Huh7.5 cells were then fused by PEG and analysed by FACS to determine the 
proportion of cells that had dual fluorescence (Fig 3.1 H). To account for any 
background in dual fluorescence caused by adherence between the THP-1 and 
Huh7.5 cells, a non-PEG treated fusion control was also included (Fig 3.1 G). FACS 
analysis of fusion control showed the Huh7.5 and THP-1 cells as distinct populations. 
In non-treated cells around 6% of the total cell population were found to contain dual 
fluorescence (Fig 3.1 G). When the cells were treated with PEG the percentage of 
cells with dual florescence rose to approximately 13% (Fig 3.1 H). Statistical analysis 
of 4 independent fusion experiments revealed that this increase in dual fluorescence 
was significant in cells treated with PEG compared to the non-PEG control (Fig 3.1 J).  
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Fig 3.1 FACS analysis of Capture Fusion 
FACS plots of THP-1 and Huh7.5 cells stained with Cell Trace Violet (B) and CMRA Orange (D) 
cytoplasmic dyes. Non-coloured cell populations were included as controls (A, C, E, F). To assess the 
levels of fusion coloured THP-1 and Huh7.5 cells were fused with PEG and analysed by FACS for dual 
fluorescence (H). The oval gate in the upper right quadrant defines cells as fluorescent for both dyes. 
A fusion control was included by co-culturing coloured THP-1 and Huh7.5 cells without exposure to 
PEG to account for dual fluorescence caused by adherence between the two cell types (G). The plots 






























































and PEG fusion with this assay revealed a significant increase in dual fluorescence with PEG fused 
cells. Statistical analysis was performed using a Man-Whitney U test (J). 
3.1.2 Analysis of Fusion by immunofluorescence 
To demonstrate that PEG resulted in fusion events between Huh7.5 and THP-1 cells 
we sought to visualise fused cells by fluorescent microscopy. An alternative staining 
strategy to that used in the FACS experiments was employed due to difficulties 
encountered detecting the cell-trace violet stain with the fluorescent microscope. THP-
1 cells were stained with CMRA orange before fusion to Huh7.5 cells, while Huh7.5 
cells were stained by immunofluorescence for the liver specific protein albumin post-
fusion. Examination of the PEG fused cells revealed multinucleated cells with orange 
staining in the cytoplasm likely due to amalgamation of the two cytoplasmic 
membranes characteristic of PEG fusion (Fig 3.2). This staining pattern was not 
observed in the fusion control however the THP-1 cells were seen to be in close 
proximity to the Huh7.5 cells indicating that these cells adhere to one another when 
co-cultured in the absence of PEG. The direct immunofluorescence experiments 
confirmed the results from the FACS experiments that cell fusion is relatively 
uncommon but given the complexity of this technique we continued to use the FACS 




Fig 3.2 Immunofluorescence of PEG fusion 
THP-1 cells were stained with CMRA orange before PEG fusion to Huh7.5 cells. A non-PEG treated 
control for fusion was also included. Cells were left to recover for 24hrs post-fusion and then fixed in 
4% PFA. Huh7.5 cells were then stained for the liver specific protein albumin by an anti-albumin 
monoclonal antibody and all cells were counter stained with DAPI. Red arrows indicate fused cells. 
Representative images were taken by a Leica DM5000 fluorescent microscope.   
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PEG-fusion between THP-1 and Huh7.5 cells is critical for replication of patient-
derived HCV in the capture fusion assay (Cunningham et al., 2014). These 
experiments illustrate that the efficiency of PEG fusion between THP-1 and Huh7.5 
cells is low. The FACS based assay employed here allows an estimation of the degree 
of fusion between THP-1 and Huh7.5 cells despite the presence of cell to cell 
adherence between THP-1 and Huh7.5 cells, as evidenced by the non-PEG-treated 
fusion control and fluorescent microscopy images. Including a no fusion control when 
using this assay to account for the level of cell-to-cell adherence between THP-1 and 
Huh7.5 cells is therefore essential to obtaining a more precise assessment of the level 
of PEG-fusion.  
 
3.2 Improving PEG fusion using a Biotin-Streptavidin-Biotin Bridge. 
A recent study claimed to improve the rate of PEG-mediated fusion by creating a 
Biotin-Streptavidin-Biotin (BSB) bridge between cells before fusion, (Li et al., 2014). 
The principle of the method is to coat both cell types with biotin; one of the cell types 
is then further treated with streptavidin (SA), which will covalently bind to the biotin 
coating the cell’s surface. The biotin-SA coated cells then act like ‘hooks’ to form a 
biotin-SA-biotin bridge with the other cell type, treated with biotin only, to bring both 
cell types within close proximity enhancing PEG fusion.   
 
This method was applied to the capture fusion assay. THP-1 and Huh7.5 cells were 
treated with biotin before PEG fusion, with the Huh7.5 cells being further treated with 
SA to form the biotin-SA ‘hook’. Cells were then combined to allow the formation of 
the biotin-SA-biotin-bridge between the Huh7.5 and THP-1 cells and then fused as 
before with PEG.  
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Fig 3.3 PEG fusion with Biotin-Streptavidin-Biotin Bridge 
(A) FACS analysis of THP-1/Huh7.5 PEG fusion either with or without Biotin-SA-Biotin (BSB) bridge 
formation. THP-1 (Cell-trace Violet) and Huh7.5 (CMRA-orange) cells were first coated with biotin; 
Huh7.5 cells were further treated with Streptavidin before being incubated with biotin-treated THP-1 
cells. PEG fusion was performed as before and cells analysed by FACS. Background non-fused double 
positive cells were accounted for by a non-fused co-culture control. Representative FACS plots are 
shown. (B) Comparison of PEG fusion +/-Biotin-SA-Biotin bridge in PEG fusion. 5 PEG fusions 
performed without BSB bridge formation was compared to 5 fusions with the BSB bridge. Values 
obtained from the fusion control were deducted from the values obtained for PEG fusion to account for 


















































































































































































FACS analysis of PEG fusion with the BSB-bridge revealed no improvement in the 
degree of cell fusion, in fact presence of the BSB-bridge appeared to cause a reduction 
in the percentage of fused cells compared to fusion in the absence of the bridge (Fig 
3.3B). Though this reduction was not significant (p=0.095) this method does not 
appear to have a beneficial effect on fusion between THP-1 and Huh7.5 cells. Only a 
slight increase in dual positivity (fused cells) was observed in the FACS plot indicating 
that the BSB Bridge was having a minimal effect on increasing cell adherence between 
THP-1 and Huh7.5 cells. As the BSB-bridge did not appear to enhance THP-1/Huh7.5 
cell fusion alternative approaches were examined.   
 
3.3 pH Dependent Cell Fusion Using Viral Fusion Proteins  
Entry of enveloped viruses into cells often involves fusion of the viral and cellular 
membrane by viral proteins with fusogenic properties [Reviewed in (Podbilewicz, 
2014)]. These proteins undergo conformational changes when confronting various 
cellular environments such as a low pH, exposing hydrophobic fusion peptides and 
fusion loops causing membrane destabilisation and fusion (Harrison, 2008). The 
properties of viral fusion proteins can be utilised to cause fusion between cells in in 
vitro models, a notable example being the treatment of cells with inactivated Sendai-
virus which causes cell fusion via the fusogenic-F protein (Okada, 1993).      
 
Gottesman and colleagues published a method of cell fusion which exploited the pH 
sensitive fusion properties of the G protein from the Vesicular Stomatitis Virus (VSVG) 
(Gottesman et al., 2010). The method relied upon stable expression of VSVG in 
human fibroblasts, which resulted in cell fusion as observed by time-lapse microscopy. 
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We speculated that VSVG expression on Huh7.5 cells might facilitate a better method 
of cell fusion in the HCV capture fusion assay.  
 
3.3.1 Lentiviral transduction of Huh7.5  
Lentiviral constructs expressing VSVG with a GFP tag (pHeGFP-VSVG) were donated 
by Y. Lazebnik, Cold Spring Harbour Laboratories. To ascertain the lentiviral titre 
Huh7.5 cells were transduced with a range of lentiviral dilutions and then assayed for 
GFP fluorescence by FACS (Fig 3.4A). Transduction with un-diluted lentivirus 
achieved 100% GFP positivity in Huh7.5 cells, which decreased with increasing 
dilutions of the virus. To achieve a population of cells stably expressing VSVG, Huh7.5 
cells were re-transduced with an MOI of 1 and cell sorted into a GFP positive 
population (Fig 3.4C). The cell-sorted population was placed under puromycin 
selection with resistant Huh7.5 colonies observed after 2 weeks of antibiotic selection. 
Colonies were grown to confluency at which point a sample was taken for RNA 
extraction. Expression of the VSVG construct was examined in the cDNA by PCR, 
however no band corresponding to size of VSVG was observed in the cDNA from the 





Fig 3.4 Huh7.5 transduction with pHeGFP-VSVG lentivirus 
(A) Huh7.5 cells were transduced with a 1:2 serial dilution series of the pHeGFP-VSVG lentivirus to 
establish a titre. After 48 hrs cells were assessed for GFP positivity by FACS. Lentiviral titre was 
determined to be 1.03x10^6 transducing units/ml. The FACS plot is representative of 2 independent 
experiments (B) Transduced Huh7.5 cells were cell sorted for GFP and placed under puromycin 
selection. (C) Puromycin resistant colonies were assessed for VSVG expression by PCR. The proviral 
pHeGFP-VSVG plasmid containing the 1.5 Kb VSVG gene was used as a positive control in the PCR 
reaction. The above is a representative example from 3 independent transductions.    
 
Transduction of the Huh7.5 cells with the pHeGFP-VSVG construct was repeated 
thrice with the same outcome. It was postulated that the Lentiviral vector used in these 
experiments was unable to express VSVG despite conferring puromycin resistance. 






































gene under control of a PGK promoter while VSVG expression was driven by IRES. It 
is possible that the IRES driven VSVG expression is impaired in some way in the 
Huh7.5 cells despite being previously used to express VSVG in human fibroblasts 
(Gottesman et al., 2010). It was therefore decided to re-clone VSVG into the pTRIP 
lentiviral system that had been previously used to transduced Huh7.5 cells to create a 
fluorescence based HCV cell reporter assay (Jones et al., 2010).  
 
3.3.2 Cloning of VSVG into the pTRIP lentiviral vector 
The RFP-NLS-IPS cassette was first excised from the pTRIP plasmid by restriction 
digestion with XhoI and XbaI (Fig 3.5A). The 1.5kb VSVG gene was then amplified by 
PCR with XhoI and XbaI restriction sites designed into the forward and reverse primers 
respectively to ensure the gene was cloned into the pTRIP vector in the correct 
orientation (Fig 3.5B). Transformed pTRIP colonies were screened for the presence 
of VSVG by PCR and restriction digestion with XbaI/XhoI. A 1.5Kb product consistent 
with the size of VSVG was observed in both restriction digestion and PCR of the 
pTRIP-VSVG plasmid (Fig 3.5C, D). Orientation of the VSVG gene as well as the start 
codon was validated by sanger sequencing. 
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Fig 3.5 Cloning of VSVG into the pTRIP vector 
(A) The pTRIP vector was digested with XbaI and XhoI to remove the 1Kb HCV fluorescence reporter 
cassette from the plasmid backbone. (B) VSVG was amplified by PCR from a lentiviral pVSVG envelope 
plasmid with complementary XbaI/XhoI restriction sites allowing the gene to be directionally cloned into 
the pTRIP backbone. (C) Resulting colonies were shown to contain a 1.5Kb band consistent with the 
















































































confirmed by PCR. The pVSVG used as the initial template for VSVG was included as a positive control. 
The original pTRIP plasmid was also included as a negative control. 
 
3.3.3 pTRIP-VSVG lentiviral transductions 
The pTRIP-VSVG was used to make lentiviral particles for subsequent transduction 
into Huh7.5 cells. As an additional control to test the viability of the lentivirus a sample 
of the 293FT cells used to make the pTRIP-VSVG lentivirus was also transduced. RNA 
and protein samples were taken 48 hours post-transduction to establish VSVG 
expression. Immunoblot analysis of protein extracted from transduced Huh7.5 
confirmed VSVG expression (Fig 3.6). A 56 KDa protein band consistent with the size 
of VSVG was observed in cell lines transduced with this lentivirus.  
 
 
Fig 3.6 Transduction of Huh7.5, THP-1 and 293FT with pTRIP-VSVG  
VSVG expression in transduced Huh7.5 and 293FT cells was assessed by immunoblotting, with bands 
consistent with the size of VSVG observed in cells transduced with the pTRIP-VSVG lentivirus 





































































Huh7.5-VSVG cells were then tested for the ability to fuse cells when exposed to an 
acidic pH as shown in (Gottesman et al., 2010).  THP-1 cells and Huh7.5-VSVG cells 
were stained with violet and orange cytoplasmic dyes respectively (Fig 3.7A, B). Both 
cell lines were co-cultured and briefly exposed to an acidic buffer to induce the 
fusogenic property of VSVG. After a 24-hour recovery period cells were analysed by 
FACS as before for the presence of fused cells with dual fluorescence. No noticeable 
increase in double positive cells was observed between THP-1/Huh7.5-VSVG cells 
treated with an acidic buffer (6.2%) (Fig 3.7D) compared to the non-treated control 
(6.09%) (Fig 3.7C). Cell fusion with the Huh7.5-VSVG cells was compared to PEG 
fusion of Huh7.5 and THP-1 cells. FACS analysis of the two fusion methods revealed 
that PEG fusion caused a 2-fold increase in double positive cells whereas comparable 
levels of double positive cells were observed between VSVG fusion and the no-fusion 
control (Fig 3.7E). These experiments indicate that while VSVG is expressed in 
Huh7.5–VSVG cells the acid treatment does not cause any detectable fusion events 
as assessed by FACS, certainly not at the levels seen with PEG fusion. 
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Fig 3.7 Ability of Huh7.5-VSVG cells to fuse with THP-1 cells 
THP-1 (violet) (A) and transduced Huh7.5 (orange) (B) were co-cultured then treated with an acidic 
buffer to induce VSVG fusion (D). Non-Acid treated cells were used as a non-fusion control (C). Cells 
were analysed by FACS to determine the amount of cell fusion by measuring the percentage of cells 











































































































































THP-1 and Huh7.5 cells with double positive cells measured by FACS analysis. Data presented is 
representative of 2 independent experiments. 
 
3.3.4 HCV RNA levels are higher in PEG fusion compared to VSVG fusion 
Despite the lack of cell fusion with the Huh7.5-VSVG cells, we speculated that the 
quality of fusion may be improved with VSVG expression and therefore performed 
functional experiments with these cells. We compared the ability of VSVG mediated 
fusion to replicate patient derived HCV to standard PEG fusion. Stimulated THP-1 cells 
were incubated with patient-derived HCV sera and either fused using PEG or fused by 
incubating with Huh7.5-VSVG cells and exposed to a low pH buffer. After incubation 
for 5 days HCV RNA levels were quantified by qPCR. 
 
Fig 3.8 HCV replication in Huh7.5-VSVG cells  
THP-1 cells challenged with patient derived HCV sera were either fused to Wt Huh7.5 cells by PEG or 
fused using the VSVG transduced Huh7.5 cells by low pH exposure for 60 secs. Controls included 




















































Huh7.5 cells co-cultured with infected THP-1 cells with no fusion (Co-Culture) and finally Wt Huh7.5 
exposed directly to patient sera (Sera + Huh7.5). Experiment was left for 5 days before harvesting and 
HCV RNA was quantified. Above represents pooled data (mean ± SEM) obtained from experiments 
performed with 5 different HCV sera. Statistical analysis was performed using a Mann-Whitney U-Test 
 
Significantly higher levels of HCV were obtained from PEG fusion compared to VSVG 
fusion (p=0.048) (Fig 3.8). HCV RNA levels were comparable between VSVG fusion, 
non-VSVG expressing Huh7.5 exposed to the same low pH buffer (pH Control), co-
cultured HCV-sera-exposed THP-1 and Huh7.5 cells exposed directly to sera. 
Together these data indicate that the Huh7.5-VSVG cells are not a functional 
replacement for replicating patient derived HCV in the HCV capture fusion assay 
 
3.3.5 Summary of VSVG experiments 
Transduction of Huh7.5 cells with the pTRIP-VSVG lentiviral construct enabled 
expression of VSVG within this cell line as determined by western blot and PCR. 
Functional FACS based experiments assessing the ability of the Huh7.5-VSVG cells 
to fuse with THP-1 cells revealed an apparent lack cell fusion when compared to cells 
treated with PEG. Finally, when the Huh7.5-VSVG cells were used to fuse THP-1 cells 
exposed to patient-derived HCV, viral RNA levels were significantly higher in cells 
fused by PEG compared to VSVG fusion. It was concluded that VSVG expression was 
not a viable replacement for PEG fusion in the capture fusion model and further work 




3.4 Expression of SEC14L2 to study HCV replication  
A recent advance in the in vitro study of HCV by Saeed et al has been the development 
of a cell culture system which is reported to permit the propagation of patient derived 
HCV without the need for culture adaptive mutations. This is achieved by the 
overexpression of SEC14L2, also known as tocopherol-associated protein 1 (TAP1) a 
cytosolic lipid binding protein, expressed in primary human hepatocytes but not human 
hepatoma or non-hepatoma cell lines. SEC14L2-expressing Huh7.5 cells displayed 
higher replication levels of HCV replicons such as Con-1, H77, J6 and JFH-1. Notably 
SEC14L2 cells were able to propagate G1 and G3 HCV derived from patient sera, 
which was attenuated by the addition of the NS5A inhibitor daclatasvir (Saeed et al., 
2015). To create a system whereby these cells could be used to phenotype drug 
sensitivity of patient derived HCV, the length of time HCV could be propagated in 
SEC14L2 expressing cells first needs to be established. Saeed et al cultured patient 
derived HCV for a total of 7 days with the addition of drugs on day 5 resulting in a 10-
fold reduction in HCV RNA levels. In capture fusion drugs are added 24 hours after 
fusion and maintained for 7 days. It was therefore of interest to establish whether a 
similar time scale could be utilised with the SEC14L2 cell system.  
 
3.4.1 Assessing HCV replication in SEC14L2 expressing cells by PCR 
SEC14L2 expressing Huh7.5 cells were kindly donated by P. Simmonds and used to 
examine their utility in the detection of antiviral drug sensitivity in patient derived HCV. 
The SEC14L2 cells clearly have the potential to obviate the need for the capture fusion 
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technique and we therefore examined the ability of these cells to replicate virus from 
our patients. The time course of replication in these cells was first examined.  
 
SEC14L2-Huh7.5 cells were infected at an MOI of 1 with sera from 2 G1 and 2 G3 
patients with high viral loads. HCV RNA levels were then quantified over a period of 
10 days. A decline in HCV RNA from day 0 was observed for both genotypes between 
days 3-5. For the 2 G1 sera (JW060 and MJ018) a further decline was observed up to 
days 7 and 10. However HCV RNA levels for the two genotype 3 sera (JW057 and 
MJ018) was seen to increase slightly on day 7 and then continued to decline on day 
10 to levels comparable to the G1 serum (Fig 3.9). These data do not provide robust 
evidence of HCV replication in these cells and further attempts were made to 
determine whether or not these cells are of value in viral phenotyping assays. 
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Fig 3.9 HCV replication in SEC14L2 expressing cells.  
Sera from 2 G1 and 2 G3 patients were used to infect SEC14L2 expressing huh7.5 cells at an MOI of 
1. HCV RNA was quantified by RT-qPCR in triplicate at indicated time intervals. Data presented is 
representative of 2 independent experiments. Graph shows mean ± SEM.  
 
3.4.2 Using a SEAP reporter system to detect HCV replication in SEC14L2 
expressing cells  
The SEC14L2 cells have the potential to propagate HCV at similar levels to capture 
fusion. In both methods detection of HCV relies upon RNA extraction and RT-qPCR, 
which is a time consuming and labour intensive process. Other methods of HCV 
detection that do not rely upon HCV RNA quantification but rather the mechanics of 
HCV replication do exist but have been discounted for use in capture fusion due to the 
limited level of HCV replication and the complex nature of the fusion process 
(Cunningham et al., 2014). One such method developed by Iro and colleagues 
describes a cell-based secreted alkaline phosphatase (SEAP) reporter assay to detect 
in-vitro HCV replication. This system consists of the SEAP reporter construct 
containing a recognition sequence for the HCV NS3/4 serine protease that, when 































present, will release SEAP into the extracellular medium which is then detected via 
chemiluminescence (Iro et al., 2009).  Huh7-J20 cells containing the SEAP reporter 
were kindly donated by A. Patel, Glasgow University, and were stably transfected with 
a SEC14L2 expression plasmid. J20-SEC14L2 cells were tested for their ability to 
detect HCV by infection with increasing MOIs of JFH-1 and sera from a G3 HCV 
patient. SEAP levels in J20-SEC14L2 cells were observed to be considerably higher 
than the J20 mock-transfected cells when exposed to JFH-1 and patient sera. The 
chemiluminescent signal appeared to reflect the amount of virus used as relative 
SEAP activity increased with an MOI of 0.3 compared to 0.1 of JFH-1 (Fig 3.10A). For 
this system to be a viable alternative to capture fusion it would need to be able to 
detect a dose-response to anti-viral drugs from patient derived sera. To this end J20-
SEC14L2 and J20-Wt cells were infected with JFH-1 and MJ018 sera for 24hrs and 
then treated with SOF for 5 days after which SEAP activity was measured. Treatment 
with increasing doses of SOF did decrease luminescence in both the JFH-1 and 
patient-sera infected cells (Fig 3.10B). The effect of SOF was more prominent in the 
JFH-1 infected cells causing only a very slight decrease in luminescence in cells 
infected with MJ018 HCV sera. Despite several attempts, a robust response to SOF 
could not be attained using patient-derived sera. Additionally, difficulties were 
encountered achieving reproducible data with these cells due to a high background 
signal resulting in the decision not to continue with the development of this system to 
evaluate antiviral phenotype. 
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Fig 3.10 Detection of HCV replication in J20-SECL14L2 cells  
(A) J20 Wt and J20-SEC14L2 cells were seeded in a 96 well format and infected with either JFH-1 or a 
G3 patient sera (MJ018) at the indicated MOI. SEAP activity in the culture medium was detected 5 days 
post infection. Relative SEAP activity was normalised to uninfected cells to account for background 
luminescence. (B) J20-SEC14L2 were infected with JFH-1 (MOI 0.1) and MJ018 (MOI 1) for 24 hours 
and then treated with the indicated doses of SOF for 5 days after which chemiluminescent SEAP activity 
was measured. Above data is representative of 2 independent experiments with graphs depicting mean 
± SEM.  
 
3.4.3 Using SEC14L2 Cells to Evaluate Antiviral Sensitivity of HCV Sera by 
qPCR 
Experiments thus far have not confirmed the data from Saeed et al showing general 
replication of virus in SEC14L2 expressing cells (Fig 3.9). However, there was an 
indication that for the two samples containing G3 HCV some replication did occur after 
7 days. We therefore sought to determine whether inhibition of replication could be 































































MOI of 1. Cells were then treated with a range of SOF and DAC doses either day 3 or 
day 5 post-infection with HCV RNA quantification performed 7 days post-infection in 
both cases. However consistent data could only be obtained with two of these sera, 
MJ018 and JW057 as RNA levels were too low in the others to detect reliably. Both 
periods of drug treatment caused a decline in HCV RNA in response to increasing 
doses of SOF and DAC, indicating replication in these cells (Fig 3.11A-D). IC50 values 
calculated from HCV RNA were observed to increase slightly with drug treatment at 5 
days post infection compared to 3 days post infection (0.011-0.045µM and 0.017-
0.026µM for SOF and DAC respectively). This is likely due to the virus having more 
time to propagate in cell culture combined with a shorter duration of antiviral treatment 
when drug treatment is performed 5 days post-infection compared to 3 days.  
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Fig 3.11 Drug inhibition in SEC14L2 cells.  
SEC14L2 cells infected with G3 sera were treated with either sofosbuvir (SOF) or daclatasvir (DAC) 3 
days post infection (A/B), or 5 days post infection (C/D) at indicated doses. HCV RNA in both 
experiments was quantified 7 days post infection and IC50 values calculated. Data presented for each 
drug at day 3 and 5 is pooled data from 2 patient sera MJ018 and JW057. Graphs depict mean ± SEM. 
 
These experiments suggest that for these two G3 viral samples infection and 
replication within the SEC14L2 cells could be observed and this model could be used 
to assess drug sensitivity. We therefore examined the impact of drug treatment in 
these cells using time courses that were similar to those previously used in the 
capture-fusion experiments (Cunningham et al., 2014). We tested SOF on these sera 
with treatment applied to the SECL4L2 cells 24 hours after infection. Cells were 
incubated with SOF for a total of 7 days with medium and drug being replaced after 3 
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days. Capture fusion experiments with the same sera using Huh7.5 cells were also 
performed alongside direct infection of SEC14L2 expressing cells.  
 
Fig 3.12 Drug inhibition with SEC14L2 cells 24 hours after infection.  
(A) SEC14L2 cells were infected with G3 sera JW057 and MJ018 respectively at an MOI of 1. Cells 
were treated with indicated doses of SOF 24 hours post infection with drug replacement on day 3. (B) 
Capture fusion experiments were performed with the same sera with the same time scale of drug 
inhibition as the SEC14L2 cell infections. For both experiments, HCV RNA was quantified 7 days post 
infection from which IC50 values were calculated. (C) HCV copy numbers obtained at day 7 from capture 
fusion and infection of SEC14L2 cells with MJ018 and JW057 sera. Data presented is pooled from 
experiments with both sera. Graphs depict mean ± SEM. 
 
Similar IC50 values for SOF were obtained with direct infection of the SEC14L2 cells 
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inhibition post infection with the SEC14L2 cells can be done in a similar fashion to 
capture fusion and the output IC50 is similar to that of experiments with a different 
duration of drug exposure. Additionally, this set of experiments demonstrates the 
potential of the SEC14L2 cells to be used as a system to phenotype the sensitivity of 
G3 HCV sera to antiviral drugs. HCV copy numbers at day 7 were compared between 
capture fusion and direct infection of SEC14L2 cells as a relative measure of the 
amount of HCV replication in each system (Fig 3.12C). For both sera HCV copy 
numbers were reduced in direct infection of SEC14L2 cells compared to capture 
fusion. The impact of this reduction in these experiments was minimal due to the 
reasonably high replication rates and viral load of the sera used. However, not all 
patient derived HCV replicates equally well in the capture fusion model with drug 
phenotypes to ‘low replicators’ being challenging to determine. We tested five serum 
samples and HCV replication was only detected in the two samples illustrated here. 
Therefore as validation of these cells could only be determined with two G3 sera and 
as the replicative abilities of these cells may be dependent on the relative fitness of 
the patient derived virus used to infect them we decided not to continue with this 
approach.  
 
3.4.4 Using SEC14L2 cells in the HCV Capture Fusion Assay 
We speculated that the Huh7.5-SEC14L2 cells might serve as a more favourable 
platform for the replication of patient sera than Huh7.5 cells in the capture fusion 
assay. To this end we compared the HCV copy number in capture fusion experiments 
with matched G3 sera performed with either Huh7.5 cells or Huh7.5—SEC14L2 cells. 
For all samples tested HCV RNA levels were found to be significantly higher (p=0.016) 
in capture fusion experiments using Huh7.5-SEC14L2 cells compared to Huh7.5 cells, 
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indicating that the Huh7.5-SEC14L2 cells may be more beneficial to the replication of 
patient-derived HCV in the capture fusion assay.      
 
 
Fig 3.13 Comparison of Huh7.5 to Huh7.5-SEC14L2 cells in Capture Fusion 
THP-1 cells infected with sera from 5 genotype 3 clinical isolates were fused to either Huh7.5 or Huh7.5-
SEC14L2. After fusion cells were incubated for 5 days after which RT—qPCR quantified HCV RNA 
levels. Each patient isolate was assayed in quadruplicate for fusion experiments with both Huh7.5 and 
Huh7.5-SEC14L2 cell lines. Statistical analysis was performed using a Mann-Whitney U-test.  
 
3.5 Discussion 
This chapter describes my attempts to improve upon our current viral phenotyping 
assay, the ‘capture-fusion’ model of HCV replication. The development of the FACS 
based assay allowed the efficiency of different approaches to fusion to be evaluated. 
The assay revealed a large amount of self-adherence between THP-1 and Huh7.5 
cells that could overestimate the proportion of cells deemed fused. To account for this 
THP-1 and Huh7.5 cells that had been co-cultured but not fused were an essential 
control in these experiments. PEG fusion between THP-1 and Huh7.5 cells occurs at 
































in a significant increase in the efficiency of THP-1/Huh7.5 hybridoma formation. Given 
the additional time and resources to form the bridge in an already complex procedure, 
further study into this method was deemed impractical. Adaption of an alternative 
fusion method by the over-expression of the VSV-G protein was performed in an 
attempt to replace PEG-fusion with a seemingly better alternative. Despite overcoming 
difficulties in expressing VSV-G in Huh7.5 cells FACS based assessment of fused 
cells revealed that these cells were unable to fuse THP-1 cells when exposed to a low 
pH and were subsequently shown in a viral replication setting to be a non-viable 
alternative to PEG fusion. Finally, the Huh7.5-SEC14L2 cells were considered as an 
alternative to capture fusion due to their reported ability to replicate patient-derived 
HCV (Saeed et al., 2015). Time course assays showed the two G3 sera tested were 
able to modestly replicate at 7 days post infection. Comparable SOF IC50 values to 
capture fusion were obtained with these cells implicating their ability to determine 
antiviral sensitivity in patient isolates. Higher HCV copy numbers however, were 
observed in capture fusion compared to direct infection of Huh7.5-SEC14L2 cells with 
the same sera. Replacing Huh7.5 cells with Huh7.5-SEC14L2 cells in the capture 
fusion yielded significantly higher HCV levels with matched patient-derived G3 sera. 
This may be due to the fusion process being a better delivery method for virus into the 
Huh7.5-SEC14L2 cells than direct infection. The improvement attained by the Huh7.5-
SEC14L2 cells in HCV copy number, may permit the antiviral phenotyping of clinical 
isolates that were previously unable to be defined by capture fusion due to low 
replication rates. It was therefore decided to use the Huh7.5-SEC14L2 cells as the 




4 RESULTS: Sofosbuvir and Ribavirin sensitivity in genotype 3 relapse and 
SVR samples 
 
With the changing face of HCV treatment to ‘IFN-free’ regimes where the NS5B 
inhibitor Sofosbuvir (SOF) dominates, treatment relapse has become less common 
especially in G1 infected patients. Cirrhotic G3 infection remains difficult to treat 
despite these new highly potent regimes, achieving SVR rates of 68%, most often due 
to relapse after treatment discontinuation (Zeuzem et al., 2014a). Ribavirin (RBV) 
appears to retain a key role in G3 treatment as SVR rates are boosted with its inclusion 
in treatment regimes, particularly in those with difficult to cure characteristics, such as 
cirrhosis (Foster et al., 2015b).  
 
The virological reasons for relapse within cirrhotic G3 patients are poorly understood. 
One possible explanation is that relapse to G3 HCV is due to selection of mutations 
which enable the virus to resist the mode of action of these new direct acting antivirals. 
Direct sequence analysis of samples from patients who have relapsed could identify 
potential resistance associated variants (RAVs), although given the heterogeneity of 
HCV and the rarity of relapse this may be technically challenging. Host factors such 
as poor compliance with medication, presence of cirrhosis may also contribute to 
treatment failure and analysis of sequences from patients who have failed antiviral 
therapy will therefore involve a heterogeneous group of patients with a variety of 
different mechanisms of treatment failure. Identification of samples from patients 
where primary viral resistance was responsible for treatment failure would allow more 
informed sequence analysis of samples. Currently the capture fusion model is the only 
system that can determine the anti-viral drug phenotype of patient derived HCV. 
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Previous work with the assay has indicated that a reduced sensitivity to RBV exists in 
pre-treatment samples isolated from G3 infected patients who relapsed after treatment 
with pegIFN/RBV (Cunningham et al., 2014). 
 
Here we examine the hypothesis that: 
1) Failure to respond to all oral antiviral treatments is associated with a reduced 
sensitivity to ribavirin and/or other drugs involved in therapy. 
 
4.1 Sensitivity to SOF/RBV in G3 SVR samples 
To establish a suitable dose response curve for both SOF and RBV initial experiments 
used HCV sera from patients who cleared virus were obtained from The Liver Unit at 
the Royal London Hospital. Samples were taken after informed consent in line with 
ethical approval granted to Dr Morven Cunningham. Sera from 3 G3 patients were 
used in the capture fusion assay to determine sensitivity to a range of SOF and RBV 
doses. Patient serum used in this experiment was selected based on high viral load 
and clinical outcome (Table 4.1).  
Table 4.1 Details of G3 patient serum used in capture fusion 
Patient ID Genotype Viral load (x10
6 
IU/ml) Clinical outcome 
A 3a 1.2 SVR 
B 3k 10.1 SVR 
C 3 2.3 SVR 
 
Sensitivity of these 3 sera to SOF and RBV is shown in Fig 4.1. The dosage of RBV 
has been previously established for the capture fusion assay (Cunningham et al., 
2014). The SOF dose range was recommended by Hongmei Mo, Gilead Sciences Ltd. 
Average IC50 values of 0.54µM and 0.028µM were obtained for RBV/SOF respectively 
(Fig 4.1). These are comparable to values previously obtained by Cunningham et al 
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from G3 SVR samples indicating sensitivity to these drugs. The dose range of both 
drugs appears to be of suitable scope to show drug sensitivity in these patient sera 
with the ‘capture fusion’ assay.  
 
Fig 4.1 Sensitivity to SOF/RBV in G3 patient derived HCV.  
Sera from 3 individual G3 HCV patients were used in capture fusion to determine sensitivity to SOF and 
RBV. Stimulated THP-1 cells were infected with sera at an MOI of 1 then fused 24hrs later to Huh7.5 
cells. SOF or RBV was then added at indicated concentrations 1-day post fusion and replaced 3 days 
post fusion. Cells were harvested on day 5 and HCV RNA quantified by RT-qPCR. IC50 values were 
calculated from dose response curves. Graphs show mean ± sem for each drug concentration. For 
experiments with ribavirin high concentrations (1 -1.25 µM) were often associated with cell toxicity 
IC50 = 0.41µM (est) IC50 = 0.011µM (est) 
IC50 = 0.79µM (est) IC50 = 0.046µM (est)   
IC50 = 0.43µM (est) IC50 = 0.028µM (est)
RBV [log µM] SOF [log µM]
RBV [log µM] SOF [log µM]




























































































resulting in paradoxical increases in HCV RNA) 
 
4.2 Comparisons of SOF and RBV sensitivity in pre-treatment samples from 
patients who did, or did not, achieve a sustained virological response.  
To assess whether a reduced sensitivity to SOF/RBV is present in patients who 
relapsed following antiviral therapy the capture fusion assay was used to assess 
sensitivity of HCV obtained from patients who relapsed to SOF based direct acting 
antiviral therapy. Samples were sourced from the English expanded access program, 
which was a compassionate use program to treat patients with the most severe liver 
disease with SOF based treatment regimens. As part of this program the HCV national 
biobank HCV Research UK (HCVRUK) collected serum samples from all patients 
participating in the UK expanded access program with samples taken throughout their 
treatment course. Patients gave informed consent to donate their samples to the 
biobank and samples were made available to us after approval by the designated 
tissue access panel, in line with ethics approval granted to Professor Irving. Patient 
samples used in this work were obtained from the HCVRUK national biobank, with key 
criteria for patient selection consisting of: 
• Infection with G3 HCV 
• Viral load sufficiently high to provide 2x106IU, (due to difficulties sourcing 
patients with high viral loads in the cohort with advanced cirrhosis these criteria 
was subsequently relaxed) 
• Treatment with SOF/LDV or SOF/DAC and RBV 
• Full genome viral sequencing either performed or underway 
• Sample taken pre-treatment. 
As a control samples were also requested from G3 patients who had achieved SVR 
and we included two samples from our Royal London HCV patient cohort, which had 
high viral loads and were known to replicate well in the capture-fusion assay system. 
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28 samples were received from HCVRUK with the clinical details relating to outcome 
blinded. ‘Capture fusion’ experiments were performed on 12 out of the 28 highly 
viraemic samples to determine sensitivity to SOF and RBV. Limitations on serum 
volume and low viral loads prevented capture fusion experiments being performed on 
the remaining 16 samples.  
 
Capture fusion experiments of each serum sample to ascertain response to SOF and 
RBV were performed in quadruplicate for each concentration of drug. Sensitivity to 
both drugs was assayed at the same time with analysis of the phenotyping data 
performed with no prior knowledge of the clinical outcome status of the sample tested. 
Response to drugs was determined by a highly sensitive taqman-RT-qPCR assay, 
which calculated HCV copy-numbers/µg for each sample tested. Of the samples 
tested, 8 exhibited sensitivity to SOF with an average IC50 of 0.039µM, comparable to 
earlier experiments performed with SOF (Fig 4.2A). The same samples were also 
found to exhibit RBV sensitivity although the average IC50 was noted to be higher than 
observed previously (Fig 4.2C). 6 samples however did not show the same reduction 
in HCV RNA levels in response to SOF and RBV treatment (Fig 4.2B, D). IC50 values 
for this group of samples were found to exceed the maximum dose of each drug used 
in the assay indicating a loss in sensitivity to both drugs.  
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Fig 4.2 Sensitivity of Patient serum to SOF and RBV 
14 pre-treatment samples were assayed for sensitivity to SOF and RBV by capture fusion. 8 samples 
of the exhibited sensitivity to SOF and RBV (A, C) while 6 samples exhibited a loss of sensitivity defined 
as an IC50 < 0.25µM for SOF and 1.25µM for RBV (B, D). Each serum sample was tested in 
quadruplicate. Graphs depict mean ±SEM . 
  
Only after analysis of capture fusion data was complete was the clinical outcome of 
these samples revealed. Of the samples tested 2/12 achieved an SVR, 2 were from 
previous ‘good replicators’ (patients 2 and 3) and 10/14 were from patients who 
relapsed. All SVR samples and most relapse samples were treated with 
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 Table 4.2 Clinical Data of the 14 patients used in capture fusion 
 
 
Drug sensitivity data from the capture fusion assay was re-grouped by clinical outcome 
data. Individual IC50 values obtained for SOF and RBV for each sample tested were 
divided into samples that achieved an SVR and those who relapsed. Comparison of 
IC50 values between SVR and relapse samples revealed a significant overall increase 
in IC50 for both SOF and RBV (p=0.022 for SOF and p=0.088 for RBV) (Fig 4.3A, B).    









1 Sof/DCV/RBV SVR 59 m decompensated yes 2,178,912   






SVR 61 f non cirrhotic yes 2,301,777   
4 Sof/DCV/RBV SVR 59 F non cirrhotic no 2,663,854   
5 Sof/LDV/RBV Relapse 47 m decompensated no 2,321,679 Sof/LDV/RBV SVR 
6 Sof/DCV/RBV Relapse 49 m decompensated yes 1,913,455 Sof/DCV/RBV Relapse 
7 Sof/LDV/RBV Relapse 52 m decompensated yes 808,776 Sof/LDV/RBV SVR 
8 SOF/LDV Relapse 49 m decompensated no 3,100,000 Sof/LDV/RBV SVR 
9 Sof/DCV/RBV Relapse 48 m decompensated no 1,585,601 Sof/DCV/RBV SVR 
10 Sof/LDV/RBV Relapse 54 m decompensated no 255,934 Sof/LDV/RBV Relapse 
11 Sof/LDV/RBV Relapse 56 m 
non cirrhotic 
(transplant graft) yes 2,362,045 Sof/LDV SVR 
12 Sof/DCV/RBV Relapse 58 m decompensated yes 902,000 Sof/DCV/RBV SVR 
13 Sof/LDV/RBV Relapse 43 m decompensated no 5,670,819 not retreated  
14 Sof/LDV/RBV Relapse 50 m decompensated yes 570,000 Sof/LDV/RBV SVR 
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Fig 4.3 Grouping of Capture fusion data by clinical outcome 
Individual IC50 values for SOF (A) and RBV (B) obtained by capture fusion were grouped into samples 
that achieved and SVR compared to samples that relapsed to therapy. A significant difference in IC50 
vales for both drugs was found between SVR and relapse samples. Statistical analysis was performed 
using a Mann-Whitney U-test.  
 
It was noted that a group of relapse samples retained comparable IC50 values for both 
SOF and RBV to SVR samples. To highlight this dose response curves for both drugs 
were re-grouped into: SVR-drug sensitive, relapse-drug sensitive and relapse drug 
insensitive (Fig 4.4). Dose response curves from SVR patients were comparable to 
the 4 relapse patients who exhibited SOF and RBV sensitivity (Fig 4.4A-B, D-E) 
whereas the 6 relapse samples defined as drug insensitive showed little reduction in 
HCV RNA levels in response to both SOF and RBV treatment in comparison to 

















































Fig 4.4 Dose response curves to SOF and RBV grouped by clinical outcome and drug sensitivity. 
Capture fusion data for SOF and RBV were grouped by clinical outcome into patients who achieved 
SVR (A, D) or relapsed (B, C, E, F). Relapse samples were further divided in to SOF and RBV sensitive 
(B, E) and insensitive (C, F). IC50 values for each drug represent the average of the indicated number 
of patients in each group. Graphs display mean ± sem 
 
Together, these data indicate that a differential sensitivity to SOF and RBV exists in 
virus from G3 cirrhotic patients before the start of treatment. The majority of samples 
from patients in this cohort who went on to relapse to DAA therapy had a reduced 
sensitivity to both these antivirals implicating viral-drug sensitivity as a possible cause 
for relapse. However not all relapse samples were observed to be drug insensitive, 
implying that for those patients there may be alterative factors that caused relapse to 
therapy.  
 
4.3 Sensitivity of G3 SVR and relapse samples to NS5A inhibitors and a novel 
RIG-I agonist 
All patient samples studied were treated with NS5A inhibitors such as Ledipasvir (LDV) 
or Daclatasvir (DAC) in addition to SOF and RBV. We therefore performed additional 
experiments to establish if a difference in sensitivity to LDV or DAC existed in any of 
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the relapse samples. We also tested a novel agonist of the innate immunity SB 9200 
that potently amplifies the host antiviral response by the activation of the retinoic acid 
inducible gene (RIG-I) and nucleotide oligomerisation domain protein 2 (NOD2) 
signalling cascades (Iyer et al., 2010). This compound was recently used in a phase I 
clinical trial setting and shown to reduce HCV viral load with no serious adverse events 
with a similar antiviral effect to interferon (Thompson et al., 2015).  
 
We analysed, in a blinded fashion, response to DAC and LDV. However due to 
limitations in the volume of patient sera not all the previously tested relapse samples 
could be used in this experiment. In those that could be tested there was insufficient 
sample for a full dose response curve, so we developed a modified assay. Drug 
sensitivity was assessed in capture fusion by treating the infected-fused cells with a 
single concentration of LDV, DAC or SB 9200.  Fold change in HCV RNA calculated 
from the non-treated control was performed to determine drug response. A significant 
fold reduction in HCV RNA was seen with LDV and SB 9200 treatment for both SVR 
and relapse samples (Fig 4.5). No significant reduction in HCV was observed with 
DAC treatment with the samples tested. Of the relapse samples tested it was 
discovered that one sample contained the well-described Y93H mutation, which 
confers resistance to NS5A inhibitors. The presence of this resistance variant may 
contribute to the reduced response of the relapse group to DAC.  
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Fig 4.5 Sensitivity of G3 EAP samples to Daclatasvir, Ledipasvir and SB 9200. 
Capture fusion assay was performed on sera from 9 of the previously studied G3 patients who had 
either achieved an SVR or relapsed to DAA treatment. All SVR samples and 3 of the relapse samples 
were treated with SOF/DAC/RBV and the remaining 2 relapse samples were treated with 
SOF/LDV/RBV. Fused cells were treated with a single dose in quadruplicate of either Daclatasvir (DAC), 
Ledipasvir (LDV) or SB 9200 and the fold change in HCV RNA compared to the no drug control ± sem 
plotted. Statistical analysis was performed using the Mann-Whitney U-test.  
  
 
In summary, the data presented thus far show a subset of G3 patient-derived viruses 
possesses a refractory phenotype to SOF and RBV. Subsequent experiments 
assaying response of relapse samples to NS5A inhibitors showed that relapse 
samples had a reduced response to DAC likely due to the presence of the Y93H 
mutation in NS5A. However these experiments can only be used as an indication of 
response as serum limitations prevented full dose response curves to drugs being 
generated, which would have given a more representative indication of the response 





































































potential of SB 9200 as alternative to DAA’s for ‘difficult to treat’ genotype 3 HCV as 
comparable significant reductions in HCV RNA levels were observed in both SVR and 
relapse samples.  
 
4.4 Sequence analysis of SOF/RBV insensitive samples 
Samples used in capture fusion experiments underwent next-generation HCV viral 
genome sequencing (performed by Ana De Silva Filipe) as part of the HCVRUK study. 
Next-generation sequencing reads were analysed as previously reported (Thomson 
et al., 2016). Substitutions present in fewer than 15% of the sequencing reads were 
discarded and only considered sequences with a read frequency of >16%. All samples 
were initially screened for known DAA resistance associated substitutions (RAS). 
Further analysis however compared drug sensitive to drug insensitive sequences with 




4.4.1 Identification of known resistance associated substitutions in samples 
assayed by capture fusion 
Consensus files obtained for each phenotyped sample were aligned by ClustalW using 
the Geneious™ Bioinformatics and Alignment program (Kearse et al., 2012). Samples 
were screened for the presence of RAS that confer resistance to DAAs in the NS3-
NS5B regions (summarised in (Lontok et al., 2015)). No well-characterised NS3 RAS 
such as Q80K or R155K were detected in any patient sample. At position 175 all 
patients were found to have the M-L mutation that has been previously reported to 
confer resistance to Boceprevir (Lauck et al., 2012). This mutation was however only 
reported in <10% of patients who did not achieve an SVR. Its impact is also limited, 
as patients in the EAP were not given protease inhibitors as part of their treatment 
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regime. Additional RAS were detected in the NS5A region. Patient 3 had a T at position 
30 which is implied as a possible RAS but shown not to affect sensitivity to DAC in a 
genotype 3a subgenomic replicon system (Wang et al., 2013). Patients 9 and 14 were 
found to have H at position 93, which confers resistance to ledipasvir, daclatasvir and 
ombitasvir (Fridell et al., 2011; Gao, 2013). Of particular relevance to this work, no 
mutations previously indicated in resistance to sofosbuvir (such as S282T) were found 
in any relapse samples shown to be drug insensitive. This suggests that novel; 
previously un-identified mutations may exist in the NS5B region of samples affecting 
sensitivity to sofosbuvir. 

































































































1 SVR Sensitive L T V Q V S L R A Q V L M P A L P P S E Y L S C V 
2 - Sensitive L T V Q V S L R A Q I L M P A L P P I E Y L S C V 
3 SVR Sensitive L T V Q V S L R A Q V L M P T L P P L E Y L S C V 
4 SVR Sensitive L T V Q V S L R A Q I L M P A L P P S E Y L S C V 
5 Relapser Sensitive L T V Q V S L R A Q I L M P A L P P I E Y L S C V 
6 Relapser Sensitive L T V Q V S L R A Q I L M P A L P P S E Y L S C V 
7 Relapser Sensitive L T V Q V S L R A Q I L M P A L P P S E Y L S C V 
8 Relapser Sensitive L T V Q V S L R A Q I L M P A L P P M E Y L S C V 
9 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P S E H L S C V 
10 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P S E Y L S C V 
11 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P S E Y L S C V 
12 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P T E Y L S C V 
13 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P V E Y L S C V 
14 Relapser Insensitive L T V Q V S L R A Q I L M P A L P P S E H L S C V 
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4.4.2 Phylogenetic analysis of NS5B sequences in drug-sensitive and 
insensitive samples 
NS5B sequences from all patient samples were used to plot a phylogenetic tree to 
establish if insensitive samples show any distinctive changes in their NS5B sequence 
(Fig 4.6). All samples cluster into 4 distinct clades, with drug sensitive samples 
comprising most of clades A and D and drug insensitive samples comprising clades B 
and C. Two insensitive samples do not fit this pattern. Patient 9 shows more similarity 
with the sensitive samples in clade A and patient 13 does not fit into any of the 4 
clades.  
 
Fig 4.6 Phylogenetic tree based on the NS5B sequences of phenotyped samples 
Phylogenetic tree constructed using the Neighbour-Joining method. The tree is drawn to scale, with 
branch lengths next to the branches. The differences in NS5B sequences were calculated using the 
Jukes-Cantor method and are in the units of the number of base substitutions per site. The analysis 
involved 14 nucleotide sequences. All positions containing gaps and missing data were eliminated. 



















































samples; blue branches indicate drug sensitive samples Tree was constructed using the MEGA7 
program (Kumar et al., 2016). 
 
This analysis illustrates that the NS5B sequence from insensitive samples possess a 
similarity that distinguishes them from drug sensitive samples. It is possible that 
insensitive samples may have a unique substitution or set of substitutions in the NS5B 
that account for this distinctive phylogenetic grouping. However, the number of 
samples studied is too small for a definitive conclusion to be drawn.  
 
4.4.3 Identification of unique substitutions within the NS5B of drug insensitive 
samples 
NS5B sequences from SVR and relapse samples defined as SOF and RBV sensitive 
by capture fusion were collated to form a ‘drug sensitive’ consensus sequence (see 
appendix). This was used to identify unique changes within the NS5B of drug 
insensitive samples. Results of this analysis are summarised in Table 4.4. We noted 
two distinct mutation patterns with either five (K100R, A150S, G188D, K206E, T213N 
and N244I - patient 9) or two amino acid changes (A150V and K206E – patients 10-
14). These patterns were not seen in patients who were ‘sensitive’ to sofosbuvir 
although individually the A150V and K206E substitutions were observed. These 
changes have not been previously observed as natural polymorphisms within NS5B 
of genotype 3 HCV (Di Maio et al., 2014).  
 
In patients whom pre- and post-treatment viral sequencing data was available, no 
significant change in the frequency of the substitutions of interest was observed (Table 
4.4). The only notable change was observed in-patient 10, where the frequency of 
150V and 206E increased from 54% and 89% respectively to 99% for both positions 
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post-treatment.    
 
Table 4.4 Mutations within NS5B unique to drug insensitive samples 
  
 *   IC50 values for SOF and RBV were calculated from capture fusion. 
 §  Samples were deemed SOF and RBV sensitive if the IC50 was <0.25 and 1.25µM for each drug respectively 
and insensitive if the IC50 exceeded those values.  
 †  Variants were identified by comparison of NS5B next generation sequencing data from drug sensitive versus 
insensitive samples. % Values indicate the frequency each variant was present in the viral population. No data 
was obtained for sample 14 due to low viral load post-relapse. 
+ Samples were not from the EAP but were previous responders to SOF/RBV in capture fusion assay 
 
 
4.4.4 Location of identified substitutions in NS5B 
To establish any possible effect of the identified substitutions on the activity of NS5B 
we sought to plot their location on a 3D model of the polymerase. To date the crystal 
structure of the G3 NS5B has not been determined. The most recent report of an NS5B 
crystal structure used the NS5B from the G2a JFH-1 (Appleby et al., 2015). While not 







Drug sensitivity§ Relevant polymorphisms (Frequency (%) pre →post therapy) †  
Sof IC50  
(µM)* 
RBV IC50  
(µM)* K100R A150V A150S G188D K206E T213N N244I 
1 Sof/DCV/RBV SVR 0.039 0.786 
 V(98%) 






SVR 0.011 0.419 
4 Sof/DCV/RBV SVR 0.054 0.19 
    E(98%)   
5 Sof/LDV/RBV Relapse 0.06 0.43 
E(99%) 
6 Sof/DCV/RBV Relapse 0.033 0.886 
E(99%) 
7 Sof/LDV/RBV Relapse 0.04 0.72 
 V(98%) 
8 SOF/LDV Relapse 0.02 0.701        




(98→99%) D (98→97) 
N 
(98→99%) I (94→99%) 






















14 Sof/LDV/RBV Relapse 0.26 >1.26 
 V (99%)* E (100%)* 
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were plotted on this structure. 
 
Fig 4.7: 3D model of identified NS5B substitutions 
(A) Linear schematic representation of the locations of the substitutions of interest within NS5B. (B) 3D 
model of NS5B derived from a crystal structure with the positions of interest coloured red with white 
labelling.. The white structure in the centre represents a bound RNA strand. PDB crystal structure ID: 
4WTG. Structure was annotated using the PyMOL software.   
 
Most substitutions were located within domains I (“fingers”) and II (“palm”) of the NS5B 
protein (Fig 4.7A). The palm domain contains the catalytic triad that forms the RdPp 
active site. Highly conserved residues, crucial for the active site are D220, D225, 
G317, D318 and D319 (Hagedorn, 1999; Waheed et al., 2012). While none of our 
identified positions are part of or next to residues of the active site, two are close, 
K206E and T213N. The 3D structure shows that K206 (LYS-206) forms part of an 
alpha helix close to the RNA binding cleft but not directly within (Fig 4.7). This residue 
is also close to a domain previously reported crucial to the RNA binding capacity of 
NS5B (Qin et al., 2001). Thr-213 (ASP-213 in the above structure) however, is shown 
NS5B
85 100 206150 188 213 244























in the 3D structure to some distance from the catalytic site of the polymerase.  
 
The catalytic activity the NS5B is modulated by a direct interaction with NS5A 
(Shimakami et al., 2004; Shirota et al., 2002). This interaction stimulates activity of the 
polymerase but can also inhibit activity in a dose dependent manner (Shirota et al., 
2002). Specific domains on the NS5B are crucial for this interaction these are residues 
143-145, 149-155, 365-371 and 382-388. A150V is located within one of these 
domains, which may affect NS5A binding and potentially modulate of the NS5B 
catalytic activity through NS5A.  
 
4.5 Prevalence and impact of NS5B mutations in a second patient cohort 
To further examine the impact of the substitutions we examined their frequency in a 
second, independent cohort of patients with genotype 3 HCV receiving sofosbuvir 
based therapies. We studied sequences from pre-treatment genotype 3 samples from 
the BOSON trial (Foster et al., 2015b). This cohort consisted of 522 genotype 3 
patients of which approximately 50% had previous experience with pegIFN/RBV 
therapy. Approximately 37% of the entire cohort had cirrhosis. The frequency of our 
identified mutations in patients who did, or did not, achieve an SVR was examined by 
Dr Azim Ansari (University of Oxford) (Fig 4.8). Individually, each of the identified 
variants associated with reduced sofosbuvir sensitivity was not present in the cohort 
at a high prevalence making robust statistical analysis difficult (Fig 4.8A). The 
exception was the A150V variant which was present in 47% of patients and in the 204 
samples with the V residue an SVR was achieved in 153 patients (75%) compared to 
a response rate of 168 of 191 (88%) patients with the A variant (p=0.0012) (Fig 4.8B). 
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The combination of A150V and K206E was uncommon (22 patients, 6%) and was 
associated with a SVR of 82%.  
 
Fig 4.8 Analysis of identified NS5B mutations in the BOSON patient cohort 
(A) The prevalence of identified NS5B mutations was assessed from >500 viral sequencing samples 
obtained from the BOSON cohort. (B) Each mutation was tested to assess whether the frequency was 
significantly different between SVR and Non-SVR samples. Frequencies were analysed using a fisher’s 
exact test.  
 
4.6 Summary 
Using the ‘capture fusion’ assay, a set of G3 patient-derived viral samples were 
identified with a reduced sensitivity to both SOF and RBV. Analysis of next-generation 
viral sequencing data revealed that none of the drug insensitive samples contained 
any RAS previously associated with resistance to SOF or RBV, however 2 samples 
did contain the well-characterised Y93H mutation in the NS5A protein. Phylogenetic 
analysis of NS5B sequencing data indicated that SOF and RBV insensitive samples 
contained distinctive differences in their polymerase region compared to drug sensitive 
samples. By comparison of the NS5B sequences from samples defined as drug 
insensitive to those defined as sensitive to SOF and RBV we identified two a 
combination of mutations, A150V and K206E, unique to the majority of drug insensitive 










































































A150S, G188D, T213N and N244I was identified in a single isolate. To establish how 
these mutations affect SOF and RBV sensitivity they will have to be studied in the 






















5 RESULTS: Using HCV replicon systems to assess the impact of identified 
NS5B mutations on antiviral sensitivity 
 
5.1  Introduction 
Study of the HCV lifecycle has been greatly enhanced by the development of 
subgenomic and fully infectious replication systems. These systems have furthered 
our understanding of HCV replication as well providing useful screening tools for 
antiviral resistance testing [reviewed in (Catanese & Dorner, 2015)]. The highly 
variable nature of the HCV genotypes in terms of both sequence and behaviour has 
led to the development of genotype specific replicons such as con-1 (G1), JFH-1 (G2), 
S52 (G3), ED45 (G4) (Kato et al., 2003; Lohmann et al., 1999; Saeed et al., 2012).  
  
We hypothesised that the unique NS5B motifs identified in drug insensitive patient 
samples (listed in Table 5.1) affect sensitivity to SOF and RBV. To test our hypothesis, 
we used two in vitro models of G3 HCV. The first was the S52 based subgenomic 
replicon developed by Saeed and colleagues (Saeed et al., 2012), which can be used 
either in a transient replication assay or to make stable replicon cells by virtue of the 
G418 resistance marker embedded in the construct (Witteveldt et al., 2016). The 
second was a recently described infectious model of G3 HCV developed by (Ramirez 
et al., 2016), which can produce G3 virus at titres comparable to JFH-1. These 
systems allowed us to study of the effects of these mutations on the viral replication 




Table 5.1 NS5B mutations identified from drug insensitive patient samples 
 
 
5.2 Engineering NS5B mutations into the S52-Subgenomic replicon construct 
A PCR mutagenesis method was employed to introduce the mutations listed in Table 
5.1 into the S52-subgenomic (SG) replicon construct. Two overlapping fragments 
covering the entire NS5B region were amplified from the S52-SG plasmid using a set 
of primers with the desired mutations and a set off outer primers encoding unique 
restriction sites (see Methods 2.1.7). Once amplified, these fragments were used in a 
second-round PCR to create the full NS5B amplicon containing the desired mutation 
(Fig 5.1C). Using XhoI and XbaI restriction sites, mutated NS5B products were cloned 
back into the S52-SG construct, which was confirmed by restriction digestion Fig 
5.1D).  
NS5B sites to be mutated Nucleotide change 
K100R AAG – AGG 
A150V GCT – GTT 
G188D GTT – GAT 
K206E AAG – GAG 
T213N ACC – AAC 




Fig 5.1 PCR mutagenesis of the S52-SG replicon 
(A) Schematic overview of the PCR mutagenesis experiments to engineer the listed NS5B mutations 
into the S52-SG replicon. (B) Amplification of the overlapping NS5B fragments by PCR. The XhoF outer 
primer was used with the mutation specific reverse primer to amplify the 5’ fragments and the mutation 
specific forward primer was used with the XbaR primer to amplify the 3’ fragment. Size of fragments 
varied according to the location of the target mutation. (C) Second round PCR to create the entire NS5B 
amplicon contained the desired mutation. 5’and 3’ fragments were mixed in an equimolar ratio and 
serially diluted 10 fold to create a single 2.1kb product. This product was then subsequently cloned 
back into the S52-SG construct using XbaI/XhoI restriction sites. (D) XbaI/XhoI restriction digest of 
colonies after ligation showing a 2.1kb product consistent with the size of the NS5B insert   PCR results 
and restriction digests presented are representative examples for all cloning experiments 
 
Mutated constructs were validated by Sanger sequencing (Source Bioscience) 
confirming that NS5B mutations were correctly engineered and the reading frame had 
not been altered (Fig 5.2). All mutations were engineered individually and the A150V 
and K206E changes were also made in combination, as the most common sequence 


















































Fig 5.2 Sequencing of mutated NS5B sites within the S52-SG-replicon 
(A) Schematic representation of G3 S52-SG replicon. (B) Sanger sequencing traces from S52- 
constructs with indicated mutations engineered in the NS5B by PCR-mutagenesis. Mutated amino acid 
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5.3 Analysis of mutations in cells stably expressing the S52-SG replicon 
One of the properties of the S52-SG replicon is the presence of a firefly 
luciferase/neomycin resistance cassette driven by the HCV IRES (Fig 5.1A). This 
allows cells stably expressing the replicon to be obtained through G418 selection, 
generating a robust cell culture model to investigate any effect the identified NS5B 
mutations may have on drug sensitivity.  
 
Mutated S52 constructs were electroporated into Huh7.5 SEC14L2 cells and placed 
under G418 selection for 3 weeks to obtain stable replicon colonies. Despite several 
attempts (N= 3 on different occasions using different RNA preparations and cells) 
stable colonies were not obtained from constructs expressing the A150V mutation. 
Wild type (Wt) constructs or those containing K100R, G188D and K206E mutations 
only were generated. Functionality of the luciferase reporter was established by 
treatment of the cells with 1000IU/ml of IFNa-2A, which caused a significant reduction 
in luciferase activity in all replicon cells tested (Fig 5.3A). HCV protein expression and 
was confirmed in these cells by staining for NS5A, which was found to form 
characteristic punctate structures in the cytoplasm of the replicon cells (Fig 5.3B). 
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Fig 5.3 Validation of S52-SG replicon cells  
(A) Replicon cells were treated for 72hrs with 1000 IU/ml IFNa-2A after which cells were lysed to 












































































































luciferase activity. (B) Replicon cells were fixed in methanol to visualise NS5A by fluorescent 
microscopy. Cells were also counterstained with the nuclear specific dye DAPI. 
5.3.1 Response of stable replicon cell lines to sofosbuvir and ribavirin  
Despite only obtaining stable lines for three NS5B mutations, drug sensitivity 
experiments were performed to assess any effect of K100R, G188D or K206E may 
have on SOF and RBV sensitivity. Luciferase activity was used as a measure of RNA 
replication in response to SOF and RBV treatment as has been previously established 
with the S52-replicon (Saeed et al., 2012). Replicon cells were treated with serial 
dilutions of SOF and RBV for 48hrs after which luciferase expression was quantified. 
Treatment of Wt replicon cells with SOF and RBV resulted in a decrease in luciferase 
activity in a dose dependent manner (Fig 5.4A, B). The K100R mutation had a 
negligible effect upon sensitivity to SOF with a comparable IC50 obtained to the Wt 
replicon. G188D and K206E had more of a pronounced effect on SOF sensitivity 
affecting a 3.6 and 10-fold increase in SOF IC50 respectively (Fig 5.4A). These 
mutations appeared to have more of an effect on RBV sensitivity than SOF. A 5- and 
14-fold increase in RBV IC50 was observed with the K100R and K206E replicon cells 
respectively, though the greatest effect was observed in replicon cells with the G188D 
mutation where a loss of sensitivity to RBV was observed (Fig 5.4B). 
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Fig 5.4 Sensitivity of Stable replicon cells to sofosbuvir and ribavirin 
Replicon cells expressing the K100R, G188D and K206E mutations were treated with serial dilutions of 
SOF (A) and RBV (B) for 48hrs. IC50 values for both drugs shown with 95% CI were calculated from the 
reduction in luciferase activity compared to the no-drug control. Fold change in SOF and RBV IC50 were 
calculated from the IC50 value obtained from the unmodified Wt replicon line. The above represents 2 
independent experiments. Values plotted are mean ± SEM. 
 
5.4 Analysis of mutations in a transient replicon assay 
As stable replicon lines expressing all NS5B mutations of interest could not be 
obtained an alternative approach was deployed to assess their effect on SOF and RBV 
sensitivity. Transient HCV replicon assays are well defined (Kato et al., 2003; Saeed 
et al., 2012; Targett-Adams & McLauchlan, 2005; Witteveldt et al., 2016) and have the 
advantage of being unlikely to acquire cell culture adaptive mutations through the 
process of antibiotic selection that enhance replication and subsequently may affect 













Wt# 0.35 (0.25*0.47) 0.11#(0.074*0.16) 1 1
K100R 0.47#(0.31*0.71) 0.79 (0.47*1.355) 1.34 4.6
G188D 1.27 (0.89*1.80) >10# 3.63 *
K206E 3.5 (2.15*5.70) 1.64 (1.08*2.57) 10 14.9

















































































































5.4.1 Replication of G3 S52-SG replicon in a transient assay 
The G3 S52-SG replicon was transfected into Huh7.5-SEC14L2 cells, with luciferase 
expression measured at various time points. Luciferase levels peaked between 24 and 
48hrs post-electroporation and were seen to drop after 72hrs levelling out at 125hrs 
post electroporation  
 
Fig 5.5 Replication of the S52-SG replicon  
The S52-SG Wt construct was electroporated into Huh7.5 SEC14L2 cells with samples taken at the 
time intervals indicated to measure luciferase expression. A modified version of the replicon with a 
mutation in the NS5B active site impairing activity of the enzyme (S52-GND) was included as a 
replication control. Data plotted is mean±SEM.  
5.4.2 Effect of mutations in a transient replicon assay 
S52-SG constructs were transiently transfected into Huh7.5-SEC14L2 cells to assay 
response to SOF and RBV (Fig 5.6).  Cells were recovered for 24hrs and then treated 
with serial dilutions of SOF and RBV for 72hrs. Luciferase expression was then 
quantified to evaluate the effect of the antiviral treatment. The unmodified Wt replicon 
acted as a control for drug sensitivity while a replicon containing the well-described 
S282T SOF resistance mutation was created using PCR mutagenesis to serve as a 
control for SOF resistance (Svarovskaia et al., 2014). Due to the high degree of 
























variability experienced with electroporation three independent antiviral assays were 
performed with each mutated replicon. 
 
In line with data previously obtained from the stable replicon assays, K100R had a 
modest effect on SOF inducing a 2 shift in IC50 for each drug respectively (Fig 5.6A, 
C). Yet for RBV, this mutation was observed to have a much greater effect causing a 
32-fold increase in IC50 than the 4-fold increase observed with the stable replicon (Fig 
5.6B, C).  G188D was shown to cause a greater shift in SOF IC50 in this assay (11 fold 
IC50 shift compared to 3.6) than was previously shown in the stable cell line but 
retained its effect on RBV inducing up to a 15-fold increase in IC50. The effect of K206E 
on SOF was similar in this assay (fold shift of 8.3) than was observed with the stable 
cells (fold shift 10) (Fig 5.6A, C). Likewise, with RBV K206E induced an 11- fold 
increase in IC50, which was similar but slightly reduced to the 14-fold shift observed 































































































































































































































































































































































































































Fig 5.6 Sensitivity of NS5B mutations in transient replicon assay 
Huh7.5-SEC cells transiently transfected with S52-replicon constructs with indicated NS5B mutation 
were assayed for their response to SOF (A) and RBV (B). Cells were treated with SOF for 72hrs after 
which luciferase expression was quantified. Luciferase values were normalised to a sample taken 4hrs 
post-electroporation for each construct. As a control for SOF resistance a replicon containing the SOF 
resistant S282T NS5B mutation was included in all transient SOF sensitivity experiments. (C) IC50 
values for SOF and RBV for each replicon construct are shown with 95% confidence intervals. Fold 
change in IC50 for SOF and RBV was calculated for each mutated construct using the unmodified wild 
type S52-replicon as a baseline. Relative luciferase levels compared to the Wt replicon construct for 




The main advantage of the transient replicon assay was that it allowed the effect of 
the additional NS5B mutations for which stable cells lines could not be established to 
be assessed such as T213N, N244I and A150V). T213N had a comparable IC50 to the 
Wt replicon for SOF but reduced sensitivity to RBV by approximately 9-fold. N244I 
S52-Replicon SOF IC50 [µM](CIlow-CIhigh)




Fold change in 
RBV IC50
Luciferase 
levels as % of 
Wt (mean ±SEM)
Wt 0.63 (0.40-0.99) 1
0.70
(0.47-1.05) 1 100.00 (±10.33)
K100R 1.26(0.64-2.50) 2.00
23.61
(9.96-55.95) 32.85 72.45 (±13.18)
A150V 4.88(2.70-8.827) 7.75
28.03
(17.14-45.83) 40.04 98.17 (±11.59)
G188D 6.84(2.47-18.90) 10.86
15.19
(4.94-46.67) 21.70 74.02 (±17.11)
K206E 5.25(2.96-9.33) 8.34
7.40
(4.66-11.75) 10.57 59.35 (21.05)
T213N 1.71(0.85-3.43) 1.27
6.12
(3.58-10.54) 8.74 108.20 (±18.19)
N244I 10.32(5.28-20.16) 16.38
1.49
(0.78-2.86) 2.13 55.95 (±13.01)
A150V+K206E 22.54(12.47 to 40.74) 35.77
48.69
(20.81-113.9) 69.55 120.40 (±17.75)




however had more of an impact on SOF sensitivity causing a 16-fold increase in IC50 
but had almost no effect on RBV sensitivity. The most informative finding from the 
transient replicon experiments was the combination of two mutations found most 
frequently in the SOF/RBV insensitive samples (A150V/K206E). Presence of each 
mutation individually had relatively minor effects on SOF sensitivity, causing a 7.75 
and 8.12 -fold increase in IC50 respectively. When both mutations were engineered in 
the same replicon a more dramatic effect in drug sensitivity was observed, resulting in 
the highest fold shift in SOF IC50 than any of the other mutations. This increase in IC50 
was not as marked as that seen in the replicon containing S282T but indicates a 
notable loss in sensitivity to both SOF and RBV.  Similarly, the combination of these 
mutations caused the greatest loss in RBV sensitivity compared to their individual 
expression (Fig 5.6B, C). 
 
5.5 Analysis of mutations in G3 Infectious clone 
Use of subgenomic replicons, which contain only the HCV non-structural proteins 
allow studies of viral genome replication but no other part of the lifecycle can be 
studied. In this context, transient subgenomic replicon assays have demonstrated that 
possession of both NS5B mutations A150V and K206E impact the sensitivity of the 
polymerase to both SOF and RBV. We sought to confirm our findings in an infectious 
HCV model, which covers all stages of the viral lifecycle and is thus more 
representative of the situation in vivo. Most infectious HCV models are focused on the 
genotype 2a JFH-1 clone, which is a robust model of HCV infection [reviewed in 
(Catanese & Dorner, 2015; Ortega-Prieto & Dorner, 2016)]. The variability between 
HCV genotypes makes the study of genotype 3 specific NS5B mutations in a genotype 
2a infectious unsuitable as there are significant differences between the genotypes. A 
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recent study by (Ramirez et al., 2016) created a genotype 3a based infectious clone 
(designated DBN3acc) with 15 cell culture adapted mutations that could generate high 
titre viral stocks and infect naïve Huh7.5 cells. Here we used this infectious clone to 
test whether the loss of sensitivity to SOF observed in our subgenomic replicon 
experiments caused by A150V and K206E is also recapitulated in an infectious model 
of genotype 3 infections. 
 
5.5.1 Creating genotype 3 HCVcc with the A150V and K206E mutations  
A150V, K206E and the combination of both was introduced into the NS5B of the 
DBN3a construct by a one-step site-directed mutagenesis reaction using overlapping 
primers encoding the desired mutation. This approach was favoured over using PCR 
mutagenesis due to unfavourable restriction sites in the DBN plasmid as well as being 
a faster more efficient method of introducing the mutations.  
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Fig 5.7 Site-directed mutagenesis of DBN3acc Plasmid Construct 
(A) Schematic representation of the site-directed mutagenesis reaction (Adapted from the QuickChange 
II lighting kit manual, Agilent). Each mutation was introduced into the plasmid construct using 
overlapping mutagenic primers that annealed to the template and are extended by a high-fidelity 
polymerase to create a new plasmid construct with the desired mutation. The parental DNA is then 
degraded by digestion with Dpn-I, a restriction enzyme specific for methylated DNA. (B-D) Sanger 
sequencing traces showing the presence of the A150V, K206E and combination of both mutations in 
DBN$A150V
DBN$K206E
145 146 147 148 149 150 151 152 153 154 155 156 157
201 202 203 204 205 206 207 208 209 210 211 212 213














the DBN3acc construct. Numbers depict amino acid positions from the start of NS5B, with mutated 
position highlighted in red.  
Overlapping mutant oligonucleotides were designed to introduce the A150, K206E and 
their combination into the DBN3acc construct. Site-directed-mutagenesis reactions 
were carried out for each mutation with the produce of the reaction transformed into 
competent cells to obtain bacterial colonies of the mutant constructs (Fig 5.7A). 
Colonies were screened for the presence of the mutation by Sanger sequencing with 
constructs harbouring the A150V, K206E and dual mutation obtained (Fig 5.7B-D). 
 
Huh7.5-SEC14L2 cells were transfected with the unmodified Wt, A150V, K206E and 
A150V+K206E constructs to generate stocks of each virus. After 7 days, transfected 
cells were shown to be positive for HCV determined by indirect immunofluorescent 
staining of NS5A (Fig 5.8A). It was at this time point that virus-containing supernatants 
were harvested. The presence of A150V and K206E did not appear to affect the 
infectivity titre of the DBN virus as comparable infectivity titres were observed for the 
A150V, K206E and combination viruses to the un-modified DBN-Wt between days 7-
20 post-transfection (Fig 5.8B). 
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Fig 5.8 Validation of DBN virus stocks 
(A) Huh7.5-SEC14L2 cells transfected with the DBN viral constructs were stained for NS5A by 
immunofluorescence 7 days post-transfection (B) Infectivity titre of DBN viruses was determined by 
focus forming assay and compared between virus stocks containing the A150V, K206E and dual 
mutation. Time in days refers to the number of days post-transfection the virus containing supernatants 
were harvested.  
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5.5.2 Effect of the A150V and K206E mutation on the viral growth curve 
As the presence of the A150V and K206E mutations were within the active site of the 
polymerase protein we sought to assess whether these changes altered the 
propagation of virus in culture. To this end we infected naïve Huh7.5-SEC14L2 cells 
with a low MOI of Wt and mutant virus and monitored HCV RNA levels over a period 
of 6 days. After 2 days of infection RNA levels between the viruses were comparable, 
however between Days 2-3 RNA levels for the Wt DBN virus still increased by 
approximately 1-log whereas RNA levels for the mutated viruses begin to plateau (Fig 
5.9).  At day 6 RNA levels of the WT were significantly higher (p=<0.001) than levels 
observed for the mutated viruses. This indicates that the A150V and K206E mutations 
may confer a slight fitness cost to the DBN3acc infectious clone. This cost may be due 
to a reduction in replication efficiency as viral levels were still observed to increase but 
not to such a high level as the Wt virus. 
 
 
Fig 5.9: Effect of A150V and K206E on growth of the DBN3acc virus 
Naïve Huh7.5-SEC14L2 cells were infected with Wt and mutated DBN virus at an MOI of 0.05. Samples 
were taken at the indicated time points for quantification of HCV RNA by RT-qPCR. Data presented is 











































5.5.3 The effect of A150V and K206E on Antiviral sensitivity in an infectious 
system 
The creation of viruses bearing A150V, K206E and the combination of both allowed 
us to assess whether the effect on SOF sensitivity seen in the G3 subgenomic replicon 
was maintained in an infectious system. The DBN viruses with the A150V and K206E 
substitutions were used to infect Huh7.5-SEC14L2 cells and their response to antiviral 
treatment assessed by RT-qPCR and focus forming assay (FFA). A recent genome 
wide association study identified a strong association between the A150V mutation 
and the human interferon lambda 4 gene indicating a possible interaction between this 
position and the host innate immune response (Ansari et al., 2017) and we therefore 
tested the anti-viral effects of type I interferons on these viruses. 
 
Using the un-modified DBN-Wt virus we performed initial experiments to establish the 
timing and dosage of antiviral treatment on infected Huh7.5-SEC14L2 cells. Cells were 
infected with DBN-Wt virus at a multiplicity of infection (MOI) of 0.5 for 24hrs before 
treatment with a range of SOF and IFN doses. Infected cells were kept under drug 
treatment for 48hrs and then harvested for HCV RNA quantification by qPCR. Analysis 
of HCV RNA levels revealed an acute sensitivity of the DBN-WT to both SOF and IFN. 
Treatment with the lowest doses of each drug caused a >60% decrease in HCV RNA, 
which continued until levels were virtually undetectable (Fig 5.10A, B). IC50 values 
calculated for SOF and IFN reflected the acute sensitivity of the DBN-WT virus yielding 
a value for SOF 100 times less than that observed for the G3 subgenomic replicon 
(see Fig 5.6). This experiment demonstrated that treatment of infected cells for 48hrs 
with either SOF or IFN was sufficient to see the antiviral effect of both drugs. Yet the 
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severe effect the lowest dose of both drugs had on HCV RNA levels indicated that the 
doses used were too high. It was therefore decided to expand the range of 
concentrations of both drugs so a more dynamic dose response curve could be 
attained. 
 
Fig 5.10 Establishing the SOF and IFN dose response with the DBN virus 
Huh7.5-SEC14L2 cells were infected with DBN–WT at an MOI of 0.5. After 24hrs cells were treated 
with a range of SOF and IFN for a further 48hrs and then harvested in Trizol for HCV RNA quantification 
by RT-qPCR. IC50 values were calculated from % change in HCV RNA levels compared to the non-
treated control. Values are shown with 95% confidence intervals. The above is representative of 2 
independent experiments. Graphs depict data mean ±SEM.  
The antiviral infection experiments were repeated with the A150V, K206E and 
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B
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A150V+K206E viruses with an extended dose range for both SOF and IFN. The length 
of drug treatment and MOI were kept the same as the previous experiments. The 
presence of the A150V mutation had a minimal impact on SOF sensitivity (IC50 
0.033µM) but caused an approximate 100-fold increase in IFN IC50 (109.5IU/ML 
compared to 0.73IU/ml for WT virus) (Fig 5.11A, B). The presence of K206E 
conversely caused a more notable effect on SOF sensitivity, causing an approximate 
5-fold increase in IC50 (0.10µM compared to 0.018µM for WT virus) but had only a 
minimal impact on IFN with an IC50 comparable to the WT virus (Fig 5.11A, B). Virus 
containing the combination of A150V+K206E was observed to decrease sensitivity to 
SOF and IFN in a similar manner to K206E and A150V in isolation. The SOF IC50 
obtained for the combination virus was higher but comparable to the K206E virus, 
whereas the IC50 for IFN was found to be slightly higher (109.50IU/ml) than that 
observed for A150V alone (70.95IU/ml) (Fig 5.11E). The effect of these mutations on 
RBV sensitivity was also assessed. While the presence of A150V and K206E did 
reduce sensitivity to RBV the fold change observed with the infectious virus was not 
as marked (Fig 5.11C). Additionally, obtaining a dose response curve to RBV was 
achieved with some difficulty due to high concentrations used of the drug having a 
cytotoxic effect on the infected cells, which may explain the overlapping confidence 
intervals observed with the various viruses (Fig 5.11E). Viruses were also treated with 
a range of doses of the NS5A inhibitor DAC as a control to show that the A150V and 
K205E mutations had a specific effect to NS5B inhibitors.  Treatment even with the 
lowest concentration of DAC resulted in a dramatic reduction in DBN RNA for all 
viruses indicating an acute sensitivity to DAC. IC50 values obtained were comparable 
even in the presence of A150V and K206E indicating that these mutations did not 
impact upon sensitivity to NS5A inhibitors.   
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Fig 5.11 Sensitivity of DBN viruses to SOF, IFN, RBV and DAC 
Huh7.5-SEC14L2 cells were infected with an MOI of 0.5 for 24 hrs before treatment with a serial dilution 
series of SOF (A), IFN (B), RBV (C) or DAC (D). After 72hrs cells were harvested for quantification of 
HCV RNA by RT-qPCR. IC50 values for SOF, IFN, RBV and DAC were calculated from % change in 
HCV RNA levels compared to the no drug control (E). Values are presented with 95% confidence 
intervals. Fold change in IC50 was calculated by comparison of IC50 values obtained from the mutant 
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viruses to that of the Wt. The above is representative of at least 3 independent experiments. Graphs 
depict is mean ±SEM.  
 
In addition to drug sensitivity experiments performed with qPCR we also used a 
modified focus-forming assay to confirm the impact of these mutations on SOF and 
IFNa sensitivity. Using the percentage of cells positive for HCV antigen was the 
technique that Ramirez and colleagues used in antiviral sensitivity assays with the 
DBN clone. We sought to replicate that technique with regard to our mutated A150V 
and K206E containing viruses to confirm our findings on the effect these mutations 
have on SOF and IFNa treatment. Cells were infected as before and drug treatment 
duration was the same as for qPCR assays. Percentage of cells positive for HCV 
antigen was determined by NS5A staining and quantified using an INCELL automated 
microscope. Fold change in SOF IC50 using this method showed a comparable shift 
with the A150V, K206E and combination viruses (1.08, 6.44 and 10.38 respectively) 
as determined by qPCR. Correspondingly, viruses containing the A150V mutation 
caused the largest change in IFN IC50 >70-fold in this assay, which again was similar 
to that shown by qPCR. SOF and IFN IC50 confidence intervals were noted to be wider 
in this assay than shown by qPCR. Though despite this effect of A150V and K206E 
on drug sensitive assay corroborated data obtained by qPCR.  
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Fig 5.12 Sensitivity of DBN viruses to SOF and RBV using a FFU based assay 
Huh7.5-SEC14L2 cells were infected with DBN virus at the same MOI and timing as for previous drug 
sensitivity experiments. Infected cells were seeded on a 96 well plate and treated with SOF (A) and 
IFNa (B) for 72hrs after which cells were fixed and stained for NS5A. Number of cells per well positive 
for NS5A was quantified using an INCELL 2200 automated microscope (GE). Dose response curve 
were calculated by comparison of NS5A levels between the un-treated control and wells that were 
treated with a serial dilution of each drug. (C) Fold change in IC50 was calculated by comparison of IC50 
values obtained from the mutant virtues to that of the Wt. The above is representative of at least 3 
independent experiments. Graphs depict is mean ±SEM.  
 
These data confirm the contribution of the A150V and K206E on drug sensitivity. While 
A150V has little effect on SOF in isolation it has a major effect on sensitivity to IFN. 
Conversely K206E has almost no effect on IFN but a greater effect on SOF. The 
combination of these mutations in the same virus (most commonly found in drug 



















































































5.5.4 Reduced potency of SOF in cells lacking an IFN response 
Data obtained thus far from the infectious clone indicates that in isolation A150V has 
a negligible effect on SOF sensitivity but a greater effect on IFN. K206E however has 
a much greater effect on SOF but almost no effect on IFN in isolation. When these two 
mutations are combined the greatest reduction in both SOF and IFN is observed. This 
led us to hypothesise that to achieve maximum potency SOF may require an intact 
type I IFN response to effectively clear a virally infected cell.  
 
To test this hypothesis we used a Huh7.5-SEC14L2 cell line expressing the V protein 
from the parainfluenza virus 5 (PIV5-V), which degrades STAT-1 causing this cell line 
to be unable to mount an IFN response (kind gift from Professor Mark Harris). Huh7.5-
SEC14L2 cells expressing PIV5-V (Huh7.5-VSEC) were infected as before with the 
DBN Wt and mutant viruses and their sensitivity to SOF compared to assays 
performed with Huh7.5-SEC cells. A dose response to SOF was still obtained in these 
cells indicating that the loss of the IFN response did not totally blunt the effectiveness 
of SOF (Fig 5.13A). Yet, IC50 values calculated from treatment of Huh7.5-VSEC cells 
infected with Wt and mutant virus with SOF were found to be on average 10-fold higher 
than values calculated from infection of Huh7.5-SEC cells. Additionally infection of the 
Huh7.5-VSEC cells with viruses containing the A150V mutations had no effect on SOF 
sensitivity resulting in a comparable SOF IC50 to Wt virus (Fig 5.13B). However, 
response to SOF with the K206E and the combination virus did cause a small fold 
change in SOF IC50 albeit to a much lesser degree than seen from infection with 
Huh7.5-SEC cells. Data from these experiments indicate that in IFN-unresponsive 
cells the antiviral effect of SOF is less effective but not completely diminished. This 
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indicates, that to achieve maximum antiviral potency SOF requires cells to have an 
intact STAT-1 mediated IFN response. 
 
Fig 5.13 Sensitivity of DBN viruses to SOF in an IFN unresponsive cell line 
(A) Huh7.5-VSEC cells were infected with DBN-WT, A150V, K206E and A150V+K206E for 24hrs before 
treatment with SOF serial dilutions of SOF. After 72hrs cells were harvested and HCV RNA levels were 
quantified by RT-qPCR. (B) IC50 values obtained for these cells were compared to those obtained from 
assays performed with Huh7.5-SEC cells. Data is representative of 3 independent experiments. Graph 
indicates mean ±SEM. 
    
5.6 Summary 
Together data presented in this chapter indicate that the NS5B mutation K206E has 
an impact on sensitivity to SOF in isolation and in combination with A150V. While in 
isolation A150V has a minimal effect on SOF sensitivity and it appears to slightly 
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enhance the anti-SOF effect of K206E when present in combination in the NS5B. 
These findings were consistent in both a transient subgenomic replicon assay and in 
the context of a fully infectious G3 virus. In addition although a stable replicon cell line 
could only be established for the K206E mutation alone, this also showed a reduction 
in SOF and RBV sensitivity. Differences in the relative fold shift in SOF and RBV IC50 
were found between assays performed with the subgenomic replicon assay and the 
DBN infectious clone. While both assays indicate that the combination of A150V and 
K206E cause the largest reduction in sensitivity to SOF, the subgenomic replicon 
indicates this change is a 35-fold increase in SOF IC50 compared to the wild type, 
whereas the infectious virus indicates this causes only a 10-fold change in SOF IC50. 
The fold changes in SOF sensitivity for the DBN virus were confirmed both by qPCR 
and viral antigen expression level, which are both direct measures of viral replication. 
The luciferase measurement of the activity of the subgenomic replicon while 
representative of the relative replication of the construct may not be as accurate a 
measure as qPCR for example. Furthermore the virus allows consideration of the 
impact of these mutations on the entire viral life cycle whereas only viral replication 
can be considered with the subgenomic replicon, making the DBN virus more a 
representative model of HCV infection in vivo. 
 
The cause for this difference may be due to both systems having different baseline 
sensitivities to SOF implied by the IC50 for the WT DBN-virus being approximately 10-
fold lower than the Wt S52 subgenomic replicon. Both systems are derived 
 
A surprising finding was the significant impact of A150V upon sensitivity to IFN. 
Presence of this mutation in isolation or in combination with K206E substantially 
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reduced sensitivity of the DBN virus to IFNa. Furthermore it was shown that in cells 
unresponsive to IFN through a lack of STAT-1 the antiviral effects of SOF on DBN 
infection were less potent. Together this suggests while K206E has the greatest effect 
of SOF sensitivity in isolation, the anti-IFN effects of A150V, reduce the potency of the 
drug when this mutation is present in combination, therefore reducing the sensitivity 
to SOF even further. Possible mechanisms as to how A150V causes such a dramatic 


















6 RESULTS: Analysis of the effect of the A150V polymerase polymorphism 
on Interferon Signalling  
 
We investigated the mechanism behind the loss of responsiveness to IFNa of DBN 
viruses bearing the A150V mutation in the NS5B protein. We hypothesised that the 
A150V mutation either disrupted the cellular response to IFNa through the signal 
transduction pathway or allowed the virus to evade the IFN antiviral state. To this end 
we designed experiments to investigate if infection of Huh7.5-SEC14L2 cells with 
DBN-A150V virus impaired the ability of the cell to respond to IFNa through interferon-
stimulated-gene (ISG) production. We also overexpressed the NS5B with the A150V 
mutation in Huh7 cells to assess whether exogenous expression of the protein without 
the rest of the non-structural proteins could affect IFN signalling. 
 
6.1 MxA induction in cells infected with DBN-A150V 
We set out to determine whether infection with DBN-A150V impaired induction of 
crucial antiviral ISGs such as MxA when cells were treated with IFNa. Huh7.5-
SEC14L2 were infected with DBN-Wt, A150V and K206E viruses and allowed to 
propagate for 3 days to allow the virus to establish infection. Cells were then 
challenged with 10 and 100IU/ml of IFNa-2A with samples taken 24hrs post IFN 
treatment to quantify MxA and HCV levels by RT-qPCR. Comparable levels of MxA 
induction were observed at 100IU/ml of IFNa between uninfected cells and infected 
cells, though a high degree of variation was observed between each virus infection. A 
slight but not significant (p>0.05) reduction in MxA was observed at 100 IU/ml IFN with 
the A150V+K206E virus (Fig 6.1B). MxA fold induction with 10IU/ml of IFNa was 
comparable between un-infected cells and cells infected with the DBN Wt and DBN-
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K206E virus (Fig 6.1B). These levels however did drop in cells infected with the DBN-
A150V virus and the dual mutant though neither approached significance (p>0.05). 
Viral levels for the DBN-Wt and K206E decreased in a dose dependent manner with 
IFNa treatment (Fig 6.1C). While levels did drop with the DBN-A150V and DBN-
A150V+K206E virus, the reduction was not as marked as observed with the Wt or 
K206E virus.   
 
Fig 6.1 MxA expression in Infected Huh7.5-SEC14L2 cells  
(A) Schematic of the timings of the experiment.  Huh7.5-SEC14L2 cells were infected with an MOI of 
0.5 with the infection allowed to propagate for 3 days. Cells were then treated with 10 and 100IU/ml for 
24hrs before harvesting in Trizol. Relative expression of MxA (B) and HCV (C) was quantified by RT-
qPCR using the pflaffl method to normalise gene expression to the 5S housekeeping gene. Data is 
representative of 2 independent experiments. Graphs depict mean ±SEM. 
 
6.1.1 Effect of the DBN-A150V virus on the Interferon Stimulated Response 
Element 
To assess whether the slight reduction in MxA levels observed in the previous 
experiments reflected a reduced activation of MxA transcription by factors that drive 
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of ISG expression, including MxA, is directed by the IFN-Stimulated-Response-
Elements (ISRE), which are activated when bound by IFN-stimulated gene factor 3 
(ISGF-3), formed as a result of the JAK-STAT signalling pathway in response to IFN 
(Kanazawa et al., 2004). Using a reporter plasmid containing firefly luciferase under 
the control of the 6-16 canonical ISRE sequence the relative activity of the ISRE within 
a cell can be evaluated. Huh7.5-SEC14L2 cells infected with the DBN viruses for 72hrs 
were transfected with the luciferase reporter plasmid prior to treatment with a range of 
IFNa doses with Luciferase levels quantified 24hrs after IFNa treatment. ISRE activity 
was comparable between infected and un-infected cells increasing in a dose 
dependent manner with IFNa treatment. Infection of cells with the DBN-A150V or the 
DBN-A150V+K206E virus did not have an observable impact on ISRE activity in 
comparison to the DBN-WT (Fig 6.2A). Infection of cells was confirmed by 
quantification of HCV RNA levels by RT-qPCR (Fig 6.2B).  These data indicate that 
the effect of A150V on the cellular response to interferon may not be mediated via the 
classical Stark-Kerr-Darnell ISGF3 signal transduction pathway. However, recent work 
(Sung et al., 2015) has indicated that alternative signalling pathways do exist and it is 
possible that A150V interacts with one of the alternative pathways.    
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Fig 6.2 ISRE activity in DBN infected cells 
(A) Huh7.5-SEC14L2 cells were infected with virus 3 days prior to transfection with the pGL4.45 ISRE-
Firefly reporter plasmid along with the pNL1.1 Nanoluc reporter plasmid to account for transfection 
efficiency. After transfection cells were treated with indicated doses of IFNa-2A for 24hrs then harvested 
to quantify luciferase activity. Firefly luciferase levels were normalised to Nanoluc luciferase to account 
for transfection efficiency. Fold induction of ISRE activity was calculated from the no-IFN control. (B) 
To confirm cells were infected HCV RNA levels were quantified from the non-treated control by RT-
qPCR. Data presented is representative of 3 independent experiments. Graphs depict mean ±SEM. 
  
 
6.1.2 Virus with A150V can overcome the Type I IFN mediated antiviral state  
Data thus far indicates that cells infected with DBN-A150V can result in a slight 
suppression of MxA induction when treated with a low dose of IFNa yet has no effect 
on the classical interferon signalling pathway. We speculated that A150V might enable 
the virus to resist the cellular antiviral state that occurs by the activation of the type I 
IFN response or interact with the recently described ‘late’ U-ISGF3 signal transduction 
pathway.  To examine this we pre-treated Huh7.5-SEC14L2 cells with IFNa for 24hrs 
to activate the classical signal transduction pathway and induce ISGs. Cells were then 
infected with DBN-WT, A150V, K206E and A150V+K206E viruses and allowed to 





























































































































































Fig 6.3 Infection of cells pre-treated with IFNa 
Huh7.5-SECL14L2 cells were pre-treated with 10 and 100 IU/ml of IFNa-2A for 24hrs before infection 
with the DBN viruses at an MOI of 0.5. Infected cells were incubated for a further 3 days before 
harvesting and quantification of HCV RNA levels by RT-qPCR. Data is representative of 3 independent 
experiments. Statistical analysis was performed using Graphpad Prism 7, p<0.05 = . Graphs depict 
mean ±SEM.  
 
 
A marked decrease in HCV RNA was observed in cells pre-treated with 10 and 100 
IU/ml of IFNa when infected with the DBN-Wt and K206E viruses compared to the 
non-treated control (Fig 6.3). In contrast, comparable levels of virus were obtained 
with infection of the pre-treated cells to the non-treated control with the DBN-A150V 
virus. A slight decrease was observed with infection of cells pre-treated with 100 IU/ml 
IFNa however this was not as striking as that observed with the Wt or K206E virus. 
The impact of IFN pre-treatment was also reduced with the DBN-A150V+K206E virus 
with higher viral levels observed compared to the DBN-Wt. Though not as distinct as 











































cells pre-treated with 100 IU/ml IFNa revealed significantly higher levels of HCV RNA 
with the DBN-A150V and DBN-A150V+K206E viruses (p=0.015 and 0.029 
respectively). These experiments suggest that the A150V mutation interferes with the 
cellular response to IFN downstream of the classical signal transduction pathway. 
 
6.1.3 Generation of a cell line overexpressing NS5B-A150V 
We next sought to develop a stable platform to conduct experiments to dissect any 
potential interference of the NS5B-A150V mutation on IFN signalling. As we were 
unable to generate a stable G3 replicon cell line harbouring the A150V mutation we 
decided to clone the DBN-NS5B with A150V, K206E and A150V+K206E into the 
pRetroX expression vector to generate stable cell lines expressing the mutated NS5B 
protein. This system would be complementary to our infectious model, but have the 
advantage of constitutively expressing the NS5B-A150V mutation minimising variable 
rates of infection between the different viruses. 
 
The 1.7Kb NS5B gene was amplified from the original DBN plasmids used to generate 
the infectious virus. NS5B amplicons were obtained from the WT, A150V, K206E and 
A150V+K206E DBN constructs (Fig 6.4A). Each amplicon was engineered to contain 
a BamHI and EcoRI restriction sites at the respective 5’ and 3’ ends to allow directional 




Fig 6.4 Cloning of NS5B into pRetroX 
 (A) NS5B was amplified from the DBN plasmids with the indicated mutations. Each amplicon was 
engineered to contain a Kozak sequence, start and stop codon as well as BamHI and EcoRI restriction 
sites at either end of the amplicon. (B) Bacterial colonies obtained from the ligation of NS5B into 
pRetroX were digested with BamHI and EcoRI to screen for the presence of the 1.7Kb NS5B gene. 
Vectors found to contain the correct size product were sent for sanger sequencing for confirmation. 
Representative images of each step are shown. (C) Plasmid constructs were transfected into Huh7 
cells with stable colonies selected for by puromycin. NS5B expression was confirmed by 
immunofluorescence. 
 
Presence of NS5B in the vector was confirmed by detection of a 1.7Kb band when 
digested with BamHI and EcoRI (Fig 6.4B). All vectors were subsequently sequenced 
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C 
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presence of the A150V and K206E mutations in the respective vectors. Constructs 
were transfected into Huh7 cells with stable colonies obtained after 2 weeks of 
puromycin selection. Expression of NS5B was confirmed in these cells by 
fluorescence microscopy with NS5B found to localise mainly to the cytoplasm. 
Staining was observed to be less prominent in the Huh7-5B-A150V+K206E cells, 
possibly reflecting an impact of these mutations upon NS5B expression. 
 
With NS5B expression confirmed in these cells we looked at the affect this had on 
response of these cells to IFNa. We first assessed the activity of the ISRE by 
transfecting the cells with the ISRE reporter plasmid as before and challenging them 
with a range of IFN doses for 24hrs. ISRE activity was observed to be greater in un-
transfected Huh7 cells with 1000 IU/ml compared to those expressing NS5B (Fig 6.5). 
No substantial difference in ISRE activity was observed between the Huh7-5B-Wt cells 
and those expressing A150V, K206E or A150V+K206E when treated with 10, 100 and 
1000 IU/ml of IFNα. Despite a slight reduction in ISRE activity when cells expressing 
NS5B with the K206E and double mutation where treated with 100 and 1000 IU/ml 
IFNα, this was not significant at either concentration when compared the Huh7-5B-Wt 
cells (p=0.32 and p=0.13 for 100 IU/ml and p=0.33 and 0.22 for 1000 IU/ml 
respectively).  These data confirm the data in virally infected cells showing that the 




Fig 6.5 ISRE activity in NS5B Huh7 Cells 
Huh-NS5B cells were transfected with the ISRE reporter plasmid and treated with a range of doses of 
IFNa-2A for 24hrs after which cells were lysed and luciferase activity quantified. Cells were co-
transfected with a Nanoluc expression vector to account or transfection efficiency. Fold induction of 
ISRE was calculated from the no-IFN treated control. Data presented is form 2 independent 
experiments; graphs depict mean ±SEM. Statistical analysis was performed using GraphPad Prism 7. 
 
We next assessed whether over-expression of Wt or NS5B bearing our mutations of 
interest had any impact on MxA induction in response to IFNa. We treated cells with 
10 and 100 IU/ml of IFNa sampling MxA levels at 6 and 24 hrs post treatment. 
Comparable levels of MxA were detected in all cell lines after 6hrs and in the Huh7 
and Huh7-5B-Wt cells after 24 hrs of IFN treatment (Fig 6.6A, B). However, MxA 
induction with 100 IU/ml of IFNa in cells expressing NS5B with A150V, K206E and 
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A150V+K206E mutations was found to be significantly reduced (p= 0.0083, 0.039 and 
0.011 respectively), in cells treated for 24 hours, with the greatest reduction observed 
in the cells expressing the NS5B A150V mutation.  
 
 
Fig 6.6 MxA mRNA levels in Huh7-NS5B cells 
MxA mRNA expression was measured in Huh7 and Huh7-NS5B cells bearing indicated mutations in 
NS5B. Cells were treated with 10 and 100 IU/ml of IFNa-2A and MxA levels quantified at 6 (A) and 24 
hrs (B) post-treatment by qPCR. Fold induction of MxA was calculated by comparison of treated values 
to that of the no-IFN control. Data is representative of 2 independent experiments. p<0.001 =  p<0.05 
=  Statistical analysis was performed using Graphs depict mean ±SEM.   
 
Taken together, these results indicate that the ‘late response’ to interferon is reduced 
in cells expressing the A150V variant NS5B protein and confirm data from cells 
expressing intact virus. NS5B expressing cells provide a more stable platform for 
dissecting the effect of the A150V mutation on the type I IFN pathway and will allow 






































































































6.2 Huh7-NS5B cells with the A150V mutation have reduced basal levels of 
STAT-1 and STAT-2 
Recent work has shown that prolonged infection of hepatocytes and Huh7.5 cell lines 
result in a considerable production of IFN-ls and IFN-ß, which continually stimulate 
hepatocyte cells to produce IRF9, STAT-1 and STAT-2 without tyrosine 
phosphorylation) (Sung et al., 2015). We hypothesised that the impairment of MxA 
production in the Huh7-5B-A150V cells may be due to a dysregulation or reduction in 
basal levels of key signalling molecules such as STAT-1 or STAT-2.  
 
To this end, expression levels of STAT-1 and STAT-2 were examined in both infected 
cells and cells expressing Wt and mutated versions of NS5B.  Infected cells showed 
comparable expression levels of STAT-1 and STAT-2. Though a very slight reduction 
was observed in STAT-2 in cells infected with the DBN-A150V virus.  A more 
noticeable reduction in total STAT-1 and STAT-2 levels were found in cells expressing 
the NS5B-A150V mutation compared to un-transfected Huh7 cells and cells 
expressing Wt NS5B(Fig 6.7). As an additional control for potential proteasomal 
degradation, cells were treated with a proteasome inhibitor to see if any reduction in 
STAT-1 or 2 could be rescued. A slight increase in STAT-1 and STAT-2 with the 
A150V can be seen with this treatment, however it does not appear to restore 
comparable expression levels to the Huh7 to Wt-NS5B control.  
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Fig 6.7 STAT-1 and STAT-2 Expression in DBN infection and Huh7-NS5B cells 
(A) Huh7.5-SEC cells were infected with the DBN WT and mutated viruses at an MOI of 1 for 3 days 
after which cells were lysed for protein extracts. Expression of STAT-1, STAT-2 and NS5A were 
assessed by immunoblot. Actin was used as a loading control. (B) Expression of STAT-1 and STAT-2 
in Huh7-NS5B cells. Cells were treated with the 10nM of the proteasomal inhibitor bortezamib for 16 
hrs before immunoblotting of STAT1 and STAT2 was performed. Expression levels were compared to 

















































Together, the data presented here implies that the A150V polymorphism in Genotype 
3 HCV impairs interferon signal transduction.  Viruses bearing the A150V mutation are 
able to more readily infect and propagate in cells pre-treated with IFN indicating that 
these viruses interfere with the action of ISGs downstream of classical signal 
transduction. The development of the NS5B expressing Huh7 cells provided a more 
stable platform to dissect the contribution of this mutation to MxA induction without the 
inherent variability of viral infection. Stimulation of these cells with IFN revealed that 
while MxA levels could be induced 6 hrs post treatment, presence of NS5B with A150V 
caused these levels to drop after 24hrs. Basal levels of STAT-1 and 2 were slightly 
reduced in NS5B-A150V expressing cells, which may contribute towards a reduced 
activation of U-ISGF3 ISGs as part of the ‘late’ IFN response. An exact mechanism as 
to how A150V can overcome the IFN response has not yet been defined and further 












7 Discussion  
The remarkable change in the treatment landscape for HCV brought about by the 
replacement of pegIFN/RBV with a regimen of highly effective antiviral drugs has 
resulted in the WHO declaring a target of HCV elimination by 2030. Yet to eradicate 
this virus potent antiviral therapy may not be sufficient. The biology of HCV, with its 
high mutation rate, gives the virus the ability to develop mutations to overcome antiviral 
drug treatment. While modern DAA therapy achieves high SVR rates, approaching 
100% in some clinical trials, the genotype being treated remains one of the largest 
factors in determining optimal response to treatment as well as previous treatment 
with IFN therapy and stage of liver disease (EASL, 2017). In particular response rates 
to G3 HCV from patients with advanced liver disease are reduced in comparison to 
treatment of G1 or G2, in both clinical trial and real world setting (Cheung et al., 2016; 
Foster et al., 2015b). It was the aim of this work to determine if there was a virological 
cause for the reduced response rates observed in G3 virus from patients who did not 
respond to SOF based therapy. Using a novel assay we were able to determine the 
antiviral phenotype of G3 virus derived from patients who relapsed following SOF 
based therapy and we found that a subset of these patients had a reduced sensitivity 
to SOF. Subsequent sequencing analysis revealed a unique mutational pattern in the 
NS5B of patients who were insensitive to SOF. Introduction of these mutations into 
both a subgenomic and infectious viral system recapitulated the reduced sensitivity to 





7.1 Capture fusion assay as a system to phenotype patient virus 
The HCV capture fusion assay is the only published method to assay the antiviral 
phenotype of patient derived virus (Cunningham et al., 2014; Jones et al., 2017). 
Limitations of the assay include the low replication levels observed in certain patient 
samples, the short duration that fused cells can be sustained for and the reliance on 
a sensitive RT-qPCR assay to detect viral replication. It was postulated that improving 
the rate of fusion between infected THP-1 and Huh7.5 cells would improve HCV RNA 
making detection of viral replication more robust.  
 
Two attempts using different rationales were pursued to improve fusion between THP-
1 and Huh7.5 cells. The first was using a biotin-streptavidin-biotin (BSB) bridge to 
improve cell-to-cell contract between two cells which was reported to improve PEG 
fusion (Li et al., 2014). Despite several attempts this system did not improve rates of 
PEG fusion between THP-1 and Huh7.5 cells, though it is not known whether this was 
a failure in the biotin coating of the cells or in the establishment of the BSB-bridge 
between the cells.  The second attempt at improving rates of PEG fusion was replacing 
the fusion method itself with a reportedly more efficient viral fusion protein based 
system by the expression of the acid-inducible fusogenic G-protein from Vesicular 
Stomatitis Virus (VSVG) (Gottesman et al., 2010). While expression of VSVG was 
confirmed in the Huh7.5 cells exposure to the recommended acid buffer fusion did not 
result in detectable fusion events with THP-1 cells assessed by a FACS. A functional 
assay to assess whether ‘VSVG fusion’ could support viral replication further revealed 
that HCV RNA levels were significantly higher in cells fused by PEG compared to 
‘VSV-G fusion’.  The lack of fusion events between Huh7.5-VSVG and THP-1 cells 
strongly suggests that the VSVG protein is unable to perform its fusogenic function in 
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these cells. While VSVG expression was shown by immunoblotting to be present in 
the Huh7.5-VSVG cells it is possible that the protein was not being expressed at a 
location where it could fuse cellular membranes. Additional work that could be 
performed involves expressing VSV-G on the THP-1 cells to assess whether that cell 
line might express VSVG in an arrangement more conducive to VSV-G fusion. Though 
as the THP-1 cells are critical for binding of patient derived virus in capture fusion, 
expression of VSV-G within the cell may affect this process. In conclusion our 
experiments suggest that PEG fusion remains the best method to fuse infected THP-
1 and Huh7.5 cells in the capture fusion assay to propagate patient derived virus. 
Although more efficient means of fusion may exist they did not improve either fusion 
or HCV replication in this context and our attempts to improve fusion were not pursued 
further. 
 
The recent identification of SEC14L2 as a key host factor for both HCV replicon and 
clinical isolate replication (Saeed et al., 2015) led us to assess whether Huh7.5-
SEC14L2 cells could either be an alternative to capture fusion or be incorporated in to 
the assay. In our hands we found direct infection of these cells to yield variable levels 
of replication of patient derived HCV and we were unable to replicate published work 
showing that these cells are permissive to HCV infection with a variety of different 
isolates. Viral RNA levels of samples tested tended to decrease over a period of 10 
days particularly in G1 samples, indicating that RNA replication was either occurring 
at a very low level or not occurring at all.  A small increase in HCV copy numbers was 
however observed with direct infection of G3 samples possibly indicating that these 
cells were more permissive to G3 infection. The viability of cells as an antiviral 
phenotyping assay was assessed both by a RT-qPCR assay and a HCV specific 
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SEAP reporter. While use of the HCV SEAP reporter system did distinguish between 
SEC14L2 expression producing a higher luminescent signal in the presence of 
SEC14L2, a robust dose response to SOF could not be established. However 
assessment of viral RNA levels by qPCR did reveal a dose response curve in 
SEC14L2 cells though only in two G3 samples with high viral loads. Direct comparison 
of capture fusion to infection of SEC14L2 cells did result in comparable IC50 values for 
SOF indicating that both systems can determine the sensitivity of matched clinical 
isolates at a similar level. It was noted however that the level of HCV RNA replication 
was lower with direct infection of Huh7.5-SEC14L2 cells compared to capture fusion 
in matched patient isolates. This may reflect the fusion process being a more efficient 
‘delivery’ method of clinical virus into naïve Huh7.5 cells than direct infection with 
clinical virus. While use of the Huh7.5-SEC cells appears to be able to replicate patient 
virus from high-titre samples, its failure to replicate and establish dose response 
curves in all virus samples resulted in it being a less robust system on its own than 
capture fusion. Yet, the incorporation of Huh7.5-SEC14L2 cells into the capture fusion 
assay in the place of Huh7.5 cells significantly increased HCV RNA levels in all viral 
samples tested. Hence, while direct infection of these cells is not superior to capture 
fusion the use of these cells in capture fusion does enhance the assay.   
 
While the identification of SEC14L2 is an important discovery in our understanding of 
critical host factors required by HCV to propagate, there may be more to be 
discovered. The beneficial effects of SEC14L2 are proposed to be protection of the 
virus against lipid peroxidation (Saeed et al., 2015; Witteveldt et al., 2016). For this 
protection to occur patient derived virus must still enter the cell and is therefore reliant 
on the natural HCV infection pathway. The fusion of infected THP-1s into Huh7.5 cells 
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introduces virus directly into the cytoplasm of Huh7.5 cells, where it can benefit from 
the positive influence of SEC14L2 on its replication without having to negotiate the 
HCV infection pathway. This in turn may explain why expression of SEC14L2 in 
Huh7.5 cells improved levels of HCV clinical isolates in capture fusion.  
 
7.2 Identification of G3 relapse samples insensitive to SOF and RBV using the 
capture fusion model 
A key aim of this work was to assess whether baseline viral samples from G3 patients 
who relapsed to SOF based had a phenotypic difference in drug sensitivity compared 
to those who achieved an SVR. We tested our hypothesis by determining the 
sensitivity of G3 clinical isolates to SOF and RBV by capture fusion. We identified a 
group of G3 relapse patients who had significantly reduced sensitivity to both SOF and 
RBV. The strength of our analysis came from all phenotyping experiments being 
performed in a blinded fashion to clinical outcome, so that our analysis was not 
influenced by prior knowledge of which patients relapsed and which achieved an SVR. 
Subsequent analysis of the viral sequencing data did not reveal any previously 
reported variants known affect either SOF or RBV sensitivity in drug insensitive 
samples, though some instances of the NS5A resistance variant were reported. 
 
A central finding of these experiments was that not all patients who relapsed were 
insensitive to SOF and RBV as a minority of samples retained comparable sensitivity 
to both drugs to the SVR samples. This was of particular importance in our more 
extensive analysis of the NS5B sequences, which grouped the sequencing data by 
SOF and RBV phenotype as opposed to clinical outcome. Our analysis identified two 
mutational patterns in insensitive relapse patients. The first was only observed in one 
 195 
sample and consisted of a multitude of changes across the NS5B that were seemingly 
unique to that patient. The second was a combination of two changes A150V and 
K206E that while observed in isolation in drug sensitive samples, the combination was 
only observed in insensitive relapse isolates. Phylogenetic analysis of the NS5B 
sequences found that samples with this particular motif formed a distinctive group. 
Analysis of the frequency of these mutations in the viral population in each sample 
revealed that both A150V and K206E dominated the quasispecies. Furthermore, these 
mutations continued to dominate in sequencing samples taken from patients post-
relapse. This may indicate that these changes are important to the viral population in 
the face of antiviral treatment. It would have been of interest to this study to have 
tested post-relapse samples in capture fusion, which was unfortunately not possible 
due to insufficient viral loads post-relapse to robustly perform capture fusion 
experiments.   
 
We went on to assess the prevalence of these mutations in a second independent 
cohort from the HCV BOSON trial. We demonstrated that the A150V mutation had a 
significant negative impact upon SVR rates in G3 patients, with V at this position 
having a higher association with relapse than SVR. In this cohort the both the K206E 
and combination mutation were present at a frequency too low to accurately determine 
its effect upon SVR.  
 
7.3 Impact of identified NS5B mutations in HCV subgenomic and infectious 
assays  
We utilised two models of HCV subgenomic replication and a newly described G3 
infectious clone to assess the impact of NS5B mutations identified by sequence 
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analysis on sensitivity to SOF and RBV. HCV subgenomic replicons are well-
described systems whereby the HCV replication complex can be analysed (Blight et 
al., 2000; Blight & Norgard, 2006; Saeed et al., 2013; Saeed et al., 2012). In particular 
generation of stable cell lines expressing HCV replicons with a suitable reporter is a 
particularly robust system to determine sensitivity to antivirals. Drawbacks with this 
system are that transfection of replicon RNA by electroporation is an inefficient 
process coupled with stable colonies taking a substantial amount of time to grow 
through G418 selection. Also, the selection process itself can generate adaptive 
mutations throughout the genome that can affect replication efficiency. Our attempts 
at creating stable replicons resulted in only 3 out of the 6 NS5B mutations, K100R, 
G188D and K206E being created as stable lines. Antiviral sensitivity experiments 
performed on these replicon lines demonstrated that K100R and G188D mutations 
had a modest effect on SOF but more of an effect of RBV. The K206E mutation did 
reduce SOF sensitivity to a greater degree than either the K100R or G188D mutation 
indicating that in isolation this mutation can affect SOF sensitivity. Yet patients with 
only this mutation did not exhibit SOF insensitivity when assessed by capture fusion. 
Though it should be noted that a slight increase in IC50 values was observed from SOF 
sensitive patients with only the K206E mutation. 
 
The stable replicon system while robust did not permit the study of all of the NS5B 
mutations of interest or the key A150V/K206E combination. An alternative approach 
was to use the S52 subgenomic replicons in a transient assay by preforming drug 
sensitivity experiments immediately after the cells have been electroporated. 
Transient subgenomic replicon assays using the G3 subgenomic replicon are well 
described and can also be enhanced by the use of the Huh-SEC14L2 cell line 
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(Witteveldt et al., 2016). Use of the G3-subgenomic replicon in a transient assay 
allowed us to rapidly test the sensitivity of replicons bearing all our mutations to SOF 
and RBV. However a high degree of variability was observed with this system between 
experiments due to the variable transfection rates of electroporation. Nevertheless the 
reproducible pattern of response seen in the transient assay led us to conclude that 
the polymorphisms under investigation did modify the response to SOF.  
 
Using this system we found that the combination of A150V and K206E had the 
greatest impact upon sensitivity to SOF and RBV sensitivity then any mutation 
assessed in isolation. Although the reduction in sensitivity was not as severe as the 
well described SOF resistance mutation S282T (Svarovskaia et al., 2014). This was 
the first evidence that the presence of this combination of mutations has the ability to 
reduce sensitivity of HCV to the anti-viral effects of both SOF and RBV. In the single 
patient isolate with a rare set of multiple NS5B mutations, the two that had the greatest 
effect on SOF sensitivity were G188D and N244I. Though these mutations were not 
assessed in combination, their individual effects on SOF were likely the cause of the 
loss of SOF and RBV sensitivity observed in this patient isolate. 
 
To confirm our findings we engineered the A150V and K206E mutations into the newly 
described DBN3a genotype 3 infectious clone, which allowed us to assess the effect 
of these mutations in the context of the entire viral life cycle (Ramirez et al., 2016). 
Drug sensitivity experiments performed with these mutated viruses supported data 
obtained from the subgenomic replicon, that the combination of A150V and K206E 
caused the greatest reduction in sensitivity to both SOF and RBV. The ability of this 
system to produce high titre virus is based on 15-cell culture adaptive mutations 
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engineered throughout the HCV genome. While these mutations are not in regions 
close to either A150V or K206E they are artificial mutations that adapt the virus to 
replicate in cell culture not patients. However, this system is an improvement on 
subgenomic replicon assays as all stages of the viral life cycle are considered not just 
expression of non-structural proteins and the HCV replication complex. 
 
Together with the data from the subgenomic replicon, these data indicate the 
combination of A150V and K206E mutations in the NS5B resulted in the loss of 
sensitivity to both SOF and RBV observed in clinical isolates with this mutation pattern. 
Variable fold shifts in SOF and RBV IC50 were observed between the infectious clone 
and subgenomic replicon, with the mutations appearing to exert more of an influence 
on drug sensitivity in the subgenomic replicon than the infectious virus. A cause for 
this discrepancy might be that the as the virus infects the cell it will be sensed by the 
host immune response through classical antiviral detection pathways, which may 
enhance the effect of SOF treatment. The subgenomic replicon is however introduced 
via electroporation, which in itself is quite an invasive process, and may not be 
detected so readily by the immune response. Importantly in both assays show that the 
greatest effect on SOF and RBV sensitivity is the combination of A150V and K206E.  
 
The association of the A150V mutation to the IFNl3 gene made in a recent genome 
wide association study led us to discover that infectious virus with this mutation had 
an almost 100 fold reduction in sensitivity to IFNa (Ansari et al., 2017). The dramatic 
effect of A150V on the host IFN response led us to hypothesise that to achieve the 
maximum antiviral effect SOF requires an intact immune response. Our findings that 
in a cell line lacking an IFN response the IC50 of SOF in response to DBN-Wt viral 
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infection is reduced by approximately 10-fold support this hypothesis. Furthermore in 
these cells A150V had little effect on SOF sensitivity while viruses with the K206E 
mutation including the dual mutant still reduced sensitivity to SOF albeit to much less 
of an extent then observed in cells with an intact IFN response. K206E however was 
not found to have any impact on the IFN sensitivity suggesting that this mutation has 
a direct effect on the antiviral properties of SOF. The area in which this mutation is 
located is close to a domain previously reported to effect the RNA binding properties 
of the NS5B (Qin et al., 2001). Whether this mutation can affect RNA binding of NS5B 
is unknown however additional work to characterise any potential of this mutation may 
explain how it exerts its effects on SOF sensitivity.  
 
7.4 The effect of A150V on the host IFN response  
Work to characterise the mechanism behind the substantial reduction in IFN sensitivity 
was undertaken to assess if virus with A150V could disrupt the IFN signal transduction 
pathway or evade the antiviral effects of ISG induction. In infected cells presence of 
A150V had a minimal impact in the ability of the cell to produce MxA in response to 
IFN treatment or on the activity of the ISRE. The mutation was found to have more of 
an impact on enabling the virus to resist the IFN induced anti-viral state evidenced by 
higher infection rates with A150V virus on cells pre-treated with IFN. A stable cell line 
was generated expressing the mutated NS5B to create a more robust system whereby 
the effect of the A150V mutation could be more reliably investigated. It was found that 
in cells expressing the A150V mutated NS5B a significant reduction in MxA was 
observed after treatment with IFN for 24hrs while comparable levels of induction were 
observed after 6hrs indicating ‘late response’ to IFN is reduced. Immunoblot analysis 
of STAT-1 and STAT-2 expression showed no real change in basal levels of these two 
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key signalling proteins in cells overexpressing NS5B with A150V. The reduction in 
signal was slight and it is likely that there may be other elements that may explain this 
effect that are as yet unknown. Additional work would need to be performed to fully 
characterise the effect the A150V mutation is having on the cellular IFN response. 
Experiments that may be informative would be performing an IFN gene expression 
array on both infected cells and NS5B expressing cells to assess if any expression of 
key genes involved in the IFN response are affected in any way by the A150V 
mutation.   
  
7.5 Concluding remarks 
This work has identified a novel set of NS5B mutations that reduce response to DAA 
based therapy in G3 patients. Characterisation of the effect of these mutations in two 
models of HCV replication consistently shows that the combination of both A150V and 
K206E have the greatest impact on sensitivity to SOF. Furthermore the observation 
that the A150V mutation could significantly reduce sensitivity to IFNa, led to the 
observation that SOF has a reduced potency in a cell line unable to generate an IFN 
response. This suggests that the way in which A150V exerts its effect on SOF 
sensitivity is through reducing the effectiveness of the host IFN response resulting in 
less immune mediated clearance of the virus from the cell. This however is not 
sufficient to allow the virus to evade the antiviral effects of SOF. There is a requirement 
for the K206E mutation, which exerts a direct effect on SOF sensitivity, reducing the 
effectiveness of the drug even further preventing total clearance of the virus from the 
cell. How the A150V mutation allows the virus to evade the host IFN response remains 
undefined. Yet this work may allude to a unique way in which G3 HCV is able to 
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